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Abstract 
 
Background: Continuity of care (CC) is associated with increased rates of engagement with drug 
treatment, and drug treatment is associated with reductions in crime.  However, performance rates 
of CC reflecting the prison-to-community transition for substance misusing prisoners (SMP) are low 
and, although guidance is extensive, non-clinical quantitative research describing this key process 
point within the UK criminal justice healthcare pathway is limited. 
Objectives:  From a systems perspective, utilising a bespoke prison-to-community CC counting 
mechanism, this study aimed to: establish whether CC is associated with improved rates of drug 
treatment engagement, reduced waiting times and rates of return-to-prison (RTP); evaluate the 
impact on those measures post the introduction of the reconfigured single service delivery model 
‘InsideOut’.  Also, given this study’s pilot introduction of the statutory drugs data collection system 
into the local prison, describe a ‘first look’ pre-incarceration client treatment outcomes profile (TOP). 
Design: Observational, encompassing a quasi-experimental (before and after) analysis of impact. 
Participants: Adult, male substance misusing prisoners (N = 808) transitioning from the prison 
system to a local community drug partnership between April 1st 2008 and March 31st 2012. 
Results: ‘System’ level prison-to-community CC was associated with increased rates of and reduced 
waiting times to drug treatment. The introduction of the InsideOut service was associated with a 
stepped change in performance.  Compared to individuals engaged with community recovery, SMPs 
reported a significant deterioration in all outcome domains prior to incarceration. 
Conclusions: Whilst the increased rates of prison-to-community continuity of care reported here 
were supported by the UK Department of Health’s statutory reporting mechanism, the decreased 
rates of return-to-prison contradicted UK Home Office reoffending outputs.  Analysis of the national 
administrative statutory health and crime datasets is suggested to address this and other issues 
associated with study power, confounding and validity. 
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Chapter 1 – The study 
1.0 Introduction 
Continuity of care (CC) is key to treatment engagement (National Institute for Health Care 
Excellence, 2014; National Treatment Agency, 2009c, 2009d, 2011), and drug treatment is associated 
with reduced crime (National Treatment Agency, 2009b, 2012a, 2012b, 2012c, 2012e). From a 
systems perspective, utilising data drawn from the community-based National Drug Treatment 
Monitoring System (NDTMS), the Treatment Out Profile (TOP)(Public Health England, 2015b, 2016) 
and the prison-based Drug Intervention Record Web-based (DIRWeb) (Home Office, 2007a) 
databases, this study tested the assertions that the prison-to-community continuity care transition 
was primarily associated with: increased rates of ex-prisoner engagement with community drug 
treatment; decreased waiting times to drug treatment; and is secondarily associated with: 
increased lengths of time in drug treatment; decreased rates of return to prison. 
This study tested the hypothesis that: an integrated (single) compared to a siloed (twin) 
service delivery model, bridging the prison and community drug recovery settings, would improve 
the rates of prison-to-community continuity of care journeys and reduce the associated waiting 
times to community drug treatment. 
With a view to improving the rates of prison-to-community continuity of care, a strategic 
commissioning exercise, involving the realignment of the prison and community criminal justice drug 
treatment funding streams, was undertaken in order to facilitate the introduction of the ‘InsideOut’ 
service (EDAP, 2009; National Treatment Agency, 2009h; Westminster Drug Project, 2010). This 
innovative service, which is essentially a consolidation of the Counselling, Assessment, Referral, 
Advice and Throughcare (CARAT) prison service and the community Drug Interventions Programme 
(DIP), began to operate on April 1st 2010. 
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1.1 Background - the Drug Systems Change Pilot 
The opportunity to study the prison-to-community continuity care transition presented in the form 
of the UK Government’s introduction of the Drug Systems Change Pilot (DSCP) initiative (National 
Treatment Agency, 2009g). This programme was introduced in order to tackle a wide range of drug 
systems issues that had been highlighted within the review of prison-based drug treatment fund 
arrangements (PriceWaterhouseCoopers, 2008). Amongst several recommendations, and with an 
emphasis on poor rates of prisoner continuity care to the community drug treatment setting, the 
review strongly supported suggestions from the field that implementation and testing of innovative 
commissioning models should be encouraged. A further recommendation was that the National 
Drug Treatment Monitoring System (NDTMS) should be introduced into the prison drug treatment 
system (PriceWaterhouseCoopers, 2008). These recommendations, in conjunction with the local 
commissioner’s and information manager’s experiential observations, provided the impetus for the 
locality-based drug treatment system change reported here.  
Coordinated by the local Drug and Alcohol Action Team’s (DAAT) Strategic Commissioning 
Lead, a consortium of senior strategic commissioners drawn from the police, probation and prison 
services awarded the reconfigured Criminal Justice Intervention Service (CJIS) contract to a third 
sector organisation (TSO) for an initial period of five years, inclusive of a grace period. A key element 
of the CJIS was the establishment of the InsideOut intervention to manage the prison-to-community 
continuity of care transition. The InsideOut service, essentially a consolidation of the Counselling, 
Assessment, Referral, Advice & Throughcare (CARAT) and the community Drug Interventions 
Programme (DIP), began operations on 1st April 2010 (Westminster Drug Project, 2010). and at the 
time of this writing, had entered its final year in that configuration. The decision to research and 
evaluate prison-to-community continuity of care transition, and the impact on delivery with the 
introduction of the InsideOut service, was sanctioned by the local drug and alcohol partnership 
board and was supported by both the NTA regional and national performance teams. 
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In order to better understand the impact of the introduction of the InsideOut service and 
service user perceptions, the mixed methods Process & Treatment Outcomes Research Study 
(PTORS) was developed and registered with the Integrated Research Application System in early 
2011 (Connor, 2014). The PTORS study incorporated two Ph.D projects: one exploring the client’s 
journey from the service user’s perspective, and the second, this quantitative analysis of the prison-
to-community continuity of care transition. The study and its academic elements gained favourable 
ethical opinion from the NHS Eastern Region Ethics Committee in 2011 (see appendix 1.0).  The 
complementary qualitative investigation, describing client perceptions of their experiences with the 
InsideOut service and their views on what recovery from drug addiction means to them as 
individuals, is reported separately; this is located within the University of Essex's PhD archive and is 
published (Senker & Green, 2016). 
Funding for the systems change intervention and this evaluation was granted by the central 
government to the Essex Drug & Alcohol Partnership (EDAP) during 2009, following a successful 
outcome to a competitive bidding process undertaken between the autumn of 2008 and the 
summer of 2009 (National Treatment Agency, 2009e). 
 
1.2 Aims of the study 
Rates of prison-to-community continuity of care associated with substance misusing prison leavers, 
whilst stable, are suboptimal. The purpose of this study is to establish whether service 
reorganisation, involving the integration of two sets of service delivery activities, is associated with 
increased rates of prison-to-community continuity of care transitions, increased rates of 
engagement with the community drug treatment system, reduced waiting times and decreased 
rates of return-to-prison. This is the first study in the field entirely devoted to investigating the 
prison-to-community continuity of care transition from a non-clinical (administrative) perspective. 
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1.3 Nature of this study 
Observational, cross-sectional investigation encompassing a quasi-experimental design, evaluating 
system and organisational level process and outcome performance outputs. 
 
1.4  Hypotheses and supporting research questions  
Integrated prison and community (non-clinical) single-service delivery (1), is associated with 
improved rates of prison-to-community continuity of care (CC), (2) is associated with improved rates 
of treatment engagement, (3) is associated with reduced rates of return-to-prison and (4) is 
associated with reduced mean waiting times to treatment. In order to test these hypotheses, a 
series of descriptive, univariate (Chi Squared and student t-tests) and covariate (Kaplan Meier 
Survival and Mantel Cox log rank tests), supported with effect size calculations where applicable, will 
analyse the data to set study context and attempt to the answer the following research questions: 
(1) is CC associated with increased rates of drug treatment engagement? 
(2) is CC associated with reduced waiting times to drug treatment? 
(3) is CC associated with increased length of time in drug treatment? 
(4) is CC associated with reduced rates of RTP? 
(5) is drug treatment engagement associated with reduced rates of RTP? 
(6) is CC and engagement with drug treatment associated with reduced rates of RTP? 
Secondary strategic concerns associated with issues related to data silos, standardising 
treatment delivery and information sharing were addressed through this study’s piloting of the 
NDTMS and Treatment Outcome Profile (TOP) into the local prison (National Treatment Agency, 
2012d).  While a specific hypothesis was not studied, the study’s introduction of the NDTMS into the 
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local prison allowed for a somewhat opportunistic ‘first look' at the self-reported outcomes data 
collected from prisoners as they engaged with prison drug treatment. Although not the primary 
focus of this study, standardisation of the local drug treatment data systems was deemed necessary 
to achieve longer-term strategic objectives and, importantly, paved the way for a national rollout. 
The study analysis was undertaken in six stages.  Firstly, the study group were contextualised 
via a comparative analysis with regional and national demographical information. Secondly, a ‘whole 
system’ descriptive, chi-squared and student t-test analysis was undertaken to establish potential 
associations between continuity of care and treatment in line with the research questions.  Thirdly, a 
series of survival analyses were undertaken to strengthen the univariate stage, again at the ‘system’ 
level. Fourthly, the study’s hypotheses were tested by way of comparative and survival analyses of 
the CARAT vs. InsideOut CC, treatment engagements and waiting times activities. Fifthly, the prison-
to-community continuity of care performance outputs generated by this study were compared to 
those as published by the DIRWeb, and latterly NDTMS, statutory performance reporting 
mechanisms. And finally, and peripheral to this study’s main aims and objectives, an opportunistic 
comparative univariate analysis of the pre-incarceration TOP data vs. TOP outcomes data collected 
from those in community recovery was undertaken, so that an initial look at the extent of the 
lifestyle deterioration experienced by individuals in the period leading up to their incarceration 
might be tentatively described. 
 
1.5  Conceptual framework 
This study was conceptualised within a ‘systems thinking’ (or theoretical) and strategic 
commissioning framework. The conceptualisation presented here was initially developed from 
experiential observations associated with data flow and performance management issues. Those 
early data flow constructs were subsequently strengthened with the incorporation of some of the 
key elements of systems dynamics (Forrester, 1968, 1971) and soft systems methodology 
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(Checkland, 1999, 2012), the latter being a branch of managerial science that attempts to better 
understand and improve individual human and organisational level interactions. 
 
Figure 1: Drug system change located within a process linked to outcomes conceptual framework 
 
This study specific conceptual schematic positions the system change (green) within the broader 
Partnership or community systems, and defines several boundaries, both physical and virtual 
(information management), which may display closed or open properties. The recovery system 
incorporates clinical and non-clinical drug treatments, recovery support services, 
housing/accommodation agencies, employment/training/education (ETE) bodies, etc. The criminal 
justice system includes the police, probation, and judiciary. Dependent upon context, these systems 
may operate independently or may interact with each other; for the purposes of this model, the 
prison is located at the centre of interdependency between the two. The flow of people and 
information can be uni or bi-directional, as indicated by the double-headed arrows. The degree of 
influence, and the frequency of system interactions, are shown by solid (robust and many) or broken 
(weak and few) arrows.  
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1.6 Definitions 
For the purposes of this study, continuity of care was defined as the process of transitioning from 
prison to community drug recovery systems. This event was recorded as the first episode of release 
and pick up as reported by the prison-to-community DIRWeb data systems.  Treatment engagement, 
viewed as a study outcome, was defined as the first episode of release (case closed date, prison 
DIRWeb) linked to the first episode of treatment (triage date, community NDTMS); waiting times 
(process) were calculated accordingly.  Return-to-prison was also viewed as a study outcome and 
was defined as reappearing on the local prison (DIRWeb) system within twelve months of first 
release, as measured from discharge date (community NDTMS) to case opened date (prison 
DIRWeb). Assignation to the opiate- and or crack/cocaine-using (OCU) cohort followed the NDTMS 
business definitions and guidance as at 2009 (National Treatment Agency, 2009f). Individuals not 
recorded as ‘White British’ were coded to the black/minority or other ethnicity (BME) group. All 
study participants were adult males. 
The ‘system’ data (N = 808) reported here were comprised of three sub-organisational 
elements, namely CARAT (n = 255), InsideOut (n = 278) and HMP Other (n = 275). The CARAT activity 
data were collected between April 1st 2008 and March 31st 2010.  The InsideOut activity data were 
collected between April 1st 2010 and March 31st 2012. And the HMP Other activity data were 
collected between April 1st 2008 and March 31st 2012.  This latter group was comprised of people 
returning to the local drug recovery partnership from prisons located externally and is included to 
strengthen ‘system’ level outputs. 
Within this study’s context, the term ‘clinical’ refers to medical interventions, e.g. 
methadone maintenance (and its compliance), whilst the term ‘non-clinical’ refers to key (care) 
working and administrative/managerial/commissioning functions. For the purposes of clarity, this 
study is predominantly concerned with continuity of care as viewed from the non-clinical, 
administrative perspective, but does incorporate the ‘care’ aspect in order to help explain why rates 
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of prison-to-community continuity of care might may be influenced with the utilisation of peer 
mentors. 
 
1.7 Assumptions 
This study was conducted under the assumption that prison-to-community continuity of care was 
associated with increased rates of treatment engagement and reduced waiting times, and that drug 
treatment was associated with crime reduction. For the purposes of this study, it was also assumed 
that the local criminal justice system was ‘closed’. HMP Chelmsford is a local prison, meaning most 
Essex residents will be resident there prior to release and will be returned there upon 
reincarceration.    
 
1.8 Scope, limitations and delimitations 
This study was small-scale, non-randomised, and confounded, as—for example—it was unable to 
account for prison leavers who were drug-free. Lack of access to the national DIRWeb and NDTMS 
datasets restricted this study’s interpretations and generalisability. The possibility of researcher bias, 
given this author’s proximity and input into the service design and recommissioning processes, 
should be considered. If this line of research is developed, a suggested direction would be to apply 
an action research or soft systems method approach, incorporating professional perceptions and 
feedback relevant to systems integration. 
 
1.9 Personal role and motivation 
During 2001, the National Treatment Agency for Substance Misuse (NTA), an executive NHS agency, 
was created (National Treatment Agency, 2001) in direct response to the United Kingdom’s 
burgeoning heroin epidemic of the 1990s and early 2000s. The NTA’s remit was to deliver an 
efficient drug treatment system as directed by the principles and guidelines set out within the 2002 
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Models of Care for the Treatment of Adult Drug Misusers guidance (National Treatment Agency, 
2002, 2006). The NTA were tasked to commission and oversee the expansion and delivery of a high-
quality and consistent drug treatment system within the community and prison settings throughout 
England and Wales. In order to support the NTA’s performance aims and objectives, the National 
Drug Treatment Database Monitoring System (NDTMS) was developed to collect, monitor, and 
research client-level data (North East Public Health Observatory, 2001). During the initial 
development phases (2002-2004), as the London Region Database Manager I was involved in the 
implementation of what is now recognised as one of the country’s foremost statutory health data 
collection and monitoring systems.  
An interest concerning healthcare pathways located within the criminal justice system, and 
drug treatment compliance issues in general, began during the period of employment with the NTA, 
when it was noted that some clients were frequently in and out of the drug treatment system. This 
phenomenon appeared to be consistently associated with people recorded in the criminal justice 
dataset, which at that time was referred to as the Arrest Referral (AR) database and subsequently 
evolved into the Home Office's Drug Intervention Record Web-based (DIRWeb) system (National 
Treatment Agency, 2005). While personal interest developed alongside work experience with a Third 
Sector Organisation (TSO) specialising in criminal justice interventions, it was only in 2009 with the 
introduction of the Drug Systems Change Pilot (DSCP) programme, that the opportunity to research 
the prison-to-community continuity of care process, and evaluate a remedial intervention to 
improve performance, presented itself. This thesis reports those investigations. 
 
1.10 Organisation of the thesis 
The remainder of this thesis is presented in four chapters. Chapter Two critically reviews the 
literature associated with continuity of care and its association with the delivery of successful drug 
treatment outcomes. As the section progresses, continuity of care for people affected by drugs who 
are transitioning from prison to community drug recovery settings becomes the focal point; 
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attention is then drawn to research limitations and the sense of frustration experienced within the 
sector. A narrative is then developed to demonstrate how our understanding of the complexities 
and vulnerabilities associated with offending substance misusers has evolved from a simple linear 
model to complex clustered models of causality. 
The third section of the review presents a descriptive narrative of the development of the 
UK Government’s anti-drug strategy from a historical perspective.  Each iteration or major refresh of 
the strategy serves as an ‘anchor point’ along a timeline upon which other government 
departmental procedures (such as commissioning guidelines), influential (UK) academics, and other 
relevant publications are located. As this section is developed, there is an increasing focus on 
material related to drug-affected prisoner throughcare and aftercare journeys, especially within the 
context of crime reduction. The chapter ends with a section introducing systems theory and 
describes how that branch of managerial science facilitated the development of this study's 
conceptual framework.   
Chapter Three details the method(s) as per the STROBE guidelines. Also included is a 
description of the project activities within the associated timeline and presents the Process and 
Treatment Outcomes Research Study (PTORS) in its entirety. The requisite data sources are 
identified and a description of the audit activities undertaken to improve the quality of the data 
thereby maximising the number of matched statistical entities made available to this quantitative 
research is also included. The relational data modelling and development of the study-specific data 
process and outcome counting model is reported, and the quantitative analysis of the process and 
outcome outputs itemised. 
Chapter Four presents this study’s results in seven stages. In the first stage, the study 
group’s demographic is contextualised within the local, regional and national profiles.  In the second, 
the four-year outputs, generated by the study-specific counting model, are grouped into a ‘system' 
count to provide research context by answering the research questions.  In stage three, the study 
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demographic is interrogated for confounding factors.  Stage four tests this study's hypotheses with 
comparative and survival analyses of the CARAT vs. InsideOut continuity of care, treatment 
engagement and waiting times to treatment. Stage five places the prison-to-community 
performance outputs generated by this research within the contexts of the Home Office’s and 
latterly the Public Health England’s performance reporting mechanisms so that the local 
performance activities reported by this study can be compared to national, other system change and 
similar drug recovery partnerships. The chapter concludes (stage six) with an opportunistic 
comparison of the self-reported TOP data of people relapsing to prison versus those who recovered 
in the community. 
 Chapter Five places the main findings of this study within the context of the literature and 
suggests how this research has reinforced and contributed to that knowledge base. The study’s 
influence regarding local commissioning practice and policy, and the influence of systems theory 
upon commissioning strategy in general, are also discussed. Study limitations and potential 
researcher biases are expanded upon and the chapter concludes with suggestions for the direction 
of future research.  Where possible, the Strengthening the Reporting of Observational studies in 
Epidemiology (STROBE) guidelines (Vandenbroucke et al., 2007) were applied, although not 
necessarily in the order published. 
 
1.11 Summary 
Although this is predominantly an applied piece of work, I propose that the study’s intellectual 
weight lies in the following: (1) its conceptualisation of the prison-to-community continuity of care 
transition within a process linked to outcomes framework, informed by systems theory; (2) its 
development of a CC/RTP counting mechanism, utilising relational data modelling techniques as 
applied to the statutory data sets at that time; and (3), the impact of the introduction of the 
combined prison and community InsideOut drug recovery service via the realigned prison drug 
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treatment funding streams as per the ‘Freedoms and Flexibilities’ granted within the remit of the 
2009 Drug Systems Change Pilot. Should this line of research not be developed further, this study’s 
legacy will be its leading role regarding the introduction of the NDTMS into the UK prison health care 
system. 
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Chapter 2 – Literature review 
2.0 Introduction 
This study is primarily concerned with the delivery of continuity of care from within a strategic 
commissioning and information management context, and relies on a systems (non-reductionist) 
approach to problem-solving within that environment.  This critical review, set within an historical 
and descriptive framework, presents this programme of research and evaluation from three 
perspectives, namely: (1) the prison-to-community continuity of care transition viewed through the 
lenses of clinical and non-clinical delivery; (2) the complexity and vulnerability associated with 
substance-misusing offenders; and (3) implementation of the drug treatment system(s) within the 
context of the UK Government’s anti-drugs strategy.   
Within each theme, the emphasis towards either a descriptive or a critical narrative is 
dependent upon this study’s focus, namely the delivery of continuity of care from a commissioning 
perspective.  For instance, the mainly academic literature describing continuity of care within the 
clinical context is critically reviewed, albeit from within a descriptive and historical framework, whilst 
the subsequent section, dealing with complexity and vulnerability, is less so.  The aim of that section 
is to describe the development of our understanding of causality as a means of emphasising the 
challenges associated with providing care to substance-misusing offenders, rather than critically 
reviewing the nature of causality (and its contribution towards policy formation) per se.   
Similarly, because the section dealing with policy and drug treatment system(s) 
implementation is primarily concerned with highlighting the frustrations associated with delivering 
continuity of care across silos and within an environment of staggered delivery, an historical 
descriptive narrative, informed by a large volume of non-peer reviewed literature, takes precedence. 
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2.1 Continuity of care and substance misusing prisoners 
Continuity of care (CC), also referred to as throughcare and aftercare, is comprehensively 
understood as key to delivering successful treatment outcomes in both general settings (National 
Institute for Health Care Excellence, 2014) and drug treatment settings (National Treatment Agency, 
2009c). And whilst prisoner continuity of care research is ongoing (Grace et al., 2016; C. Lloyd & 
Page, 2015; Scaggs et al., 2015), there are few, if any, quantitative non-clinical studies devoted 
entirely to the process of CC when associated with drug-affected prisoners at the point of their 
release. 
From a performance perspective, the delivery of CC within the criminal justice context has 
exercised commentators for some time (Edwards, Gunn, Kilgour, & Smith, 1985; Gulland, 2010; 
MacDonald, Williams, & Kane, 2012), and yet its systematic delivery, targeted towards drug-affected 
people leaving prison, has remained elusive (Dyer & Biddle, 2013; The All Party Parliamentary Drugs 
Misuse Group, 1998).  Following the publication of the UK Government’s first national anti-drugs 
strategy in 1995, successive academic, policy and guidance publications have advocated and 
reinforced the importance of delivering CC to this high-risk and vulnerable offending group of 
people. And yet, by 2004 and the publication of the Reducing Re-offending National Action Plan, 
little if any progress could be reported (Home Office, 2004a); and more recent initiatives, namely the 
‘Through the Gate’ programme, appear to have had no substantive impact on the rates of relapse to 
drugs misuse and recidivism amongst (short-term) prisoners (HM Inspectorate of Probation, 2016). 
The following sections review and discuss CC as viewed from the clinical and non-clinical 
perspectives. For the purposes of this study, the non-clinical perspective takes primacy because 
ultimately this study’s focus is the commissioning and information architecture of the system 
providing the delivery of prison-to-community continuity of care rather than with the delivery of 
drug treatment as such. 
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2.1.1 The clinical perspective 
Since the 1980s, quantitative evidence has been building describing improved health and crime 
outcomes that may be realised by people engaging with drug treatments. Notable contributions 
describing prison to community continuity of care can be attributed to the criminal justice drug 
treatment research teams located in Oregon (Field, 1989, 1998), Delaware and Texas (Broome, 
Knight, Hiller, & Simpson, 1996; Broome, Knight, Joe, & Simpson, 1996; Hiller, Knight, Devereux, & 
Hathcoat, 1996; Hiller, Knight, & Simpson, 1999, 2006; Knight, Simpson, & Hiller, 1999), and latterly 
the Baltimore team (Gordon, Kinlock, & Schwartz, 2008; Gordon et al., 2014; Gordon, Kinlock, 
Schwartz, & O'Grady, 2008a; Kinlock, Battjes, & Schwartz, 2005; Kinlock, Gordon, Schwartz, & 
O'Grady, 2008; Kinlock et al., 2007; Kinlock, O'Grady, & Hanlon, 2003; Lee et al., 2016). 
Within the UK setting, substantive contributions to the field can be attributed to, for 
example, Gossop, Strang, Marsden, Best (Best et al., 1999; Best, Man, et al., 2001; Gossop, 2015; 
Gossop, Marsden, & Stewart, 1998, 2000; Gossop et al., 1997a; Gossop, Marsden, Stewart, & Kidd, 
2003a; Gossop, Marsden, Stewart, & Rolfe, 2000a, 2000b; Gossop, Marsden, Stewart, & Treacy, 
2001; Gossop, Trakada, Stewart, & Witton, 2005; Stewart, Gossop, Marsden, & Rolfe, 2000; Strang et 
al., 1997; Unnithan, Gossop, & Strang, 1992). 
In terms of quantitative findings, early research undertaken in the United States (US) 
reported that completers (N = 43, average time in treatment = 11 months) of the Oregon 
‘Cornerstone’ prison drug treatment programme were more than four times less likely to be 
rearrested (no arrest rate = 37%) than those dropping out (N = 65) within two months (no arrest rate 
= 8%) (Field, 1989).  Similarly, the Delaware team, whilst evaluating the effectiveness of prison drug 
treatment, compared the rates of relapse and recidivism for those having received drug treatment 
pre- and post-release, with those having received treatment in prison only, reporting that prisoners 
engaging with community rehabilitation had a four times lower risk of relapse and less than half the 
risk of recidivism within the first eighteen months of their release (Inciardi, 1995; Inciardi & Martin, 
1993). 
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Building on those observational findings, Martin et al (1999) proceeded with a quasi-
experimental design and compared the outcomes for four groups; namely, prison treatment, 
community treatment, both prison and community treatment, and a control group. In that study, 
the twelve-month outcomes were positive in terms of relapse and recidivism rates, but after three 
years, the combined treatment effect appeared to have had no impact.  However, when the sample 
was restructured to the following: comparison group (N = 210), dropouts (N = 109), treatment 
completed (N = 101) and treatment completed with aftercare (N = 69), the group that received 
aftercare reported significantly lower rates of recidivism and relapse at the three-year point. 
Subsequent studies have reported similar trends. For example, in San Diego, California, a 
randomised experiment of prisoners assigned either to no treatment, or intention to treat (ITT) 
reported that within the ITT group (N = 425), dropouts from prison treatment only (n = 98) and 
prison treatment completers but aftercare dropouts (N = 35) were almost six times more likely to be 
reincarcerated than those completing both prison and aftercare programmes (Wexler, De Leon, 
Thomas, Kressel, & Peters, 1999).  And in Texas, a three-year outcome study that had allocated 
prisoners to: no treatment group (N = 103), prison treatment only (N = 123), and prison and 
community treatment group (N = 179), found that the cohort receiving prison and community 
aftercare were least likely to relapse.  In their analysis, 25% of that group, compared to 64% of the 
aftercare dropouts and 42% of the untreated comparison groups, were reincarcerated (Knight et al., 
1999). 
In 2004, a subsequent analysis of the Delaware cohort (N = 680) reported that at the five-
year follow-up point, prison treatment completers (in receipt of aftercare) were four times more 
likely to be drug-free, and half as likely to have been rearrested, compared to those dropping out 
(Inciardi, Martin, & Butzin, 2004). Later, a randomised clinical trial (N = 211) assessing the impact of 
delivering methadone treatment prior to and shortly after release found that those receiving 
methadone treatment and counselling (N = 71) were significantly less likely to test positive for illicit 
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heroin use and self-reported significantly less crime at the six-month follow-up point (Gordon, 
Kinlock, Schwartz, & O'Grady, 2008b). 
An observational study (N = 357) of the characteristics of those returned to prison within the 
mid-west (Kansas) setting, reported significant differences between programme completers and 
those who dropped out.  At all follow-up points (six, twelve, eighteen and twenty-four months), 
treatment completers were significantly less likely to be reincarcerated.  At the twenty-four-month 
point, 51% of dropouts compared to 35% of completers had been returned to prison (Severson, 
Veeh, Bruns, & Lee, 2012).  And a Canadian retrospective outcomes study (N = 856), comparing the 
return-to-custody rates of those receiving methadone maintenance post-release with those that did 
not, found significant reductions in recidivism in those continuing with their treatment (Macswain, 
Farrell-MacDonald, Cheverie, & Fischer, 2014). 
Whilst reviews continued to promote prisoner re-entry continuity of care, an underlying 
sense of frustration with the rate of progress could be detected. For instance, Prendergast (2009), in 
his systematic review of drug treatment effectiveness within the prison and community settings, 
dedicated a section to continuity of care and reported that no clear guidelines existed (at least 
within the US setting) which described the important role of continuity of care in reducing relapse 
and recidivism. However, and importantly for the purposes of this study, in conclusion, he suggested 
the possible value of using a single provider for delivering both prison and community treatment. 
And McKay (2009), having reviewed the continuity of care literature in general from three 
perspectives (1 quasi-, 2 experimental and 3 retention studies), suggested that if continuity care was 
less clinically-driven then treatment outcomes might be improved. 
 Engaging with drug treatment has been shown to promote secondary clinical and non-clinical 
gains.  For instance, in their randomised study (N = 157) of clients engaged by the Baltimore City 
Drug Treatment Court, Gottfredson et al  (2005) assessed the level or quality of relationships, 
education, wealth, mental disability and physical health and reported lower crime rates in the study 
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group compared to their control sample. Their research further reinforced that the development of 
Interventions for Seropositive Injectors – Research and Evaluation (INSPIRE), an integrated 
intervention for HIV-positive IDUs, had resulted in improved utilisation of HIV care, improved 
adherence to HIV medications, and reduced sexual and injection risk. The authors emphasised that 
there was a need for an integrated intervention for HIV-positive IDUs, and these data supported the 
acceptability of such an approach.  
In a similar context, Vlahov et al (1998) explained that enrolment in the Baltimore Needle 
Exchange Program (NEP) was associated with short-term reduction in risky injection practices. 
Consequently, Visher’s (2003) report proposed that the policymakers and service providers need to 
develop drug recovery wings that may assist in how to release and monitor prisoners returning to 
Baltimore and navigate these challenges of re-entry. In this regard, integrated care services may 
have a protective influence regarding subsequent drug use and delinquency behaviours. 
From within the UK perspective, the research outputs generated by the National Treatment 
Outcomes Research Study (NTORS) (Gossop et al., 1995-2000) and latterly the Drug Treatment 
Outcomes Research Study (DTORS) (Donmall, Jones, Millar, Barnard, & Davies, 2006-7) teams have 
substantively contributed to our understanding of the individual and societal health, crime and cost 
benefit outcomes, that may be realised from engagement with treatment for substance misuse. 
Research participants were recruited to the NTORS prospective study (N = 1075, from 54 
community drug treatment centres) during the spring of 1995 and were followed for up to five years 
(Godfrey, Stewart, & Gossop, 2004; Gossop, Marsden, Stewart, & Kidd, 2003b; Gossop, Marsden, 
Stewart, et al., 1998; Gossop, Marsden, Stewart, & Rolfe, 1999; Gossop, Marsden, et al., 2000a; 
Gossop et al., 2001; Gossop et al., 2005).  The study was the first of its kind within the UK setting and 
its findings, regarding the beneficial health, mortality and crime outcomes that might be realised 
from engaging with drug treatments, have significantly influenced drug treatment policy (Gossop, 
2015; Gossop, Marsden, & Stewart, 2000). 
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The DTORS programme of research began in 2006 (Donmall et al., 2006-7).  Of the 1796 
people recruited (from 94 areas), 504 were followed up and interviewed at about the one year point 
(Jones et al., 2007).  And whilst mainly supporting and strengthening the positive health and crime 
outcomes reported by the PTORS group (Jones et al., 2009), this study further developed a cost 
benefit analysis suggesting that for every £1.00 invested into drug treatment a £2.50 saving might be 
realised (L. Davies, Jones, Vamvakas, Dubourg, & Donmall, 2009). 
From within the clinical perspective, drug treatment has been demonstrated to improve 
health crime outcomes and reduce societal costs, however, not all reviews have been wholly 
supportive.  For example, Hedrich et al (2012), having undertaken a systematic review of 
experimental and observational studies within the European Union (EU) setting, reported that, if 
continuity of care arrangements were in place, engagement with treatment in prison predicted 
engagement with community treatment, but had no significant effect on the rates of crime and 
reincarceration. McDonald et al (2012) went further: from their analysis of healthcare availability 
within the EU criminal justice system in general (with a focus on continuity of care or throughcare), 
they observed that CC was patchy and not properly monitored, and emphasised the lack of 
coordination between prison and community systems. 
 
2.1.2 The non-clinical perspective 
As therapeutic evidence accumulated, the case for an increased focus on prisoner continuity of care 
from the non-clinical perspective has strengthened.  For example, early contributions came from 
Anglin and Maugh (1992), whose review of the associations between drug treatment and crime 
reduction identified certain strategies to maximise treatment. They suggested that ‘upon completion 
of the in-prison portion of their rehabilitation programs, probationers and parolees should be 
enrolled in community-based treatment programmes’ (p. 86). Moreover, in his paper ‘Reducing 
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Recidivism Through A Seamless System of Care’, Taxman (1998) proposed that a systemic case 
management system was required to improve the prison-to-community transition. 
For the purposes of this study, non-clinical refers to: (1) client care and support outside of 
clinical interventions such as opiate substitute prescribing; (2) administrative implementation and 
performance monitoring; and (3) the process of continuity of care located within a systems 
paradigm.  The theoretical aspects of care are briefly highlighted here because, whilst this study’s 
primary concern is with continuity of care viewed as a process within a system, a key element of the 
InsideOut service was the introduction of volunteer peer mentors to assist with the transition from 
prison to community drug recovery settings.  This type of additional care, targeted towards 
substance-misusing prison leavers, whilst innovative to the local drug recovery system, is well-
established nursing theory and practice and is likely to have contributed to the improvements in 
continuity of care reported in this study. 
Theories of care 
Outside of the clinical or adherence to treatment contexts, continuity of care can be viewed as a set 
of (non-clinical) coordinated activities (clinician- and / or care team-led) directed towards delivering 
ongoing quality healthcare during the patient or client’s treatment episode (Metz, Chard, Rhodes, & 
Pounder, 2004).  Quality continuity of care in the general sense decreases fragmentation of care and 
improves patient safety (Homer, Brodie, & Leap, 2008).  A key aspect of delivering continuity of care 
holistically is the notion of service integration (2009), which can be viewed from various aspects. 
For instance, Hunt (2009) suggests that in the community, healthcare providers may 
contribute towards continuing care by visiting patients at home to assess progress and help with 
arranging other services. In terms of patient data management, continuity of care can be enhanced 
with integrated information systems which are viewed as necessary to seamless transitions with the 
continuum. Quality of care requires data that follow the patient for a period across several health 
settings (Ball, Hannah, Newbold, & Douglas, 2009) and integrated data management systems may 
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contribute towards patient-centred care models.  And importantly for this study, there is the notion 
that case management services can harmonise transitions within and across care settings, especially 
for vulnerable people (Cohen & Cesta, 2005).  Given the nature of the intervention reported here, 
the last two examples are of interest.  
Theories of care have evolved as the nursing profession has developed (Smith & Parker, 
2015), and a number have come to the fore.  For instance, Watson’s ‘Theory of Caring’ – which, 
adopting an existentialist phenomenological approach, focuses on the patient’s body, mind, and 
spirit – embraces continuity of care as key to successful treatment outcomes (Jean Watson, 1999; J 
Watson, 2012).  Peplau’s theory describes care as an essential, interpersonal, and therapeutic 
process; it involves concepts such as assessment, communication methods, defining of problems and 
goals, responsibility clarification, and direction (Ziegler, 2005). The interpersonal theory is 
particularly useful within psychiatric nursing, dealing with psycho-social problems and the ‘ideal 
bond’ between nurse and patient (Basavanthappa, 2007). Orem’s self-care theory is comprised of 
three linked theories incorporating self-care, the theory of nursing systems, and the theory of self-
care deficit. Orem referred to every individual as a ‘self-care agent’ who can conduct self-care 
actions (Meleis, 2011). The responsibility of a nurse is to facilitate, besides augment, the self-care 
capacity in a healthcare institution. This theory embraces continuity of care for patients in homes 
and healthcare facilities among others by providing universal language in self-care, thus leading to 
enhanced communication and improved constancy in care delivery by building agreement regarding 
the goals and outcomes of nursing (Renpenning & Taylor, 2004).   
Johnson’s Theory integrates the nursing process into a general systems model. Johnson 
applied this model to care for a patient with the intention of testing, assessing, and determining its 
usefulness for predicting the impact of nursing care on a patient (Manning, 2010). In this theory, it is 
considered that subsystems interact with each other whereby the environment is said to be 
constantly acting on them. This theory embraces the continuity of care by allowing nurses to assist 
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patients in restoring the subsystems to balance and accomplish the best probable operational 
behaviour. Depending on the condition of the patient, the nurse is supposed to support the patient 
by making alterations to the environment as required and helping the patient to develop new 
behaviours (Alligood, 2014).  
Roy’s Theory advocates that an individual adapts to the environment through four modes, 
namely physiologic needs and processes, role mastery, self-concept, and interdependence 
(Swansburg, 1996). Simply, as the patient adapts to the transformations in the environment, so does 
the nurse who is delivering care to the patient. The purpose of the nurse in any healthcare 
institution is to assist the patient to adapt to the illness so that he/she could be capable of 
responding to other stimuli (Shives, 2008). This theory supports the continuity of care by enabling 
patients to adapt to their illness so that they can receive the full benefit of nurses’ care.  
In conclusion, the continuity of care is attained through discrete bridging components in the 
care pathway, whether mixed episodes or interferences by different care providers. Continuity of 
care exists where there are experienced health professionals. The experience of continuity for 
patients is the perception that care providers know what occurred previously so that nurses can 
agree on a consistent management plan for the treatment. 
Performance 
Within the UK setting, a likely early impediment to the delivery of prison-to-community continuity of 
care can be traced to the ten-year period prior to the launch of the UK Government’s 1995 anti-
drugs strategy (Lord President of the Council, 1995). At that time the Probation Service, whilst being 
directed to lead on the coordination of offender resettlement, was discouraged from doing so (M. 
Lloyd, Calderbank, Moore, Allen, & Flaxington, 2001).  Specifically, the Probation Service was 
directed not to prioritise prisoner aftercare and other post-release support (Home Office, 1984).  
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During this period, concerns were raised, not only about the growing numbers of people 
entering prison, but also – importantly in the context of this research – about the perceived lack of 
continuity of care directed towards prisoners upon their release. In correspondence to the British 
Medical Journal, detailing the minutes of a meeting discussing the state of prison health care and 
NHS collaborations operating in the Trent area, the plight of drug users within the prison system was 
made explicit (Edwards et al., 1985). The authors commented that ‘the community drug services 
were at that point not properly configured to accept drug-affected prisoners upon their release’ (p. 
1698), and observed that the community treatment centre environment experienced by those 
released would almost certainly encourage relapse because of their proximity to the drugs scene.  
They concluded that not enough was being done at discharge in terms of aftercare and, 
contradictory to the Home Office directive, suggested that the Probation Service should take a more 
proactive role in the delivery of continuity of care (Edwards et al., 1985). 
The Carlisle Committee (1988) acknowledged that the Home Office Probation directive was a 
strategic mistake, and announced that the 1984 statement was one ‘that we very much regret… . 
Reducing the priority of work with prisoners does not seem to us to be consistent with the overall 
objective of preventing further offending’ (p.90).  The UK Government responded in the form of the 
Criminal Justice Act 1991, within which the concepts of throughcare and aftercare, and the 
importance of their contributions towards preventing reoffending, were re-established.  The Act 
directed that prisoners should serve half of their sentences in the community under supervision, and 
required that a renewed emphasis be placed upon prisoner throughcare and aftercare (HM 
Government, 1991, 2003). 
However, systemic impact on the rates of prison-to-community continuity of care appeared 
muted, and towards the end of the decade, whilst it was noted that good progress had been made 
by a few dedicated prisoner staff committed to improving drug treatment provision, the All Party 
Parliamentary Drugs Misuse Group (1998) reported that they were ‘profoundly concerned’ as to the 
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level and the scale of the response, and emphasised that ‘thorough comprehensive care and 
aftercare of drug abuse and addiction among prisoners has been much neglected, since there is no 
other way to define it. We are in fact at a loss to find logical explanations of efforts aimed at 
rehabilitating short termed or remanded prisoners. Hence, it is subjective to declare that the 
remanded prisoners are the very individuals who are chronic drug users and usually steal in order to 
fund their addiction’ (para. 2.1.iv). 
This criticism was acknowledged and a response came in the form of the updated prison 
anti-drugs strategy of the same year (HM Prison Service, 1998), detailing extra funding to facilitate 
the introduction of the Counselling, Assessment, Referral, Advice & Throughcare (CARAT) schemes 
(HM Prison Service, 1999).  However, issues regarding implementation were soon realised, 
particularly regarding CARAT’s capability to deliver seamless throughcare and aftercare. Mitchell 
(1999) noted that ‘although the CARAT vision was to set up multidisciplinary schemes to incorporate 
uniformed prison staff, probation, health voluntary sector drugs workers into the CARAT equation, in 
reality and caused by prison service contracting restraints, the Probation Service were largely 
omitted’ (p, 253). This reduced the effectiveness of the CARAT provision because, without Probation 
input at the assessment and release planning stages, continuity of care was much more difficult to 
deliver. 
Further concerns were raised within the Drug Prevention Advisory Service report, which 
identified gaps in service provision and concluded that ‘large gaps in provision remain at the point of 
arrest and on release from short term…sentences’ (p. 56) and, for what appears to be a first within 
the UK literature, identified that this most problematic and high-risk of cohorts had remained 
neglected because they fell outside of statutory obligations (Edmunds, Hough, Turnbull, & May, 
1999). 
Moving into the new millennium, the organisational obstacles impacting on CC appear to 
have remained. In their assessment of the throughcare and aftercare outcomes of a small prisoner 
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cohort drawn from two London prisons, Mitchell and McCarthy (Mitchell & McCarthy, 2001) 
accentuated that one-third of prisoners of the two prisons are passed through detoxification 
services, yet this information is not a part of prisoner’s file and is not subsequently released during 
the planning of therapeutic regimes. It was important to note that while some of the component 
integrated care services were observed, better coordination and linkages were required to maximise 
the benefits of detoxification and addiction treatment in prisons (p.205).  
Limited progress was also reported by Burrows et al (2000). In their report to the Home 
Office, they noted that, whilst heroin use declined by 20% after release, only 11% of those released 
benefitted from a structured appointment with their community provider. They observed that 
substantive barriers – or as they termed it, ‘structural impediments’ – remained to the rational 
provision of throughcare which, they suggested, might be due to the nature of the recovery systems 
themselves. For instance, there was an overwhelming number of possible community contacts a 
prison worker organising a release package might have had to deal with; he or she might have had to 
contact one of 54 Probation Trusts for resettlement, one of 142 Local Authorities for 
accommodation needs, social services, etc., and one or more of the 700 community drug agencies 
and their respective health authorities (p. 2). 
This was substantiated by Harrison et al (2001) who, whilst reviewing prison drug treatment 
throughout the South East of England, noted that although treatment within prison was becoming 
established, it had been more ‘difficult to influence throughcare and aftercare’  (p.476).  They 
suggested that that difficulty reflected the complexity of the multi-agency arrangements then in 
place. Interestingly, they noted that an element of ‘game-playing’ might have been involved, 
especially by the community agencies. Their view was that the community teams might have 
deprioritised their initial post-release aftercare responsibilities to the CARAT service, because 
technically that element of the care pathway was viewed to be out of scope. They extended this 
observation by suggesting that the gaming element might have involved senior players representing 
36 
 
the Home Office and the Department of Health by way of offloading expense to each other in an 
environment of competition and scarcity of resources (Harrison, Capello, Alaszewski, Appleton, & 
Cooke, 2003). 
From the prison perspective, the Prison Inspectorate Lloyd et al (2001) reported that a major 
factor affecting the delivery of prisoner aftercare was that the community drug services were ill-
prepared to receive abstaining prisoners because their treatment systems were geared towards 
harm reduction.  This observation brought the philosophical tensions between the two recovery 
domains, i.e. punishment vs. rehabilitation, into focus. Fox (2002) reinforced the latter point by 
drawing attention to a European study which described the presence of a fundamental conflict of 
approaches. She identified that the key difference between the two recovery domains was that on 
the one hand the prison setting naturally fostered a punitive mindset, whereas on the other, 
community provision was more likely to be founded upon the rehabilitative approach. She also 
highlighted the importance of stable housing, employment, financial, and family arrangements as 
crucial to the aftercare package. 
The Social Exclusion Unit’s report, ‘Reducing re-offending by ex-prisoners’ (2002), whilst 
observing that the delivery of drug treatment throughout the prison estate was progressing, also 
noted that all the positive work undertaken within the prison environment was not being carried 
through upon release. They found that ‘no one was clearly in charge of joining up treatment 
between prison and the community’ (p.65) and highlighted that, although contractually obliged, the 
CARAT teams were not routinely offering the (up to) eight weeks of post-release support, as per 
their remit. This aspect was either not recognised by some workers, or could not be fulfilled because 
of other work pressures. The report noted that, ‘…community and the prison-based addiction 
services are considered as funded for separate services; hence, prisoners are viewed as new cases 
when they are released and they have to join the back of the queue’ (p.65) – a concerning 
observation, given the APPG’s comments some four years earlier. 
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In their review of drug treatment in the English and Welsh criminal justice settings, Kothari 
et al (2002) recommended that throughcare should be given a higher priority, and that drug 
agencies should be organised to deliver care to the prisoner on release. They emphasised ‘that 
through the whole process, continuity of care needs to be promoted and a holistic approach be 
adopted’, (p.17) and whilst acknowledging the introduction of the CARAT schemes, asserted that 
‘effective and sustained delivery of the schemes will be a major challenge’ (p.19). 
In the foreword section of Ramsey’s 2003 report, Carol Hedderman stressed that a major 
theme of the seven studies under evaluation within the report was the prime importance of 
aftercare to treatment effectiveness: ‘Without good quality aftercare both in and on release, 
treatment is much less likely to be successful’ (Ramsey, 2003). Specifically, and drawing on mainly US 
evidence, the report concludes that if quality treatment is to be effective in reducing re-offending, it 
must be adequate in length, meet individual needs, and ‘above all, [must be] followed through with 
aftercare within prison and on release’ (p. vi). The report concluded that ‘good quality aftercare 
(both for the remainder of the period of imprisonment and also on release) is absolutely vital to the 
success of treatment in prison’ (p. viii). 
During this period, as observations focussed towards the structural impediments associated 
with poor rates of prisoner continuity of care, the language associated with systems concepts could 
be seen to be emerging. For instance, in Carter’s report ‘Managing offenders, reducing crime’ (2003), 
the criminal justice system was observed to be ‘dominated by the need to manage two systems, 
rather than focussing on the offender and reducing re-offending’, and it was noted that there 
‘remain gaps in the system with, for example, interventions in the prison not being followed up in 
the community’ (p.4). 
By this time the CARAT schemes had become established, and yet effective delivery of 
prison-to-community continuity of care (a core remit) remained problematic.  In their evaluations of 
five CARAT schemes based in the North West of England, Harman and Paylor initially concluded that 
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the CARAT schemes were failing to ‘bridge the gap’ (2004) and subsequently reported that little or 
no effective continuity of care was being delivered (2005). They observed that, although all the 
teams being evaluated were fully cognisant of their post-release responsibilities, there was an 
unwritten policy of ‘no work to be undertaken’ with those released, and that time and resources did 
not allow for it. Their research indicated that the CARAT teams were working to achieve the 
minimum performance standards as opposed to ‘offering an effective post-release service’ (p.358). 
Also during this period, the Judiciary’s shift in sentencing policy (Ministry of Justice, 2016) 
and its impact upon the plight of the non-statutory (serving less than twelve months) prisoner 
cohort were being realised.  Burke and co-workers (2006) clarified the need for robust continuity of 
care practices and identified complex partnership work as a potential barrier to successful prisoner 
re-entry. They drew attention to the long waiting times (three to four weeks) experienced by prison 
leavers referred to the community drug treatment services and, perhaps more worryingly, that some 
clients felt that the waiting lists ‘were being used as a tool to test their commitment’ (p.113), leading 
many of those released to return to drug use almost immediately.  They concluded that the period 
immediately following release was crucial in terms of relapse, and that ‘reintegration is both an 
event as well as a process, and if initial re-entry is not achieved, there is less chance of successful 
long term resettlement’ (p.121). 
Failure to engage with treatment soon after release was also associated with significantly 
elevated risks of overdose and deaths (Mills, 2004), thus reinforcing the case for better coordinated 
prisoner throughcare and aftercare. In their review of the UK Home Office ‘Pathfinder’ prisoner 
resettlement project, Lewis and colleagues reported professional frustrations with long waiting lists 
for drug treatment post-release (Lewis, Maguire, Raynor, Vanstone, & Vennard, 2007). In 2007, as a 
part of its assessment of progress to the ten-year anti-drug strategy and with a view to addressing 
prison system-related drug treatment issues, the UK Government engaged a team of independent 
consultants (PriceWaterhouseCoopers) to review prison-based drug treatment funding. In their 
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report (2008) they observed that, whilst significant progress had been achieved regarding the 
provision of care and drug treatment within the prison system, implementation of robust continuity 
of care practices between the prison and community drug recovery systems remained fragmented. 
They remarked that the situation may have been exacerbated by the limited access and lack of 
information sharing between the DIP and CARAT teams.  They suggested that data attrition – caused 
by loss of hard-copy records during transition, and the fact that the separate electronic information 
systems did not facilitate data sharing – had made monitoring the CC transition difficult. However, 
they did find evidence of ‘well-managed transition arrangements between community, prison, and 
out again’, but concluded that ‘such instances were rare’ (p.18). Importantly within the context of 
this study, a key recommendation from that report was that ‘continuity of care of entry to and 
release from prison would be facilitated with the DIP and CARAT’s service being commissioned as 
one combined service’ (p.22). 
Partly in response to the PwC report, but mainly resulting from a consultation of 
professionals employed by the Prison, CARAT and community drug services, the NTA published their 
process guidance for continuity of care between prison and community (National Treatment Agency, 
2009c), within which was the tacit acknowledgement that the CARAT initiative had failed.  From that 
point they advised that the CARAT and Prison Health Care teams should be referred to as the 
‘Substance Misuse Team’ (p.3).  However, from 2009 onwards, the focus on prisoner continuity of 
care, at least from a performance perspective, appears to have diminished.  A change of government 
in 2010 and the integration of the National Treatment Agency into the Public Health England 
function have led to a move away from the central and regional performance structures and 
corresponding shifts in priorities.  Whilst prison-based drug treatment research conducted in the UK 
is ongoing (Callanan, Turley, & Simpson, 2014; C. Lloyd & Page, 2015), there appears to be little 
appetite to revisit prisoner continuity of care from within a strategic commissioning context, and – 
given the current situation within the UK prison system (2015) –there perhaps is the possibility that 
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giving less priority to CC is likely to result in more relapses ultimately leading to further pressures on 
the prison system. 
Since 1993, the UK prison population has doubled (Ministry of Justice, 2016), the Probation 
Service has undergone a significant restructuring (National Audit Office, 2016), and austerity 
measures have reduced the Prison Service budget year-on-year since 2010 (The Guardian 
Newspaper, 2014).  Combined with other factors associated with, for example, client complexity 
(discussed in the next section), efforts to deliver effective continuity of care journeys for prisoners at 
the point of release have been confounded.   
There have been several wide-ranging reports that have attempted to influence and 
reinforce the prison-to-community continuity of care agenda.  For instance, Warren’s White Paper to 
the US Department of Justice’s Institutes of Crime and Justice and National Corrections (Warren, 
2007), promoting the use of evidence-based practice (EBP) to reduce rates of recidivism, emphasises 
that ‘effective interventions … are based on chronic care model requiring a continuous framework of 
care, aftercare and support. Further, by securing the offender’s commitment to the rehabilitation 
care services, compliance with therapeutic regime and needed progressive monitoring and 
assessment of both program operations and offenders’ outcomes’ (p.68). 
In the UK setting, there have been two notable contributions.  Although not targeted 
towards substance misusers specifically, Bradley’s review of people with mental health problems or 
learning disabilities in the criminal justice system (2009) did incorporate people with dual diagnosis.  
The fundamental themes that resonate throughout the report include assessment at earlier stages 
of treatment regimes, the continuity of care, support of the offenders, and working in partnerships 
for better flow of information and later the report directed that the prison mental health teams 
need to form linkages between liaison and diversion services in order to ensure that better planning 
for continuity of care is in place prior to a prisoner’s release (p.110). 
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In 2010, Lord Patel published his comprehensive report entitled ‘Recovery and rehabilitation 
for drug users in prison and on release: recommendations for action’ (2010), in which a focus on 
prison-to-community continuity of care was firmly established within its primary remit (p.6) and 
reiterated more than thirty times throughout.  And within the context of this study, the key 
recommendation was supportive of the system change evaluated here: 
‘The appropriate place to develop a clear ‘menu’ of evidence-based, effective and cost-
effective services would be within a new national framework that spans drug treatment in 
the community and in prison to ensure consistency and continuity of care as people are 
released from prison’ (p.15). 
Whilst there appears to be a theoretical consensus that the prison-to-community continuity 
of care transition is key to improving health and crime outcomes, operationally, poor rates of prison-
to-community continuity of care have persisted (Gulland, 2010).  And relatively recent initiatives 
introduced to improve prisoner transitions and resettlement – for instance, the combined 
‘Resettlement Prisons’ and ‘Through the Gate’ schemes (Ministry of Justice, 2013) – have had little 
impact (National Audit Office, 2016). 
The commissioning architecture had not been conducive.  For instance, prior to the Drug 
Systems Change Pilot Programme, funding for drug treatment among prisoners in England (the 
Pooled Treatment Budget) had been relatively protected from significant reductions at the time of 
research. However, the level of future funding allocations was an area of concern, together with the 
money movement of this into the public health budget and removal of the ring-fence. On the other 
hand, the current context was seen as a positive opportunity for integrating services, in particular for 
increasing investment in alcohol interventions. 
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Critique of continuity of care 
The continuity of care literature reviewed by this study predominantly focuses on the health and 
crime outcome gains that might be achieved when people engage with the drug treatment services 
in general and upon their release from prison. And, whilst emphasising the importance of continuity 
of care, most of the studies reviewed have been less concerned with the process itself.  Most studies 
were small and, to date, there appears to be a single instance of a large experiment where prison-to-
community continuity of care is reported as a primary concern, (National Institute of Corrections, 
2012) and a single case where commentators have made suggestions pertinent to this research, i.e. 
the delivery of treatment in the prison and the community settings delivered by the same provider 
(Gordon et al., 2014). 
Whilst there is a common understanding that the process of continuity of healthcare is 
fundamentally associated with successful drug treatment outcomes, it is apparent, from this 
research’s review of the literature, that its implementation into the prison side of the UK criminal 
justice system can be predominantly viewed as having been ineffective. The management of short 
term prisoners at their point of release appears to have been poorly coordinated.  
During the ten-year period leading up to the launch of the 1995 UK anti-drug strategy, there 
appears to have been little research activity (in the UK at least), as observed by Hough who, one year 
into the 1995 drug strategy, noted that the literature on the topic of drug rehabilitation in prisoners 
after their release from prison has little to add to the value of aftercare (Hough, 1996). The author 
further explained that if the fundamental aspect of a successful treatment is in keeping offenders 
confined, there is no logical need to coordinate between programmes that are offered in the prisons 
and those offered by the Probation Service to offenders under post-release provision (p.6). 
Importantly for this research, Hough draws attention to the plight of short-term or non-statutory 
prisoners, i.e. those sentenced to less than twelve months, who appeared not to have benefitted 
from the care packages offered to the longer term or statutorily supervised prisoners. He observed 
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that time spent in prison should be an opportunity to reflect and effect change, thereby inferring 
that short sentences precluded these types of intervention. Without being explicit, he had identified 
a potential major flaw in the prevailing sentencing policy. 
Three primary factors have been identified that appear to have contributed towards the 
disjointed delivery of prison-to-community continuity of care; hence, either in isolation or in 
combination, these factors have confounded strategic commissioners’ expectations regarding this 
key juncture within the drug recovery journey. Firstly, from a philosophical perspective, it can be 
argued that the opposing world views or mindsets of the respective workforces (at all levels) might 
have consciously and / or subconsciously encouraged and reinforced the ‘silo’ effect – i.e. Fox’s 
‘punishment versus rehabilitation’ observation.  The mindset argument is interesting because, 
experientially, there was a palpable sense of change when crossing the prison threshold, especially 
during the initial stages of this research. However, this cannot wholly explain the situation described 
here, given that the CARAT teams were technically staffed by ‘civilians’.  Although it was the case 
that prison staff may gravitate towards the prison care teams as their careers develop, the 
overarching CARAT mindset should have been more in line with community sentiments, which, one 
would speculate, might have encouraged closer working arrangements across the prison and 
community recovery systems.  Perhaps the more likely explanation is that the internal demands (key 
performance indicators etc.) and hierarchical, top-down nature of the prison administrative system 
superseded treatment priorities.  Without further investigation, it is difficult to develop this point 
further; the latter being a recognised weakness within this research, which is expanded upon later. 
Secondly, the silo effect may have been reinforced by the nature and implementation of the 
respective prison and community data/monitoring systems. Prior to the Drug System Change Pilot 
(DSCP) the drug recovery journey was monitored by the prison side of the Drug Intervention Record 
Web based (DIRWeb) system, then by the community side of the DIRWeb system upon release and 
finally by the National Drug Treatment Monitoring System (NDTMS). Teams (and people in care 
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pathways) partitioned by data systems will naturally ensure or prioritise that their system correctly 
reports their inputs/outputs ahead of any other.  The virtual barrier also creates a physical limitation 
within working practices.  For instance, without cohesive monitoring/case management systems, 
people are less likely to pick up the phone to ensure the transfer from prison to community is 
completed. 
Thirdly, and most importantly for this research, the siloed commissioning of drug recovery 
teams, by its very nature, may have led to the creation two distinct treatment regimes, with each 
focussed inward, and not necessarily over concerned prioritising integrated health care pathways. 
For the purposes of this study, the PwC report was seminal.  It endorsed this study’s view 
that, after ten years of sustained and increasing investment, little progress had been made regarding 
the strengthening of the prisoner continuity of care journey to the community drug recovery system. 
They emphasised that better outcomes were associated with treatment completeness, provision of 
aftercare and access to wraparound services. Although reviewing the provision of the community 
drug services was not within the primary scope of their report, the PwC team highlighted the 
importance of continuity of care between prison and community systems. Their observations, which 
had been largely drawn from interviews with professional stakeholders, directed that post-release 
support should be continued after the structured throughcare and aftercare programme ended. 
They stressed that last-minute, unplanned releases should be avoided because they made continuity 
of care arrangements difficult to implement, primarily because the community recovery system was 
not configured to receive them. Crucially within the context of this research and evaluation was their 
key recommendation that the ‘continuity of care of entry to and release from prison would be 
facilitated with the DIP and CARAT service being commissioned as one combined service’ (p.22). 
Their observations emphasised that all the productive treatment outcomes realised within 
sentence were being undone upon release as the result of a combination of poor record-keeping, 
dysfunctional or non-existent inter-agency communications, and questionable community service 
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prisoner management practices, leading to a distinct lack of continuity of care between the prison 
and the community drug recovery systems.  Commentary regarding possible weaknesses within the 
research strategy noted that research attentions tended to be focussed towards the various drug 
treatment interventions in isolation, when perhaps reviews of the treatment journey in the round 
may have been more informative. Or, put another way, the effectiveness of the various discrete 
modalities of drug treatment were well understood, but relatively little was reported regarding the 
actual structure of treatment when delivered holistically, a systems term that had recently appeared 
within the drug sector’s general lexicon. A focus on the latter might have helped to determine which 
packages of treatment and interventions worked in combination, and which were perhaps non-
complementary. To paraphrase Wojick (1976), we know what treatments work; perhaps continuity 
of care itself should be developed as a ‘modality’. 
Continuity of care within a systems framework 
The process linked to outcomes conceptual framework presented here (see fig. 1) draws from the 
ontological positions and systems concepts as described by Bertalanffy’s General Systems Thinking 
(1969), Forrester’s System’s Dynamics (Forrester, 1968, 1971) and latterly Checkland’s Soft Systems 
Methodology (SSM) (Checkland, 1999, 2012).  This type of non-reductive analytical thinking can be 
applied to real-world managerial situations, and indeed not only facilitated the visualisation and 
description of this study’s aims, but also served as a ‘map’ upon which the project metrics and 
outcomes can be located. 
Classical scientific training normally requires that we adopt reductionist problem-solving 
strategies in efforts to better understand the nature of reality. Inherent within this type of scientific 
approach are the notions that macroscopic properties can be explained in terms of their microscopic 
components and that complex systems can be reduced to their component elements. On the other 
hand, and perhaps somewhat counter-intuitively, the systems approach perceives the nature of 
things as a series of interconnected hierarchical levels of systems. A key principle underpinning 
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systems thinking, and the subject of much philosophical debate, is that systems may display 
emergent, or ‘whole’ system properties that reductionist investigative strategies would not have 
predicted. Or, put another way, the whole is more than the sum of its parts. 
The ontological roots of systems theory can be traced to the teachings of the great philosophers 
of Greek antiquity. However, the modern understanding of systems theory arises from the 
pioneering work and insights of individuals such as Bogdanov and Bertalanffy. The former suggested 
that reality might be perceived as a series or levels of interconnected organisations (Bogdanov, 
2003; Midgley, 2003) and the latter proposed that that systems or wholes might display purposeful 
emergent properties as they developed (Bertalanffy, 1969). 
As with the reductionist approach to problem-solving, the systems method allows us to, to 
some extent, deconstruct problems or systems into their component parts. Where it differs from the 
reductive style of investigation, is that it views the component elements of the problem, or system, 
as in some way connected; and that crucially, a study of those connections may provide us with the 
necessary insights to resolve, or rationalise, the problem or system under investigation. However, as 
has been noted by Checkland, this shift from a reductive to a systems reasoning paradigm can 
present us with intellectual challenges that will almost certainly require us to ‘undergo a significant 
rearrangement of one’s mental furniture’ (Checkland, 2012). 
 
2.2 Client complexity and vulnerability within the context of causality 
2.2.1 Drugs, crime and causality 
Drugs and crime are linked (Bennett & Holloway, 2000; Best, Sidwell, Gossop, Harris, & Strang, 2001; 
Goldstein, 1985; Gossop, Marsden, & Stewart, 2000; Hammersley, Forsyth, Morrison, & Davies, 
1989; National Treatment Agency, 2009b), and drug treatment reduces crime (Gossop, Marsden, et 
al., 2000b; Jofre-Bonet & Sindelar, 2002; National Treatment Agency, 2012a). This simple but 
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powerful statement has increasingly underpinned the UK Government’s successive anti-drug 
strategies, and has been a key driver supporting the expansion of the UK Department of Health’s 
drug treatment provision into both the community and prison settings throughout England and 
Wales (Department of Health, 2006; National Treatment Agency, 2001). 
Although some observers have identified the 1960s as the beginning of the UK’s first heroin 
epidemic, as per increases in the number of registered addicts with the Home Office (Hickman, 
Seaman, & de Angelis, 2001), it is generally accepted that, when viewed in terms of exponential 
growth, illicit heroin misuse gained traction during the 1980s (Hayes, 2014). Therefore, for the 
purposes of this literature review, the lead statement to this section is expanded upon from within 
the context of the United Kingdom’s anti-drugs policy development since 1985. This section begins 
with an overview of the (mainly US) historical research literature reflecting upon the causal nature of 
the drugs-crime nexus, and progresses to describe how the relatively recent contributions from the 
UK perspective have served to develop current understandings of this sometimes challenging and 
complex line of enquiry. 
 
2.2.2 Three explanations 
Explicit causality has been, and remains, difficult to demonstrate, but in broad terms there are three 
schools of thought that attempt to explain the links between drugs and crime.  These are: (1) drug 
misuse leads to crime; (2) crime leads to drug abuse, and (3) the clustered cause model, whereby 
both can be mutually reinforcing, and perhaps are symptomatic of other underlying factors.  The 
linear and deterministic explanations, i.e. drug addiction leads to predatory crime or vice versa, were 
particularly prevalent during the US experience of the mid to late twentieth century, and much of 
the research produced during that period reflected those explanations; i.e. the view that the ‘drugs 
cause crime’ and, as addiction took hold, more crime was committed to fund increasing drug use 
(Faupel & Klockars, 1987; Fernandez & Libby, 1998; Greene, 1974; Hughes, Barker, Crawford, & 
Jaffe, 1971). Understandings developed throughout the 1970s and 1980s (Hanlon, Nurco, Kinlock, & 
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K., 1990; Leukefeld, 1985; Nurco, Ball, Shaffer, & Hanlon, 1985; Nurco, Hanlon, Kinlock, & Duszynski, 
1988; Parker & Newcombe, 1987), but it is only relatively recently that a third explanation, 
describing causality in terms of a complex clustering or multi-factorial ‘nest’ of associated and 
interacting phenomena, has emerged to take precedence. 
 
2.2.3 Goldstein’s Tripartite Conceptual Framework 
This latest phase of thinking was initiated by the seminal contribution to the literature from Paul 
Goldstein, who in 1985 published ‘The Drugs/Violence Nexus: A Tripartite Conceptual Framework’ 
(Goldstein, 1985). Whilst it comfortably sat within the ‘drugs cause crime’ school of thinking, it did 
lay the foundations for current understandings about the complex nature of the drugs-crime 
linkages to be developed.  Whilst his work was chiefly concerned with the associations between drug 
misuse and violent crime, he also observed what appeared to be a complex association between 
opioid users and their propensity to commit acquisitive crime to fund their expensive habits. 
Specifically, he suggested that a key motivator to drugs-crime linkage may be economic in nature, his 
so-called ‘economic compulsive model’ (Goldstein, 1985). 
Goldstein’s observations were rapidly developed. For example, Leukefeld noted that the 
connections between drugs and crime appeared complex, and highlighted the benefits of drug 
treatment (Leukefeld, 1985). Further, Nurco and co-workers, whilst reporting data suggesting 
linearity, also stressed the complexity of the drugs-crime interactions (Nurco et al., 1985). As this line 
of investigation developed, it became increasingly clear that the drug-crime causal strands were 
indeed much more complex than previously realised, and that many other factors appeared to 
influence the nature of the interaction. This view was reinforced by Faupel & Klockars, whose 
findings from a series of in-depth interviews with thirty-two people with entrenched addiction and 
offending behaviours, strongly indicated that drug use and crime were temporally and dynamically 
linked.  Importantly, they reported that the linkages between drugs and crime may be dependent 
upon lifestyle, environmental and other external circumstances (Faupel & Klockars, 1987).   
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During this period, contributions from UK observers began to emerge; notably from 
Hammersley and colleagues, who suggested based on their findings that although crime and opioid 
use were associated with criminal behaviours, they tended to influence each other in a nonlinear 
fashion (Hammersley et al., 1989). This observation complemented Nurco and colleagues’ findings 
described a year earlier in the US. The researchers recruited a random sample of 20 categories of 
criminal activity (N = 108). The quantitative and descriptive nature of the research methodology 
enabled an analysis of the statistical relationships between the dependent and independent 
variables. Their review of the evidence concluded that an elevated prevalence, and rates, of crime 
were linked with increased use of heroin and / or cocaine (Nurco et al., 1988).  However, their cross 
sectional rather than longitudinal approach limited their ability to address the causal nature of the 
association 
During 1996, as the UK Government introduced its second anti-drug strategy published 1995 
(Lord President of the Council, 1994, 1995), Hough published his review.  Building on the US 
evidence from Inciardi, Nurco and others (Inciardi & Martin, 1993; Inciardi & Wallace, 1993; Nurco, 
Hanlon, & Kinloch, 1991), it detailed the extent of drugs misuse within the UK’s criminally active 
population (Hough, 1996).  Whilst acknowledging that the majority of casual drug users did not 
progress to develop full blown addictions, he drew attention to the group of criminally active drug 
users responsible for committing disproportionate amounts of acquisitive crime to fund their 
addictions (Hough, 1996). This group became known as the ‘problematic drug-using’ (PDU) 
population. Although not chiefly concerned with causality, his report highlighted some of the drug-
crime associations experienced within this UK drug-misusing population, and described their health 
and economic impacts upon individuals and communities in the wider context. 
From his observations he noted that: (1) drug dependency could be entrenched before 
criminal activities were reported to have commenced, and that dependency increased the risk of 
further crime being committed; (2) some of those committing property crime were observed to have 
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progressed to drug dependency by way of casual misuse; (3) dependent illicit heroin and / or crack 
use increased the volume of crime committed, and (4) drug use and property crime might be 
mutually reinforcing because they both increased in an upward spiral (Hough, 1996). A subsequent 
study by Bennett and Holloway, whilst acknowledging that a direct explanation of causality was out 
of scope, reported that almost half of the arrestees in their sample perceived that their drug use and 
crime were connected, and that most (70%) reported that they committed crime to fund their drug 
addictions. The remaining 30% reported that drugs impaired their judgement or that they used the 
money from crime to buy drugs. Interestingly, not many arrestees thought that crime caused drug 
use. A total of 3,135 arrestees were selected for this study, of which 2,682 arrestees were male 
(86%) and 453 were females (14%) (Bennett & Holloway, 2000). 
Further evidence supporting a non-linear drug-crime causal strand emerged during 2000, 
when White and Gormon reported from their analysis of drug-crime data collected from seventeen 
US cities.  They observed that, although in a very general sense the positive associations between 
drug use and type of crime (e.g. cocaine use and violent crime) remained, there appeared to be a 
marked variance across sites. They noted that ‘there is no uniform association between any type of 
drug use and any type of crime … . The fact that the associations are sometimes positive and 
sometimes negative … further supports the notion that the relationship between drug use and crime 
is complex’ (White & Gormon, 2000, p. 169). Their review of the empirical research data concluded 
that: (1) drug users and offenders display heterogeneity in terms of their levels and patterns of drug 
use, and in terms of their levels of criminality and crime type; (2) that for most offending drug users, 
drug use does not initiate crime, and (3) that there were common causal factors associated with 
drug misuse and criminal activity, with ‘various sub groups displaying different causal paths’ (p.196). 
A significant contribution to the UK understanding was introduced by Best and colleagues in 
2001.  In their study of a sample of drug treatment-seeking opiate misusers they reported that, 
whilst more than half of the group (56%) reported the committing of acquisitive crime, they could 
find no direct causal link between the two behaviours.  They suggested that whilst early 
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developmental patterns involving substance misuse and criminal activity appeared to be strongly 
associated, they could find no evidence to suggest that drug use caused crime (Best, Man, et al., 
2001).  In 2002, a UK study of transitional behaviours and drug use, in which the research was 
directed towards the hypothesis that early-age soft drug use leads to subsequent hard drug use, 
Pudney implied a clustered causality model by concluding that social, economic and family 
circumstances influenced the risks of harm from drugs and crime in young people (Pudney, 2002).   
This view was supported by MacCoun, who reported that correlation did not equal 
causation, but that instead drug use might cause, promote, or encourage crime and vice versa. He 
expanded on this by suggesting that situational, environmental, disposition, and / or biological 
variables might also influence the drug-crime nexus (MacCoun, 2003).  His report suggested that 
drug-crime associations should be viewed in probabilistic and not deterministic terms. He concluded 
that the causal influences were ‘contingent and not unconditional’ (p.66). 
In their introduction to the US National Institute Justice special report of July 2003, 
Brownstein and Crossland argued that a simple, direct and linear causal direction could not explain 
the associations between drugs and crime (Brownstein & Crossland, 2003), and that perhaps, as 
McBride and co-workers later summarised within the same report, the ‘statistical relationship 
between the two activities may be a result of their common etiological origin’ (McBride, 2001).  
A further significant contribution to understandings in the UK was introduced by Albery and 
colleagues, who, in their review of the literature, observed that: (1) people who experiment with 
drugs were more likely than others to commit other forms of crime; (2) there was little direct 
evidence to suggest any causal linkage between drug use and property crime; (3) a small proportion 
of users (less than 5%) led chaotic lifestyles in which dependency to heroin and / or crack figured 
significantly, and (4) a proportion of this latter group committed crime to finance their addictions 
(Albery, McSweeney, & Hough, 2004). 
Their report suggested that entrenched drug use and persistent offending become mutually 
reinforcing. They observed that these types of chaotic and chronic disorders were particularly 
52 
 
associated with people from disadvantaged backgrounds and whose exposure to positive lifestyle 
choices was restricted.  They reported that many of this group had experienced unstable family 
backgrounds, had underachieved educationally, experienced limited employment opportunities, and 
had infrequently accessed good quality health and accommodation services (Albery et al., 2004). At 
the same time, other commentators also supported this view; for instance, Keene observed that, in 
cases where the drug use pattern is subjectively related to the different ways of criminal behaviour, 
drug use fluctuates throughout the life-course, and that the association between drugs and crime 
may also differ along the span of time for any individual. Hence, this is likely to be affected by other 
social, psychosocial, and psychosomatic aspects (Keene, 2005). 
Bennett and Holloway further clarified the complexities with their review of the literature in 
2005, and suggested that three broad explanations and five causal models described the nature of 
drug-crime association. Explanations incorporated economic theories, which suggested that more 
drug use leads to more crime (to finance dependency); the psychopharmacological view, which 
postulated that drug use affected behaviours (directly or indirectly) by way of their chemical 
properties; and the lifestyle argument, which directed that drug use was integral to the criminal 
lifestyle (Bennett & Holloway, 2005). Each explanation was described or supported in terms of a type 
or combination of one of five causal models which are identified as: (1) the ‘drug use leads to crime’ 
model; (2) the ‘crime leads to drug use’ model; (3) the reciprocal or mutually reinforcing argument; 
(4) the common cause model, and (5) the coincidence or non-causal model.  Also in their subsequent 
study of the associations between poly-drug use and crime, they noted that whilst broadly 
supporting the economic compulsive model, their findings suggested that the non-causal, or 
overlapping factors, associated with problematic and excessive lifestyles, also played a significant 
role in the drug-crime relationship. They went further to suggest that, for an anti-drug policy 
response to be effective, interventions to combat drug misuse and crime needed to be tailored to, or 
targeted towards, specific client groups and their complex needs (Bennett, Holloway, & Farrington, 
2008). 
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Understanding of the causal links between illicit drug use and criminal behaviours has 
evolved to the point where the simple linear explanations can be viewed as mainly redundant.  In 
the UK setting, it is now recognised that causality is complex, clustered and primarily non-linear 
(Bennett & Holloway, 2009), a view supported by others and reinforced by subsequent studies, for 
example Organisation of American Studies (Organisation of American Studies, 2012).  For some 
people the causal direction of their drugs and offending may be of a linear nature, however the 
evidence strongly indicates that a substantial volume of drugs misuse is not only associated with 
crime in complex ways, but is also linked to other factors such as environmental, socioeconomic, 
health and learning-related conditions, all or any of which may or can be mutually reinforcing. 
The complexities of the linkages are often misunderstood, in part due to media depiction 
and political anti-drugs rhetoric. Both these narratives tend to over-simplify the linkages and adopt a 
linear causal model. Moreover, they place the emphasis increasingly on individual responsibility, 
thereby downplaying uncomfortable realities associated with socioeconomic inequalities. 
Nevertheless, the evidence is clear that drug-crime causal linkages are complex, often mutually 
reinforcing, and predominantly associated with vulnerability and elevated rates of reoffending. In 
this regard, it is imperative to understand that patients who receive more treatments show short-
term benefits. Subjectively, the complex nature of drug addiction substantiates the fact that 
duration of integrated care is more important than the amount of care.  
In a sample of more than 20,000 patients, Moos et al (2000) reciprocated that the patients 
receiving longer-term mental health services for drug addiction have better outcomes for risk-
adjusted substance use and familial interactions.  Furthermore, patients who are drug-dependent 
and who receive prolonged episodes of residential or outpatient treatments depict lesser incidences 
of re-addictive behaviours than patients with shorter regimes. This latter point has increasingly come 
to occupy policymakers’ attentions and, for the purposes of the study described here, was the key 
driver underpinning the decision to introduce the strategic commissioning intervention targeted 
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towards prison leavers evaluated in this thesis. The main objective of the interventions was to 
reduce the rates of reoffending associated with these high-risk and complex groups, especially 
within the first twelve months of their release. 
 
2.3 Drug treatment system(s) within the context of the UK anti-drugs strategy 
2.3.1 The UK Government’s drugs policy for England & Wales 
To some, the 1960s are identified as the beginning of the United Kingdom’s first heroin epidemic 
(Hickman et al., 2001), but a substantive increase in the numbers of people affected by heroin 
addiction occurred during the latter part of the 1970s and began to display epidemic characteristics, 
or growth, throughout the 1980s and 1990s. During this period, the number of addicts registered 
with the Home Office surged from around 3,000 or so in 1980 to almost 45,000 by 1995 (see figure 
1.0). 
 
Figure 2.3: Number of addicts notified to the Home Office, 1960-96 (Reuter & Stevens, 2007) 
 
This dramatic increase in the numbers of people affected by heroin misuse was associated 
with a sharp rise in the volume of drug-related offences and other harmful health behaviours. For 
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instance, alongside the reported increased levels of acquisitive crime, health agencies reported 
many more people exhibiting chaotic or harmful drug-taking behaviours such as injecting (Edmunds, 
May, Hearnden, & Hough, 1998). This latter type of high-risk behaviour was also understood to have 
contributed to the UK HIV/AIDS epidemic of the late 1990s and the early 2000s (AVERT, 2014). 
Since 1985 there have been five headline UK Government-coordinated anti-drugs strategic 
responses (Home Office, 1985, 2008b, 2010; Lord President of the Council, 1995, 1998), two 
consultation exercises (Home Office, 2007b; Lord President of the Council, 1994), and three strategy 
updates or progress reports (Home Office, 2002, 2004b, 2013), contributing to and directing the 
national, regional, and local anti-drug responses. 
Prior to 1985, the Misuse of Drugs Act 1971 had firmly positioned the Home Office as the 
lead anti-drugs department, and had established the categories of drug and associated legal 
penalties for possession and trafficking, etc. (HM Government, 1971). However, efforts to organise a 
structured set of activities to reduce and prevent the harms of illicit drugs at the national level had 
been limited, as evidenced by the relatively low number of government strategic and policy 
publication outputs during that period. The first centrally coordinated strategic response to the 
heroin epidemic materialised in the form of the ‘Tackling Drug Misuse’ strategy of 1985 (Arnull, 
2007; Reuter & Stevens, 2007). Its content and policy direction, resulting from the deliberations of 
the then-recently convened Cabinet Ministerial Sub-Committee on Drugs Misuse, emphasised that 
five key areas should take precedence within any anti-drugs response: namely, supply reduction, 
increased enforcement and deterrence, demand reduction, and prevention and treatment with 
rehabilitation (Arnull, 2007). These initial five priorities laid the foundations for future policy 
development, and have remained, in one form or another, constant in all subsequent iterations of 
the UK Government’s anti-drug strategy and policy response. 
During this early phase of the government’s anti-drugs response, and because management 
of heroin addicts and control of the HIV/AIDS epidemic was deemed paramount, policy in general 
was geared towards the public health and harm-reduction paradigms (McKeganey, 2006). However, 
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the transition from a predominantly public health focus, which directed that the harms of drug 
addiction should be contained and minimised (Monaghan, 2012), towards an increasing emphasis on 
crime reduction, began to manifest with the dissemination of the 1994 consultation Green Paper 
‘Tackling Drugs Together’ (Lord President of the Council, 1994). This document was circulated to a 
wide variety of stakeholders with a view to soliciting their feedback regarding the government’s 
proposed three-pronged anti-drug strategy. It clearly demonstrated the government’s commitment 
to drive down drug-associated crime by means of enforcement, and (then) treatment. The resultant 
White Paper ‘Tackling Drugs Together’ published in 1995, whilst maintaining the five key priorities 
identified within the first strategy, consolidated stakeholder feedback and condensed policy into the 
three key themes of community safety, prevention, and public health (Lord President of the Council, 
1995). Its core mission statement was to ‘take effective action by vigorous law enforcement, 
accessible treatment, and a new emphasis on education and prevention by increasing community 
safety from drug-related crime, reducing acceptability and availability of drugs to young people, and 
reducing the health risks and other harms related to drug use’. 
Moreover, of fundamental importance to the government’s strategic aims was the 
introduction of the locality-based Drug Action Teams.  Their primary roles were to champion the 
government’s anti-drug strategic objectives and to coordinate various anti-drugs activities through 
collaborative and partnership work. They became directly responsible for the commissioning of drug 
treatment via the Pooled Treatment Budget and Drug Intervention Programme monies, and were 
expected to participate in a wide range of cross-departmental joint commissioning forums (Best et 
al., 2008; J. Seddon, 1985; T. Seddon, 2000; Skodbo et al., 2007). 
The 1995 UK anti-drug strategy laid the foundations upon which all future strategies and 
updates have been developed. From that point to 2008, there were two iterations bridged by two 
updated publications, and1 all focussed on the original five key themes to some degree. Whilst the 
                                                          
1
 With the exception of the 2008 document which included a communications element to its list of high level 
priorities. Since 1995, successive strategies have embraced this theme and policies have been developed to try 
and increase the numbers of drug users entering treatment in a bid to drive down crime rates. 
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lead policy emphasis may have fluctuated over the years – for instance, the 1998 release ‘Tackling 
drugs to build a better Britain’ prioritised young people as the key focus of attention, whereas the 
2008 ‘Protecting Families and Communities’ ten-year strategy brought protecting communities to 
the fore – the treatment strand has remained core to the strategic response. Importantly for this 
research, and as the treatment-reduced crime evidence base evolved, by the time of the 2004 
Changing Lives update, not only was treatment identified as a means of reducing drug use thereby 
rehabilitating existing users, it was also identified as key to the policy of crime reduction, as 
embodied by the ‘out of crime, into treatment’ strapline of that time (Home Office, 2007d).  A 
change in government heralded a change in focus and from 2010 the UK strategy has been to 
promote full recovery through abstinence whilst maintaining the earlier core themes (Home Office, 
2010, 2013).  
Whilst the policy clearly showed a commitment to the inclusion of drug treatment and its 
evidence base as a key element of the UK anti-drug response, there was (and still is) a strong moral 
tone underpinning the evolution of UK anti-drugs strategies. For example, the publication of 1995 
Drug Strategy ushered in the crime phase of drug policy.  In this scenario, the policy viewed 
addiction as less a public health concern, but rather a phenomenon strongly linked with criminality 
(N. Hunt & Stevens, 2004). 
A major criticism of the UK anti-drug policy, and its development, is that it can be viewed as 
being presented as a fait accompli piece of legislation. Political sensitivities, combined with moral 
judgements, may have set the tone and direction of policy formation ahead of the science. This is a 
view expressed, perhaps most notably, by Professor Nutt, who, having resigned his position as chair 
of the Advisory Council on Misuse of Drugs (ACMD) amid concerns that government policy routinely 
discarded evidence, has maintained that the policy response to drugs (including alcohol) should be 
proportionate towards their relative health harms, and not directed by subjective, unscientific 
thinking.  He recently reiterated this view during the course of his presentation ‘From laudanum to 
58 
 
meow-meow: drugs, science and society’, during which he highlighted a prominent government 
minister’s quote that ‘we select the evidence that best fits policy’ (Rushton & Nutt, 2014). 
Other critics, notably Seddon and Stimson in the UK literature, have expressed their 
concerns and shown scepticism towards policy formation, particularly regarding the shift in focus 
from health to crime (T. Seddon, 2000).  Furthermore, Albery has called into question the element of 
the addiction model which dictates that illicit drugs lead inexorably to addiction and crime (Albery et 
al., 2004). 
Nevertheless, for the purposes of this research, there is an evidence base that suggests that 
for a small (but not insignificant) number of complex and vulnerable people usually drawn from less 
advantaged backgrounds, once their use of heroin and or crack cocaine has progressed to 
dependency, the frequency – and in some cases, severity – of their criminal activities increases. 
Some of these people will be sentenced to prison, and some of those will return to their negative 
behaviour patterns upon release and will re-appear within the prison system within twelve months 
of release.  
In summary, to strengthen the rationale underpinning this research, the literature review 
section has drawn from a substantial volume of ‘grey’ literature.  Much of the ‘evidence’ 
contributing towards the delivery the UK antidrug policy is non-peer reviewed and might be 
academically viewed as ‘substandard’.  This research takes the view that, whilst acknowledging that 
this type of evidence based policy formation is susceptible to bias and subjective agendas, balanced 
with the peer reviewed clinical (e.g. NTORS) evidence, its inclusion allows for a fuller understanding 
of the issues addressed here.  Grey literature is increasingly recognised as a rich source of 
information, especially for early types investigations (Adams et al., 2016) and this study does not set 
precedent.  
If we are prepared to accept that substance misuse linked antisocial acquisitive behaviours is 
problematic, then policy formation, informed by grey literature that supports the case for drug 
treatment to improve health and reduce crime is acceptable, especially when much of that evidence 
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is collated by commentators established (Hough etc.) within the field and is easily accessible via 
Government websites. 
Briefly, this section of the review has broadly described the development of the UK anti-drug 
strategic policy response up to the point of the drug systems change intervention evaluated here, 
and has established that the delivery of drug treatment was (and remains) a core element of that 
response.  The next section details the development and implementation of standardised drug 
treatments into both the community and prison settings in line with policy, and increasingly focuses 
on the importance and delivery of continuity of care, especially when viewed from within the 
criminal justice to community systems context 
 
2.3.2 Introduction of standardised drug treatment system into the UK setting 
The UK anti-drug strategy of 1995 introduced a three-year drug treatment strategy. This plan 
detailed a range of aims and objectives, to be coordinated by the Department of Health, in an effort 
to expand and standardise the provision of drug treatment in both community and prison settings 
(Lord President of the Council, 1995). Following the recommendations of the 1996 Task Force 
Effectiveness Review panel, which drew upon the evidence base about drug treatment to reduce 
individual and community harm, the National Treatment Agency for Substance Misuse (NTA) issued 
guidelines to assist purchasers and providers so that they might be better enabled to commission 
and deliver effective drug treatments (National Treatment Agency, 2002). 
The 1995 strategic document emphasised the expectation that the provision of drug 
treatment should be directed towards people serving prison sentences. It stressed that the 
Department of Health, working with Her Majesty’s Prison Service, should plan for the most effective 
way to ensure that drug misusers had access to treatment and appropriate support during remand, 
sentence and release, and that this plan should be implemented in the third year (Lord President of 
the Council, 1995).  However, by 1998 and the publication of the third anti-drugs national strategy 
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(Lord President of the Council, 1998), there was a growing concern that, although drug treatment 
was shown to be effective (Gossop, Marsden, & Stewart, 1998; Gossop et al., 1997a), its delivery 
appeared to be inconsistent and generally insufficient (Lord President of the Council, 1998).  
In response, the government urged a renewed emphasis on delivering the recommendations 
of the 1996 effectiveness review (Gossop et al., 1997b), in conjunction with those detailed within the 
Health Advisory Service report on Children & Young People (Williams & Richardson, 1995). Of the 
many proposed actions, an emphasis was directed towards drug-misusing prisoners, so that their 
throughcare and aftercare arrangements might be better managed (Harrison et al., 2003).  
Whilst the UK anti-drugs strategy from the mid-1990s advocated for the expansion of 
effective drug treatment into both the community and prison settings, ten years later concerns 
remained with regards to treatment geared towards prisoners.  The next section details the delivery 
of drug treatment from a historical perspective during the first ten years of the anti-drug response, 
and identifies some of the barriers that may have contributed to the (performance related) sub-
standard delivery of continuity of care. 
 
2.3.3 The community drug treatment system response 
Between 1998 and 2002, the numbers of people entering the community drug recovery system had 
risen to approximately 118,000, which accounted for almost half of the estimated number of PDUs 
(250,000) being targeted for treatment (Hickman et al., 2001).  In 2001 the National Treatment 
Agency for Substance Misuse was created to oversee the expansion and effective delivery of drug 
treatment on behalf of the Department of Health and the Home Office.  Their remit was to ensure 
that the government’s increased investment was properly managed within both the health and 
criminal justice systems (Hayes, 2013; National Treatment Agency, 2001). 
The anti-drugs strategic update document of 2002 further reinforced the government’s 
commitment to reduce crime by way of increased treatment provision, and also placed a greater 
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emphasis on the role of the criminal justice agencies within the community settings. This strategy 
document directed attention towards the increased opportunities developing within the criminal 
justice system that might help to divert more drug-misusing offenders into treatment and out of 
crime (Home Office, 2002). In terms of numbers, the key priority at that time was to increase the 
capacity of the drug treatment system to 200,00 people engaging within the lifetime of the 1998-
2008 strategy (Home Office, 2002). 
Gaining prominence within the community drug recovery systems during this period was the 
expansion and rebranding of the Home Office’s drug prevention activities, for a time referred to as 
the Drug Prevention Advisory Service (DPAS) (Home Office, 2002), into the Drug Intervention 
Programme (DIP) (Home Office, 2003). The DIP evolved from the Arrest Referral and the Probation 
Service’s Drug Testing and Treatment Order (DTTO) schemes, and evidence was accruing that 
indicated that pre- and post-sentencing diversionary strategies directing drug-affected offenders 
into treatment were having a positive effect upon their subsequent re-offending rates (Bennett & 
Holloway, 2000; Bennett, Holloway, & Williams, 2001; Edmunds et al., 1999; Edmunds et al., 1998; 
Hough, Clancy, McSweeney, & Turnbull, 2003).  
By the time of the 2004 anti-drugs strategic update and progress report ‘Tackling Drugs: 
Changing Lives’ (Home Office, 2004b), the community drug treatment system response was very 
much developed, and could be viewed as entering a phase of consolidation. For example, the 
workforce had grown to approximately 9,000; the number of treatment contacts per annum had 
increased to 50,000; waiting times to treatment were at their lowest recorded; more than 15,000 
DTTOs had been made; and the DIP was operating in sixty-six high crime areas, with approximately 
5,000 people per month being tested for illicit Class A drug use, of which almost 1,500 were engaged 
with the treatment services (Home Office, 2004b).  
However, illicit heroin use, as reported by the Glasgow prevalence estimates, continued to 
increase. Applying a counting methodology developed from earlier work, notably from and with 
Frischer and Hickman (Frischer, Hickman, Kraus, Mariani, & Wiessing, 2001; Hickman et al., 2002), 
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Hay’s team estimated from their first sweep of 2004-2005 data that there were approximately 
325,000 opiate and / or crack users throughout England and Wales (Hay et al., 2006b). According to 
their estimates, the peak period for illicit heroin use was approached during 2005 to 2006, and from 
that time onwards its use appeared to stabilise, so that by the time of the release of the second ten-
year anti-drugs strategy during 2008, the epidemic appeared to be in decline (see figure 2.3.3). This 
is important in the context of this study because with the heroin epidemic in apparent decline, in 
conjunction with a stable and experienced workforce, there presented an opportunity to direct 
resources towards prisoner continuity of care, when, perhaps in a more challenging environment, 
this vulnerable group may not have been prioritised. 
 
Figure 2.3.3:  Prevalence of opiate and or crack use (OCU) in England and Wales  
Note: as per the Hay counting method.  From  (Hay, Gannon, Casy, & Millar, 2010, 2011; Hay et al., 2008; Hay 
et al., 2006a, 2007; Hay, Rael dos Santos, & Millar, 2012; Hay, Rael dos Santos, & Worsley, 2013). Decreasing 
OCU prevalence is indicated by the trend line of best fit. 
 
The 2008 ‘Drugs: protecting families and communities’ strategy (Home Office, 2008b) 
perhaps marked the beginnings of the move away from a reliance upon the treatment maintenance 
model as the key to reducing drug-related crime and health harms.  It laid the foundations for a 
more recovery-focussed response which is geared towards helping more people enjoy their lives 
free from drug misuse, and encourages re-integration back into mainstream society (Home Office, 
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2008b). Full and long-lasting recovery from drug misuse had always been a key element of 
successive governments’ anti-drugs response (Lord President of the Council, 1995, 1998), and with 
the treatment system reporting as consolidated and functioning effectively (195,000 people 
engaging with average waiting times reduced to two and a half from nine weeks (Home Office, 
2008b) ), the emphasis shifted towards recovery case management delivery in conjunction with 
personalised budgets, and moved away from the predominant ‘one size fits all’ approach (Home 
Office, 2008a).  
Whilst retaining the three key themes of reducing demand, restricting supply and building 
recovery, the 2010 UK drugs strategy, and its 2013 update, further devolved commissioning 
responsibility to the Local Authorities (Home Office, 2010, 2013).  Treatment monies were allocated 
via a Public Health grant who, in partnership with the Police and Crime Commissioners, were now 
felt to be better equipped to meet the demands of substance misusers (Home Office, 2013). 
Importantly, the policy acknowledged that prisons were perhaps not the best places for individuals 
to overcome their addictive and offending behaviours but nevertheless did recommend the 
introduction of the second tranche of drug recovery wings in order to create the drug free 
environments conducive to achieving full recovery. Continuity of care from the custody to the 
community setting remained a key priority and the strategy recommended that greater use of 
mentors be made, especially at the point of release. 
Prior to these relatively recent prison drug treatment system developments, the criminal 
justice system had been responding to the prior strategic demands in a variety of settings and the 
next sections detail those activities. 
 
2.3.4  The prison treatment system response 
In 1999, the (CARAT) service was established to provide non-clinical drug treatment to drug-affected 
prisoners (Gravett, 2000; McSweeney, Turnbull, & Hough, 2008). The services offered included 
assessment of drug usage, counselling and advice on how to cease taking drugs, treatment and 
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supportive care services (Home Office, 2005).  According to Roberts et al (Roberts, Hayes, Carlisle, & 
Shaw, 2007) (p. 17), the CARAT service was a prison-centred initiative that played a vital role within 
the HM Prison Service’s response to UK anti-drugs strategy. 
The Home Office recommended that the prison setting presents an ideal opportunity for the 
delivery of drug treatment (Home Office, 2007c) (p. 7) and the CARAT provision is well positioned to 
augment the clinical services. The CARAT services were primarily offered to prisoners in conjunction 
with other prison-based therapies, e.g. opiate substitution, so that effective treatment delivery was 
provided to all offenders who require it (May, 2005).  For the purposes of this study, it is important 
to mention that the CARAT intervention was originally conceived to deliver support and counselling 
services to the prisoner during their sentence and after their release (Harman & Paylor, 2004, 2005) 
and a primary contention within the Essex context is that post-release support was rare, or if it was 
occurring, there was no evidence to support it.  
A key responsibility for the CARAT was to organise client movement within and between 
prison systems, from prisons to community agencies so that the delivery of care was perceived as 
seamless (Biggs, 2011). To ensure that CARAT services were effectively and efficiently delivered to 
offenders, the Prisons Service Order outlined the minimum requirements and standards that CARAT 
workers should adhere to and that their role was instrumental in ensuring that prisoners recover 
from drug abuse and were integrated back into society (HM Prison Service, 1999, 2001, 2002). 
However, the effectiveness of CARAT provision was difficult to assess, because of the lack of 
empirical studies describing client outcomes post-CARAT intervention (Harman & Paylor, 2005; 
Harrison et al., 2003; McSweeney et al., 2008). 
Numerous challenges and obstacles faced the CARAT intervention.  For instance, client 
confidentiality, the lack of follow-up work (Farrell & Marsden, 2005), poor assessment, monitoring 
and evaluation methods to determine the impact of CARAT on offenders, and lack of funds (Malloch, 
McIvor, Schinkel, & Armstrong, 2013) all played a part in diluting service effects.  MacDonald 
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observed that CARAT objectives were further hampered by factors associated with prisoner release 
back into the community.  For instance, lack of stable housing made it nearly impossible to track and 
monitor client progress and movements, and so when clients did relapse, it was often the case that 
CARAT team would only become aware at the point of reincarceration (MacDonald et al., 2012).   
However, the Home Office (2007c) showed that numerous initiatives had been implemented 
to ameliorate some of the underlying challenges. For instance, CARAT was encouraged to work 
closely with the Criminal Justice Intervention Teams (CJITs) so that the client might be more 
successfully integrated back into society following the end of his or her sentence. In addition, CARAT 
workers had established strong working partnerships with prison resettlement teams to facilitate 
offenders’ transition from supported living to independent living. 
Although a response to the mainly non-clinical needs of drug-affected prisoners had begun 
with the introduction of the CARAT, the systematic delivery of clinical drug-related health care needs 
within the prison environment was not formally introduced until 2006. In the summer of that year, 
the release of the Department of Health’s ‘Clinical Management of Drug Dependence in the Prison 
Setting’ (Department of Health, 2006) document served to support the implementation of the first 
wave of the Integrated Drug Treatment System (IDTS) into the prison setting (Shaw, Senior, & 
McDonnell, 2008).  
In a concerted effort to expand and improve the quality of prison-based treatment and 
rehabilitation services, and to support the introduction of the IDTS into the prison system, the UK 
government committed to increasing the annual prison treatment budget to £80 million by 2008, 
which in 1998 had stood at £7 million (BMA Board of Science, 2013). This increased investment 
would support the drive to implement the health care standards as prescribed within the NTA 
Models of Care guidance (National Treatment Agency, 2002, 2006) throughout the prison estate. It 
was envisaged that, alongside those serving longer sentences, prison treatment would be expanded 
to include and support those serving shorter sentences (less than twelve months), the so-called 
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‘non-statutory’ offenders. It was also announced at this point that the prisons service would review 
the CARAT provision with a view to strengthening its links to the community recovery systems, and 
attentions would be drawn as how to best prepare prisoners for their release into the 
community/recovery system. Responsibility for managing the full implementation of the IDTS 
programme was passed to the NTA during 2008, and in that year more than 25,000 people across 76 
sites received a structured treatment intervention (National Treatment Agency, 2009b). 
Thus, whilst the implementation and development of a community treatment response 
gained momentum, and by the time of the second ten-year strategy in 2008 could be viewed as 
largely successful and effective, concerns and reservations remained about the pace of policy 
adoption within the prison setting. The PricewaterhouseCoopers prison drug treatment report of 
2008 succinctly commented that ‘any strategy needs to span community and prison provision [and] 
remove barriers to coordination on entry and release from prison’ (PriceWaterhouseCoopers, 2008, 
p. 14).  
Ten years into the UK’s anti-drug strategy, and it was evident that key barriers to the 
effective delivery of continuity of care from the prison to the community drug recovery systems 
remained. The complexity and vulnerability of the target client group, the staggered introduction of 
delivery (community then prison) of drug treatment into two rigidly defined and siloed systems, all 
interacted and contributed towards the observed (poor) rates of continuity of care.  This posterior 
knowledge, combined with an extensive managerial experience, lay behind the decision to 
reorganise the delivery of the local prison-to-community continuity of care pathway.  During the 
period leading up to the system change reported here, a particular frustration was the apparent 
inadequacy of the system’s ability to prevent people from re-appearing on the HMP Chelmsford 
system within the first twelve months of their release (Home Office, 2010). 
Furthermore, there were barriers to overcome to in linking the different parts of the criminal 
justice system: therapeutic compliance, treatment success and housing providers from the social and 
private sectors at all levels of the community framework. Also, many substance misusers in 
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treatment have reported problems with stigmatisation, and this exclusionary factor may be a reason 
contributing towards relapse (Home Office, 2010). 
 
2.3.5 Bridging the prison and community treatment systems – InsideOut 
According to National Treatment Agency for Substance Misuse (2009b, p. 3), prisons lagged in 
respect of the provision of quality drug treatment care as compared to the community based 
treatment services. This observation, combined with extensive experience, led to the commissioning 
of Essex Drug and Alcohol Partnership’s (EDAP) strategic review (EDAP, 2009).  The review suggested 
and developed a treatment mechanism, focussed within the criminal justice setting, with a view to 
commissioning and delivering a combined prison/community drug recovery provision. This resulted 
in a service known as ‘InsideOut’, essentially a merge of the prison CARAT and community DIP 
teams. By spanning both the prison and community domains, InsideOut ensures that there is 
continuity of care or recovery journey for those drug misusing offenders exiting the prison estate 
into the local community. 
At the core of this restructuring exercise was a desire to implement an enhanced continuity 
of care for service users. In particular, it aimed to improve the transition from prison to the 
community for substance-misusing offenders, which has been identified as a time of risk and 
vulnerability (Lord Patel, 2010; Merrall et al., 2010). A key element supporting the InsideOut service 
in the prison setting was the introduction of National Drug Treatment Monitoring Systems (NDTMS) 
to facilitate information sharing (National Treatment Agency, 2009h). As a result of this pioneering 
approach, all drug and alcohol recovery partnerships can potentially access the CARAT prison drug 
treatment funding stream (National Treatment Agency, 2010), and the NDTMS has been deployed 
nationwide throughout the prison estate, as evidenced by the introduction of the prison-to-
community continuity of care performance line as per the NDTMS Diagnostic Outcomes Monitoring 
Executive Summary reports. 
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According to EDAP (2009, p. 7) and the Westminster Drug Project, (WDP) (2010), InsideOut 
was to provide a continuum of treatment services to clients both when serving their sentences in 
prison and when in the community setting. Therefore, all prison-based stakeholders, such as police, 
drug workers and probation officers, should go beyond their traditional roles to ensure that a client 
breaks the chains of drug dependency and drug-related offending behaviours and lives a healthy 
lifestyle (WDP, 2010).  
InsideOut care established various mechanisms to ensure reduced relapse and reoffending. 
And specifically, the role of the InsideOut practitioner was to “contact, assess, refer and support 
substance misusers in criminal justice settings (including courts, police stations, prisons, probation 
offices), treatment agencies, the community and other appropriate settings in order to maximise 
their uptake of treatment services and access re integration”, (see appendix 6.0). Under the 
InsideOut programme, clients who were high-risk drug substance misusing (re-)offenders were 
offered robust aftercare support which may have included both clinical and non-clinical 
interventions, such as housing and employment opportunities, in order to promote continuity of 
care and improved quality of life. 
Delivering the InsideOut intervention led to the introduction of the National Drug Treatment 
Monitoring System (NTDMS) into the local prison.   Outside of overarching strategic gains, primarily, 
the decision to do so was to strengthen local information sharing protocols. This would facilitate the 
transition of a prisoner from prison to the community setting. For instance, when a substance 
misusing inmate was released from prison, information relating to his needs should be relayed to 
community services to ensure smooth continuity of treatment (EDAP, 2008, p. 18). In addition, 
information can be shared at the time incarceration to ensure that where a prisoner was under 
treatment prior to arrest, there is continued provision of care via CARATs (EDAP, 2008, p. 18). 
 InsideOut also facilitated the creation and maintenance of secondary partnerships among 
peripheral stakeholder agencies. For example, Essex InsideOut was partnered with NHS Mental 
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Health, Essex Police, HMP Chelmsford, SOVA and Essex Drug and Alcohol Partnerships (WDP, 2010). 
These partnerships ensure that drug offenders were provided with the holistic care package, which 
is instrumental in the reintegration process. 
Advantages & disadvantages of InsideOut 
The InsideOut integrated the CARAT and community DIP services and aimed to bring the best of both 
into a single provision.  A key administrative advantage that was anticipated with the InsideOut 
intervention was the reduction in bureaucracy (EDAP, 2009, p.26). Now that the two diverse, and 
perhaps sometimes disparate, services were brought together under a single management 
framework, quick decision-making and effective treatment planning were promoted, at least in 
theory. Secondly, the use of the National Drug Treatment Monitoring System (NTDMS) as an 
information sharing platform for both prison and community drug treatment services ensured that 
there was close monitoring and evaluation of clients’ psychological health, social development, 
physical health, criminal record and drug use record, which would chart clients’ potential to relapse 
– and facilitate effective support if they do relapse.  
Thirdly, previous prison-based drug treatment initiatives ceased with the prisoner’s release, 
which meant that drug offenders were vulnerable to relapse, particularly offenders who resettled in 
high-crime or drug areas or failed to secure continued community treatment care. However, 
InsideOut aimed to ensure that offenders even after release are accorded necessary treatment and 
support in the form of community care until they are fully independent.  
The aim was that through provision of non-drug essentials such as education, employment 
and housing to prisoners exiting the prison setting, ex-prisoners would more easily recover and 
integrate with society. According to Buchanan (2004) the biggest contributor to relapse among drug 
offenders is the inability to re-establish, reintegrate and resume normal life. Buchanan (p.5) further 
states that drug treatment services should concentrate more on reintegration and reorientation of a 
drug user than on drug habits. This view is exemplified by InsideOut, which primarily attempts to 
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reintegrate the client to normal routine life. Overall, InsideOut aims to support drug offenders to live 
drug-free lives, reduce re-offending and help them contribute to social development.  
The InsideOut service delivery model may have some drawbacks, not all within its gift, which 
potentially undermine its effectiveness. According to Best et al., (2010) surplus demand of aftercare 
will outstrip resources currently available, which will result in inadequate structured treatment care. 
InsideOut operates under the premise of monitoring, evaluating and controlling released drug 
offenders, which, studies have shown, may be counterproductive. According to Chanhatasilpa et al 
(2009), drug offenders who are continuously supervised or controlled are at high risk of relapse, 
suggesting that a sensible case by case approach is required, ensuring that people are encouraged to 
interact with the treatment, care and support services without said encouragement being perceived 
as overbearing or coercive.  The use of peer mentors or ‘champions’ may help in this regard. 
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Chapter 3 - Methods 
3.1 Key elements 
The primary research question/hypothesis posed by this study was, from within the context of 
prison-to-community transitions, does continuity of care improve rates of referral and waiting times 
to community drug treatments, and did a reconfiguration of a twin service to a single service 
delivery model improve upon said measures?  The literature suggests that rates of prison-to-
continuity continuity of care have remained suboptimal and that inherent system factors may be 
contributing towards a systems dysfunction at this critical juncture within the drug recovery care 
pathway. 
To answer the research question(s), this study adopted a ‘systems’ perspective.   This 
approach facilitated a deeper understanding of how the prison-to-community continuity of care 
transition point is linked to an extensive process-outcome drug recovery system.  To answer the 
research hypothesis, a quasi-experimental before and after comparative cohort approach was 
adopted.  Although subject to limitations, this type of research enquiry and its findings when applied 
to small data sets, may be supportive of further, scientifically more robust interrogations, e.g. 
randomised sampling of larger data sets. 
The findings presented here are targeted towards two audiences.  For Public Health 
commissioners located within the Local Authority setting, data are presented in the form of counts 
and percentage rates, in line with established national reporting standards, for example the PHE 
DOMES performance reports.  With respect to academic publications, the analyses of survival rates 
will predominate because this type of statistical approach incorporates the modelling of time to 
event (return to prison, engagement with treatment etc.) and is able to factor in variables or 
characteristics that may influence survival times.  In other words, a scientifically more robust 
interpretation of the data.  
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3.2 Setting 
People recorded as entering a local prison and engaging with prison drug treatment via the 
substance misuse team during the period April 1st 2008 to March 31st 2012 were followed up for 
twelve months after their first release to the local drug and alcohol recovery Partnership.  At the 
midway point, April 1st 2010, the prison-to-community continuity of care pathway was reconfigured 
into a single service provision (InsideOut) and this study tests whether that model of service delivery 
improved upon the twin service model it superseded. 
 
3.3 Context and timeline 
We understand that drug treatment is associated with crime reduction (National Treatment Agency, 
2012a, 2012b, 2012c), and that continuity of care is a key element of any successful treatment 
intervention that requires client transitions, both within and across systems (National Institute for 
Health Care Excellence, 2014). Whilst the InsideOut intervention was conceived during a period in 
which the local drug recovery system was maturing into an effective delivery mechanism, obstacles 
or barriers to optimum system performance remained. Of prime concern at that time was the 
observation that communications and client movements between the prison and community 
settings remained problematic, as reflected by the relatively poor prison-to-community performance 
outputs (see tables 4.6.1, 4.6.2. page 123). Taking advantage of the opportunity to acquire ‘systems 
change’ status, the Partnership committed to undertake a series of activities that were targeted 
towards improving this situation. 
Beginning in 2008, the foundation work that comprised acquiring systems change status, 
delivering the InsideOut intervention, and undertaking the research and evaluation activities 
reported here, took place over the course of a six-year period to 2014 (see Figure 3.2 below). 
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Figure 3.3: PTORS timeline with key project milestones 
Throughout this time several key milestones or objectives were achieved.  For instance, 
during the early stages, and prior to the Systems Change Programme, the Partnership’s contractual 
and financial obligations with its service providers, which hitherto were confused and somewhat 
tangled, were clarified. Alongside ongoing work with providers to bring the drug recovery system in 
line with the NTA Models of Care Guidance and policies, these systematising activities fostered a 
clearer and simpler understanding of the local drug recovery commissioning landscape and 
providers’ responsibilities within that framework. As the DAAT Commissioning Team’s operational 
activities progressed, so did the strengthening of its strategic relationships with its statutorily 
designated co-commissioners. Commissioning decisions, which had often been made in isolation, 
now required input from many partners, whether internally based, that is, within the Local Authority 
structures, for example the Children’s Service, or externally located within for instance, the Police, 
Probation, and Prison Services. Progress with relationship-building, and consolidation of the 
commissioning understandings and practices, helped create the environment required to facilitate 
the introduction of the InsideOut service.  
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Running parallel with and complementing these early commissioning activities, concerted 
efforts were directed towards generating a suite of comprehensive information sharing agreements 
(ISA). These ISA activities were initiated between the service providers themselves, and were 
subsequently developed to incorporate the DAAT Commissioning Team. The introduction of the ISAs 
allowed the DAAT to initiate a series of data quality and audit exercises that were undertaken prior 
to and during the roll out of the InsideOut service. This work not only improved the quality of the 
statutory performance returns, but also maximised the number of matched statistical entities, and 
their associated care pathway data, that have been made available for the quantitative research 
analysis reported here. 
 
3.4 The Process and Treatment Outcomes Study (PTORS) design 
Figure 3.4 below describes the overarching PTORS study design. The research was a cohort study 
that followed people for a particular time period. Within this study design, the quantitative research 
arm within that schematic is located (see Figure 3.2). The combined amber and blue area represents 
the CJIS strategic entity, spanning the prison and community drug recovery systems, and locates the 
primary quantitative metrics. At point (1) the number of releases were counted; at point (2) the 
number of those released who engaged with community treatment as recorded by the NDTMS/TOP 
triage were counted, and at point (3) the number of those who relapsed to prison within 12 months 
of their first release were measured. The green block arrows indicate client flow within and between 
Partnerships and the prison system, and the green broken arrow indicates a reducing number of 
clients re-entering prison. The black block arrows describe client level data flow from the recovery 
system to the research team in order to construct the quantitative contextual framework. The short 
form antecedent client data were extracted from the Home Office’s DIRWeb and the Department of 
Health’s NDTMS systems. The process and outcome points (1, 2 and 3) also served as the ‘anchor’ 
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points on which the NTA’s self-reported treatment outcomes data (TOP) were linked. These are 
explained in more detail in the final section of this Chapter. 
 
Figure 3.4: PTORS study design 
Note:  Qualitative data not reported within this thesis. 
 
The commissioning perspective as described in Chapter 2 driving the intervention evaluated 
here was perhaps paramount. Certainly, during the initial stages of the Systems Change period, 
observations as viewed through a data and performance lens, encouraged early motivations. The 
following section details the location of the data sources and the steps taken to produce a suite of 
quality assured data sets. 
 
3.5 Research ethics and information governance structure 
During the period leading up to InsideOut ‘go live’ date, (April 2010), the research project 
conceptualisation was finalised, and by the winter of that year, academic colleagues based at the 
School of Health and Human Sciences, University of Essex, were approached with a view to 
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formalising a programme of research and evaluation activity. During the period 2011 to 2012, the 
quantitative (author) and qualitative researchers were recruited, the Academic Project Steering 
Board membership identified and convened, and favourable NHS and academic ethical opinions 
secured (see appendices 1.0, 1.1). Quantitative and qualitative research data collection began in 
early 2012, and the quantitative relational data modelling and analysis was undertaken and finalised 
throughout the period 2012 to 2014. 
For the purposes of this study, the research team were incorporated into the strategic 
commissioning and research hub (safe-haven) to facilitate access to the attributable data.  Lists of 
statistical entities, comprised of initials and birth dates were identified, and were either 
matched/analysed within the hub for the quantitative analysis reported here or transmitted, via 
secure mailing, to the source agency for the purposes of arranging the interviews as per the 
qualitative arm of the PTORS project. From those data, service managers arranged for their 
administrators to locate and clarify client suitability and availability. The qualitative researcher was 
contacted by the service provider to arrange interviews. Verbal client consent was arranged by the 
service provider, and full written permissions were obtained at point of interview. 
The data sharing structures indicated in Figure 3.5 below incorporate a principal, or strategic 
and Partnership wide overarching agreement, and several operational, organisational Information 
Sharing Agreements (ISA).  A strategic or Partnership document exists which sets out the terms of 
reference, and the rationale and the principles for the sharing of data (Essex County Council, 2017).  
This agreement was signed off by Chief Officers representing the Local Authority, Police, Probation, 
Prison, and Health Trusts.  The strategic agreement was underpinned by a series of operational 
agreements which detail the governance and processes of safe data sharing between contributing 
health and criminal justice agencies, and between those agencies and the research/commissioning 
hub (see appendices 3.0, 3.1, 3.2 and 3.3).  All data/information sharing agreements complied to the 
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governance and standards as per the UK Government’s policy and guideline documents (UK 
Government, 1998, 2006).  
 
 
Figure 3.5:  Essex Drug & Alcohol Recovery Partnership information governance & data sharing structures 
Note:  Solid arrows indicate case or patient level information flows. Broken arrows indicate aggregate level 
(black) and/or desensitised (green) information flows. In this context desensitised = the NDTMS extract (short 
form antecedent with partial post code). 
 
Data sharing agreements between the hub and health service providers were embodied 
within the ongoing contractual arrangements, and were signed off by senior commissioners and 
service managers. Criminal justice data were shared as directed by guidance set out within the 
Criminal Justice Act 1993 (HM Government, 2003), and arranged via bespoke sharing agreements 
between Public Health Essex, Police, and the Prison Services.  It should be noted that health data 
was not shared if the client had opted out of the consenting agreement. Consent for health (NDTMS) 
data to be used for research, and performance monitoring identification was acquired at the point of 
the first triage. Two refusals for consent were received in a ten-year period (>5,000 triages). 
The subsequent introductions of a Partnership-wide case management information system 
and the NDTMS into the local prison to replace the DIRWeb system, commissioner calls for 
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performance reports requiring analyses of the NDTMS extract became infrequent. The data sharing 
model described here preceded those developments and was implemented primarily to eliminate 
double counting, improve data quality, and facilitate this program of research, all of which involved 
data matching exercises. The centrally managed NDTMS.net system currently produces a suite of 
reports, for example the Diagnostic Outcomes Monitoring Executive Summary (DOMES), and the 
monthly Community Criminal Justice Report, to inform commissioning strategy. 
 
3.6 Data sources 
The data analysed in this study were drawn from a number of local sources, for example, HMP 
Chelmsford, and from the drug treatment agencies operating within the Essex County Drug Recovery 
Partnership. Although deemed as ‘local’ these data sets contributed towards a set of databases that 
had been configured to monitor and report trends in drugs misuse and treatment performance at 
the national level. In line with policy developments, for example, the introduction of structured care 
pathways, supported with evidence based treatment modalities, and to better capture and report 
system progress/performance, three national drug data systems have been introduced to the drug 
recovery system. Not in chronological order, these are: (1) the Home Office’s Drug Intervention 
Record web based system, (DIRWeb) (National Treatment Agency, 2009a), (2) the Department of 
Health’s (and subsequently the NTA’s), National Drug Treatment Monitoring System, (NDTMS) 
(National Treatment Agency, 2008a), and (3) the NTA’s Treatment Outcome Profile (TOP) date set 
(National Treatment Agency, 2008b). Data collected via the DIRWeb system were collated and 
reported by the now defunct Home Office’s Drugs Intervention Management Information System, 
(DIMIS) (defunct). The outputs generated from the NDTMS data are reported by the National Drugs 
Evidence Centre, (NDEC), based at the University of Manchester (University of Manchester, 2003), 
and the TOPs data is collated and analysed within the Drugs, Alcohol and Tobacco Directorate, based 
at Public Health England, London (Public Health England, 2015a). 
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In the subsequent sections, the developments, locations, and architectures of those national 
databases are briefly described to provide: (1) this study’s quantitative analytical context, and (2) 
provide an insight into, and draw attention to, the data transition points where data attrition tends 
to occur. Data attrition leads to under-reporting and poor data quality, and this latter point 
underscores the rationale supporting the decision to undertake a forensic data audit prior to the 
analytical phase of this research study. Included also is a short report describing the remedial steps, 
and their outputs, undertaken to ameliorate data attrition to improve the quantity and quality of the 
analytical outputs. The strengths and operational limitations observed within the local criminal 
justice drugs data systems, and how those observations informed the decision to pilot the NDTMS 
within HMP Chelmsford are discussed. The prison data collection strategy reported was later 
adopted by the national monitoring team. 
 
3.7 Participants 
All study participants were adult, male substance misusing prisoners (N = 808) transitioning from the 
prison system to a local community drug partnership between April 1st 2008 and March 31st 2012.  
All participants were male, aged eighteen years and older.  Age was calculated from date of birth to 
date of first release (DIRWeb).  Each case was tracked for the first twelve-month period from the 
date of first prison release (one-year outcomes).  Data collection ceased on 31st March 2013.  Time 
to treatment was calculated from date of first prison release to date of first community drug 
treatment triage.  Length of time to return to prison was calculated from date of first release to date 
of first prison assessment (after date of first release). Subsequent releases, treatment engagements 
and returns to prisons were excluded from this analysis.  Whilst important, Partnership level 
mortality rates for this cohort were not addressed within this analysis but are discussed in detail 
within the context of clinical relevance. 
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3.8 Process/outcome measures and other variables 
The quantitative evaluation of system performance at the heart of this research study began with 
the identification and location of the key intra- and inter-system process/outcomes points of 
measure.  In this study, three national and two project-specific process counts were identified as key 
measures and variables, which, in conjunction with an analysis of TOP data and supported with a 
bespoke interpretation of local rates return to prison, were utilised to assess the performance of the 
system in general and compare the prison-to-community activities of the CARAT and InsideOut 
teams. 
 
3.8.1 Process and outcome measures 
The primary process and outcome indicator developed by this study was the prison-to-community 
continuity of care measure. This tier 2 measure recorded the number and percentage rate of prison 
clients referred from the Prison (Prison DIRWeb, date case closed, case closed reason), and engaged 
by the community DIP team (Community DIRWeb, date of assessment within 28 days of and = to or 
> than date of release).  People identified as returned to prison before their community assessment 
were excluded. 
To calculate the study specific tier 3 treatment engagement rates, the client antecedents 
and first case closed date, as recorded by the prison side of the DIRWeb, were matched to the client 
antecedents and the date of first triage (greater than or equal to the DIRWeb prison side case closed 
date), as recorded by the NDTMS.  Cases were excluded from this count if a date of (re) assessment 
was found to be recorded between the case closed and triage dates.   
The length of time (process) between the two was labelled as this study’s ‘waiting time to 
treatment’ measure.  Length of time in treatment (outcome) was calculated from (1) the date of 
first triage to date of first discharge as recorded by the NDTMS or (2) the date of first triage 
(NDTMS) to date of (re) assessment as per the prison DIRWeb system, if that date preceded an 
NDTMS discharge date.  
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The two ‘new’ measures introduced within by study were the rate of ‘returns to prison’ 
(RTP) within the first twelve months of release from prison and the ‘length of time’ spent in the 
community prior to the RTP event.  The percentage rates of and length of time in the community 
(survival) RTP were calculated from the prison side of the DIRWeb system by simply interrogating 
the system for the next date of (re) assessment after the first recoded instance.  
All cases were followed for twelve months only therefore, cases associated with an NDTMS 
triage date and reporting no other event data were deemed to be in treatment for 364 days and 
cases associated with a DIRWeb case closed date and no other event data were deemed to have 
‘survived’ for 364 days after their first release from prison. 
Throughout the analysis described here, and for the purposes of comparison, records were 
assigned to the following groups. The process and outcome activities of those people having 
received the continuity of care, as reported by the DIRWeb system, were flagged as ‘with cc’, and 
those having not received the intervention as ‘without cc’. The activities of those people having 
been transitioned from HMP Chelmsford, (with or without continuity of care), into the Essex 
community during the two periods prior to the introduction of the InsideOut service, were flagged as 
‘CARAT’ clients. Those data were compared to the activities of those people transitioned from HMP 
Chelmsford during the two-year period after the introduction of the InsideOut service, who were 
labelled accordingly. To strengthen the overall ‘system’ count, those people released from prisons 
external to the Essex County Partnership, during the entire four-year study period, were included 
and labelled as ‘HMP Other’. 
 
3.8.2 Other variables 
For the purposes of contextualisation, study participants were described by age, ethnicity and drug 
profile as compared to the national and regional outputs.  Age was calculated from date of birth to 
first date of case closed, as recorded by the prison side of the DIRWeb system.  Cases recorded as 
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not ‘White British’ were allocated to the BME group and client drug profiling followed the NTA’s 
(now Public Health England) OCU business and technical definitions (Public Health England, 2015b). 
Regarding the analysis of the TOP data and for the purposes of this study, the term 
‘recovered’ is defined as exiting the Essex treatment system either drug-free or not using opiates 
and/or crack cocaine.  And the term ‘relapsed’ is defined as having been sentenced to HMP 
Chelmsford for drug-related offending.  For ease of interpretation, people appearing in both data 
sets were excluded from the analysis.  It is also important to note that the analysis of those in prison 
included non-Essex residents who were sentenced to HMP Chelmsford. 
The system described in this TOP context is comprised of Essex residents having reported their data 
to the community NDTMS/TOP database at their last contact with treatment and those who 
completed an initial TOP form at triage in HMP Chelmsford.  Because the TOP questionnaire collects 
twenty data items covering four domains, for the purposes of Illustration and ease of interpretation, 
the TOP items are reported within two pairs of domains. The NDTMS triage date is linked to TOP 
start, review, and exit dates, and hence, the fields required to calculate ad hoc analysis of the wider 
system TOP data. The TOP variables used for the outcomes analysis were the use of: alcohol, illicit 
opiate, crack, cocaine, amphetamines, cannabis, and other drugs during the previous twenty-eight 
days (substance misuse). The total number of days of injecting during the previous twenty-eight 
days, plus any activity of sharing of injecting equipment, and other drug paraphernalia, were 
calculated to indicate levels of risk. Criminal activity was captured via the total number of days of 
shop lifting, selling drugs, the committing of other acquisitive crime, and whether assault or 
violence had taken place within the last twenty-eight days. Health and social functioning were 
captured as a rating of psychological health on a sliding scale of 0 to 20 (20 indicating good), total 
number of paid work days, days attended education, physical health rating, presence of acute 
housing problem, and risk of eviction. Lastly, the client’s rating of overall quality of life was 
measured, again on a sliding scale of 0 to 20, (20 representing good). For each client recorded as 
engaged with the TOP system, a change in their outcome status was calculated by comparing their 
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score or activity for each item from base line to last available TOP within that episode. Clients with a 
start TOP only, were not included in the outcomes analysis. 
 
3.9 Data collection 
Integral to the analytical success of this quantitative programme of research, and the monitoring of 
system-wide performance in general, was the ability to quickly locate and access the required data, 
which had not always been the case. Interrogation of client-identifiable crime and health records 
was particularly challenging at the onset of systems change. This was mainly due to the inherent 
sensitivities associated with the client record being located within both the criminal justice and 
health domains, and because, in the absence of a generic, non-identifiable client attributer, strict 
data governance protocols were in place that tended to create substantive barriers to the dynamic 
movement of data within and across systems. Both issues were redressed with the introduction of a 
Partnership wide, all-encompassing information sharing agreement (see previous section).   
Within the context of this research study, the ISA permitted record level access to the NDTMS and 
TOP data extracts, the local community DIRWeb data, and the in-house prison data system. A 
bespoke system change pilot, ‘freedom and flexibility’, providing access to the HMP Chelmsford side 
of the DIRWeb system, was negotiated with the national team (National Treatment Agency, 2010), 
and proved crucial to the success of the analysis reported here. Access to the patient identifiable 
data (initials, date of birth and gender), allowed the construction of the ‘unique’ client key field, 
which not only prompted the pre-analytical audit exercise phase, but was crucial to the development 
of the counting model deployed throughout the analytical phase described in this research. The 
EDAP ISA permitted a level of formal access to client ‘attributable’ data which, up to that point 
(experientially), had rarely been achieved at the locality level. 
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3.9.1 Sanitising the data via audit  
Prior to, and during the early stages of the system change intervention circa 2008, the CARAT team 
based at HMP Chelmsford, and several of the community drug recovery providers, were reliant upon 
paper-based processes when administering client transfers between, and sometimes within, their 
respective systems. Because systems performance was reported in the round, but data were siloed 
within the DIRWeb and NDTMS systems, special attention was devoted by this study to ensuring that 
the client attributer, with its associated key performance dates, corresponded throughout the local 
recovery system. 
Although data compliance work is, in practice, a continuous aspect of day to day data 
management, there were two special or distinct phases during the early stages of the EDAP drug 
system change. Efforts to improve the quality of the data, so as to increase the number of statistical 
entities available for the research analysis and to improve the veracity of the associated key date 
information, were particularly heightened. During the twelve-month period leading up to the 
InsideOut ‘go live’ date, and developing work already undertaken to support the community DIP 
reporting stream, an intra-prison DIRWeb system audit was undertaken. This was followed with an 
inter-prison-community client attributer audit exercise, finalised prior to the 1st April, 2010 InsideOut 
service commencement date. Forensic audits of this type are labour–intensive, and so to assist with 
the administrative burden, an automated software routine, utilising ACCESS database query and 
macro technologies, was developed to support the manual aspects of the exercise. 
The software developed for this data cleansing exercise was based on the work developed 
by Winkler (1995), but for this study applied a less mathematical approach.  Instead of applying 
predictive statistical algorithms to text strings, in this study the positions of each of the characters 
on the client attributer were compared for similarity. Suspect or near-match records were manually 
checked via a process of triangulation involving the in-house prison, DIRWeb, and the NDTMS 
systems. Final corrections or amendments to the client attributer located within the DIRWeb and 
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NDTMS system were only undertaken after the identity of the record was verified by all three 
systems. Figure 3.9.1 below identifies the complete data cleansing process. 
 
Figure 3.9.1:  Attributer matching and data cleansing 
For this audit exercise, the ‘unique’ key is generated in the concatenated form of first and 
last name initials, date of birth, and the first letter of gender, and notated in the alphanumeric 
structure, XXDDMMYYYYG for example MC05011962M (Figure 3.9.1 above). The first stage of the 
data checking software brought all the attributers together (grouped in database terms), to produce 
an initial set of ‘unique’ attributers. In this example, during the first level of the comparison process, 
attributers that appeared similar, but contained different characters at position ten on the string 
(year of birth), were identified for manual audit. This process is repeated for all positions on the 
string. During the second level comparison, the iterative checking process is repeated, but instead of 
interrogating single positions, clusters of characters are compared. In this example, the client’s 
initials comprise the first cluster and are isolated, allowing the remainder of the string to be ‘paired’. 
In other words, two attributers have been identified as a possible match by their dates of birth, but 
the initial in both records needs to be checked. The outputs from both levels of comparison were 
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reported in an ascending list format, assigned with an appropriate system generated text 
recommendation, and were transmitted to the respective administrative teams for action. 
Counts of the attributers, and matched entities, were taken before and after the data audit, 
and those outputs are reported in Table 3.9.2a below. Prior to data cleansing, 1,720 unique 
attributers were recorded within the community DIRWeb system, and 3,534 attributers were 
observed within the prison side DIRWeb database. The audit reduced those counts by 4% and 10% 
to 1,659 and 3,179, respectively. 
Table 3.9.2a:  Number of Prison Data Entities before and after Data Audit 
DOMAIN  
Attributers 
% Δ ↕ 
Base line 30/06/2009 
Community 1,720 1,659 4% 
Prison 3,534 3,179 10% 
 
The number of people being reported as transferred from the Essex DAAT to other prisons 
(or DAATs), was improved by 8%, from 594 to 645, and the number of client transitions into the 
DAAT from external prisons (or DAATs), was improved by 29%, from 769 to 989 (see Table 3.9.2b 
below). 
Table 3.9.2b:  Referrals between the Community and Prison DIP Teams 
Matched attributers 
Transfer direction 
Counts  
% Δ ↕ 
Base line  As at 30/06/2009 
From Essex 594 645 ↑ 8% 
To Essex 769 989 ↑ 29% 
 
Within the drug recovery system, data attrition is particularly prevalent when people 
transition from one system to another, for example from the criminal justice system to the health 
care system. The forensic audit exercise reported here brought the nature and scale of the problem 
to local strategic attention, and from both the research and operational perspectives, proved crucial 
in terms of the improvement, veracity, and robustness of the data for analytical and performance 
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reporting purposes. Outputs from this audit reinforced local concerns regarding the quality of the 
data management within HMP Chelmsford and, alongside the recommendations made within the 
PwC Report, seeded the notion to pilot the NDTMS/TOP data collection systems within HMP 
Chelmsford. Introducing the community data capture system into the prison environment not only 
complemented local strategic commissioning and information management intentions, but also 
provided the data, (TOP), that confirmed the nature and extent of the chaotic lifestyles experienced 
by this vulnerable group of people prior to being sentenced to prison. 
In 2012 the NDTMS/TOP data collection system replaced DIRWeb in prisons throughout 
England and Wales, and has been largely responsible for the step change in drug treatment service 
delivery within prisons. Since the Essex Partnership chose to introduce its community case 
management system into HMP Chelmsford, the administrative burden historically associated with 
the management of two, often disparate data sets and incongruous service delivery models has 
been greatly reduced and has strengthened the case to move towards further rationalisations within 
the local NDTMS/TOP system.  For instance, at the time of writing, there has been a move away from 
the many agency-specific NDTMS codes towards a handful of organisational codes. The goal is to 
reach a position where partnership wide NDTMS data will be transmitted to the regional NDTMS 
team via a single Partnership system code. 
 
3.9.3 Data attrition 
During the audit phase, it was observed that several prison records reported a case closed 
date after the community triage date, which would have excluded them from the research analytical 
outputs. On closer inspection, the main cause of those misaligned dates appeared to be associated 
with a system-wide, community and prison, administrative misunderstanding of the importance of 
verifying each prison case closure and the linked community treatment start and discharge dates. 
When records with this type of error could be verified through audit, they were amended 
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accordingly and assigned to the PTORS study cohort for analysis. However, in a number of cases the 
incongruous dates remained unresolved, and therefore, those records (n = 22), could not be 
included. 
 
3.9.4 Data domains and relational modelling 
An understanding of where and how the drugs data system is located and modelled, and the 
identification of the rate-limiting steps or ‘pinch points’ within the systems, was fundamental to the 
development of the counting strategy developed in this research. In broad terms, the type of care 
pathway modelling described here is reliant upon certain data fields being linked to each other in 
such a way throughout the system’s component tables, as to reflect a person’s recovery journey as it 
progresses. Unlike many other forms of health intervention, people in recovery from substance 
misuse tend to experience multi-episodes of treatment, incorporating a number of treatment 
modalities, within relatively short periods of time. Relational, entity database modelling succinctly 
captures these types of patient journeys and can be viewed as a group of tables or spread-sheets, 
being joined together by a series of so-called ‘one-to-many’ relationships.  
The thought processes involved when developing these types of care pathways, and their 
data storage systems, are similar to those applied when differentiating and integrating in the 
mathematical context. For instance, the care pathway modelling described by the NDTMS can be 
regarded as an unfolding or differentiating series of treatment events which generate many lines of 
two-dimensional data. The integrative aspect relates to the production of the algorithms required to 
reverse engineering or ‘refit’ those two-dimensional data outputs, into a multi-dimensional storage 
array or database, from which client activities can be recorded and reported.  
The care pathway models developed by the Home Office and the NTA teams, were/are 
predominantly performance-focussed, and as such, are reliant on a number of key pieces of 
information. In the model described here, the data are located in what are termed ‘data entities’ or 
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tables. Specifically, these are the client, episode, and modality/TOP tables within the NDTMS, and 
the DIR and Activity tables within the DIRWeb system. In both systems, each table is linked via a 
number of key data fields. Of these, first and foremost and common to all tables, is the short form 
client antecedent, or ‘unique’ record identifier, without which records cannot be matched either 
within or across the NDTMS/TOP and DIRWeb systems.  
  During the early phase of database development, it was realised that due to the chaotic 
lifestyles led by many of the target client group, the system-wide collection of the NHS number 
would be too problematic. In response, a ‘unique’ identifier, abstracted from the client’s antecedent 
information was created, so that client records could be followed within and between the DIRWeb 
and NDTMS systems. In this example, the client entity is joined to the episode entity via the client 
attributer, which in turn is connected to the modality and TOP entities via the attributer in 
conjunction with the triage dates, the episodic key variable. The DIR and Activity tables are similarly 
linked. The combining, or concatenation of the attributer and various date information confers the 
‘uniqueness’ of each record. 
Figure 3.9.4 below describes the drugs data collection model/system in its entirety. In 2005, 
the NDTMS system was augmented with the introduction of NTA’s Treatment Outcome Profile (TOP) 
system, and whilst both datasets are collected via the same virtual portal, and are clearly associated 
within the entity modelling schema, they are treated as separate data systems. The prison and 
community domains are represented in the upper section of the Figure with the bi-directional 
arrows indicating client flow or data flux. In this representation, the DIRWeb system spans both the 
prison and community domains, incorporating the CARAT and DIP data sets, but in practice the data 
is effectively partitioned by the prison gate. The DIRWeb and NDTMS monitoring systems described 
by the lower section of Figure 3.8.4 are depicted within a relational, data entity modelling 
framework. 
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  Although in practice each database will hold its own client table, in this schematic, the 
database systems are connected to a single client entity in such a way as to draw attention to the 
importance of those data in terms of their ‘linking’ qualities. Each component entity or data table is 
connected via the Martin or Crow’s Foot Cardinal Notation System (ConceptDraw, 2015). 
 
Figure 3.9.4:  Drug data collection systems domains and their respective relational associations 
Note: The National Offender Management Information System, (NOMIS), is incorporated here for the purposes 
of locating the reference data utilised for triangulation as per the data audit exercise. Also, the inclusion of the 
DTR and RA pathway acknowledges the Essex Recovery Partnership’s recent progression towards Drug Testing 
on Arrest, and completes the drugs data collection picture circa 2012. 
 
For example, the relationships between the client (green), the DIR (orange), and the NDTMS 
(blue) (Compton et al.), episodic entities, are of the one-to-many type, that is, a client or individual 
may have numerous episodes of treatment. As such, they are represented by the zero, one or many, 
(crow’s foot), on the right-hand side of the relationship, and the one and only one, (denoted by the 
two-bar gate), on the left-hand side of the connection. Within the NDTMS episode, there may be a 
number of modalities or treatment interventions (same notation), but in the instance of a Required 
Assessment (RA) record being opened, there can only be one and only one type of relationship on 
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each side of the connection. TOP data is collected at least three times during a successful drug 
treatment episode and can be collected post exit. Each TOP data collection is associated with a 
particular episode, the relationship between the episode and the TOP is of the one and only one 
variety, which is also the case within the drug testing pathway. Each positive drug test is associated 
with a single required assessment process which is comprised of two elements. The green stars are 
located between tables and stress the crucial ‘pinch points’, where data attrition is most likely to 
occur when client records are transferred. 
 
3.9.5 Study specific data modelling 
In 2011, and complementing the formalisation of the conceptual framework described earlier, four 
‘clean’ data sets were available for the quantitative analytical phase. Specifically, these were 
DIRWeb prison and community databases and the community NDTMS and TOP data sets. The prison 
NDTMS and TOP data sets were made available during 2013. In the first instance, these datasets 
were linked to create the relational data entity model described in Figure 3.9.5 below. Located at the 
hub of this framework is the client entity, (one record per client), which is linked via a series of one-
to-many relational connections, to the downstream data entities, (DIRWeb, NDTMS-TOP), each of 
which may contain multiple lines of data per client. The Crow’s Feet Notation System describes the 
nature of the relationship or joins that connects each of the tables or entities. 
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Figure 3.9.5:  The study’s entity relational diagram 
The schematic presented here describes the end-product of the entity data modelling work, 
which began during the data cleansing phase of the project. Each entity or table was attached 
sequentially in the order: (1) prison DIRWeb to client, (2) community DIRWeb to client, (3) 
community NDTMS to client, and (4) TOP to community NDTMS. The client entity held the ‘unique’ 
attributer, (short form antecedent), which was originally drawn from all the records held on DIRWeb 
and NDTMS systems, and downstream entities held the data items required for the research 
analysis.  
The notion that people seeking recovery from substance misuse may well experience one or 
more episodes of treatment, each of which will involve one or more modalities or type of 
intervention, is a relatively simple one to convey. Describing the technical aspects associated with 
relational entity modelling and the mechanisms required to house the data generated by this type of 
care pathway, is perhaps less so. However, once grasped, an understanding promotes a 
sophisticated approach towards research and monitoring data investigations. Within a relational 
model, the data associated with people’s recovery journeys are collected, stored, and reported in 
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such a way as to reflect their health care journeys and needs. These data contribute towards the 
enhancement of local service delivery and ultimately improve system performance in the broader 
context. The introduction of the NDTMS, and to some extent the DIRWeb, data system to support 
the delivery of the NTA’s programme of Models of Care, has standardised the delivery of drug 
recovery to an evidence-based paradigm, and is now recognised internationally as an exemplar of a 
national healthcare data collection system.  
 However, their siloed natures, both internally and between systems, especially prior to the 
emergence of local case management information systems, could have led to increased data 
attrition and under reporting. In the absence of a non-identifiable client key variable, common to all 
data systems, for example the NHS or NI numbers, the use of the client attributer may have 
compounded the problem because of: (1) the sensitivities associated with the sharing of patient 
identifiable information, and (2) the stringent governance required to do so. Within DAAT or 
Partnership areas where data and administrative resources are underdeveloped, poor reported 
system performance may result. Thus, relational care pathway modelling allows for people’s 
recovery journeys to be better reflected. Yet applying this type of data model to a system that 
strives to incorporate as broad a spectrum of understandings as possible, but which at some point is 
limited, requires a level of local administrative expertise and data compliance that is not always 
available. 
 
3.10 Sample size 
Collating data from the community and prison DIRWeb datasets identified a ‘system’ cohort of 808 
Essex individuals as having had contact with the prison drug recovery system (HMP Chelmsford and 
HMP Other), and as being managed and released by either the CARAT or the InsideOut teams. This 
system cohort was comprised of: 255 CARAT, 278 InsideOut and 275 cases recorded as entering the 
Essex drug recovery system via other HMP non-Essex establishments, but managed by the WDP 
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service (see Figure 3.10 below).  This latter group were included within the research question testing 
or study contextualising stage because, at the system level, they contributed to and strengthened 
the process and outcome counting. They were not included within the hypothesis testing stage. 
 
Figure 3.10:  System cohort identified for quantitative research analysis  
Note. Prior to the launch of the InsideOut service in 2010, WDP had managed the community DIP provision 
throughout Essex (from 2006). Thus, for the purposes of the analysis described here, all clients entering the 
recovery system from other prisons are labelled HMP Other to differentiate them from those people receiving 
the InsideOut service. 
 
3.11 Analytical strategy 
In order to maximise the volume of quantitative research data available for analytical purposes, the 
analytical strategy adopted here was to: (1) develop a counting or continuity of care data (person) 
flow model, in line with national guidelines, with a view to generating the process and outcome 
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variables required to answer the study hypothesis and supporting research question; (2) locate and 
describe the study sample within national and regional contexts; (3) test the study assumptions via a 
combination of univariate, survival and size effect statistical analyses at the ‘system’ level; (4) test 
the study hypothesis by comparing the CARAT and InsideOut prison-to-community continuity of 
care, treatment engagement/waiting times and return-to-prison; (5) compare the CARAT and 
InsideOut continuity of care performance outputs with those generated by the statutory reporting 
mechanisms with a view to strengthening this study’s findings, and (6) compare the self-reported 
crime and health outcomes of those engaging with the community recovery system with those 
people being returned to prison within the first year of their release. 
Schematically, the data (people) flow is represented in Figure 3.11 below. People are 
released to the community with or without continuity of care and they may engage with drug 
recovery or otherwise. People may remain healthy and crime-free (in treatment or not), or they can 
relapse to prison within twelve months of release. 
 
Figure 3.11:  People flow and points of process and outcomes data capture 
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3.12 Statistical methods 
The study data were described within the context of the National and Regional age, ethnicity and 
drug profile estimates utilising student t (for age, section 4.4.1) and Chi squared tests (for ethnicity 
and drug profile).  For pragmatic reasons, associated with audience type and performance reporting, 
the study specific process and outcomes outputs namely; prison-to-community continuity of care 
(within twelve months of first release from prison), waiting times to community treatment (within 
twelve months of first release from prison) and return to prison (within the first twelve months of 
first release from prison), were compared utilising three types of statistical tests.  In the first 
instance, Chi squared tests (see figure 3.12a below) were used to assess levels of significance 
between the observed and expected frequencies of the cases assigned to the process outputs 
(categorical data), namely the number and rate of treatment engagements. 
Chi square groupings 
Outcome 1 (observed) 
(With continuity of care) 
Outcome 2 (observed) 
(Without continuity of care) 
Group 1 (into treatment) a b 
Group 2 (not into treatment) c d 
Figure 3.12a: Example 2*2 contingency table 
In the second instance, because the continuous data were right censored (post twelve 
outcomes were not recorded), Kaplan Meier survival analyses (Mantel Cox log rank tests included) 
were applied to assess differences associated with the time dependent outcomes data. And in the 
third instance, where there appeared to be between (discrete) group differences, analyses of effect 
size were undertaken to assess the ‘strength’ of the effect (see Figure 3.12b below).  Importantly, in 
all instances the analyses were seeking to identify relationships between variables rather than 
making inferences about causality. 
Variable (units) 
Data type Statistical test (p alpha set at 0.01) 
Continuous Categorical 
Descriptive                     
(mean, min, max 
& StDev) Chi (X2) student t 
 (*) Effect size 
(Cohen's d, Glass' 
Delta or Hedges' G) 
Age (years)          
Time to treatment (days)        
Time in treatment (days)        
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Time to return to prison (days)        
Continuity of care (yes/no)         
Treatment engagement (yes/no)         
Return to prison (yes/no)         
TOP items (days & yes/no)        
Figure 3.12b: Study variables, type, units and statistical tests applied. 
 
The survival analysis was conducted using the variables defined in Figure 3.12c below and 
where appropriate, supported with effect size testing. 
Variable Measures 
Length of Time in Drug Treatment Days 
Continuity of Care 0 = No; 1 = Yes 
Drug Treatment Engagement 0 = No; 1 = Yes 
Waiting Time to Drug Treatment Days 
Return to Prison 0 = No; 1 = Yes 
Time to Return to Prison Days 
Age Years 
Ethnic Background 0 = White-British; 1 = BME 
Type of Substance Misuse 0 = Other; 1 = OCU 
Service Delivery Model 1 = CARAT; 2 = InsideOut; 3 = HMP Other 
Figure 3.12c: Study variables processed within the Survival and Mantel/Cox log rank analyses. 
 
Notably, the introduction of the TOP system to HMP Chelmsford took place towards the end 
of the systems change period reported here, thereby restricting this study’s analytical options 
regarding being able to report the study cohort’s entire ‘outcome journey’ in full. However, its 
introduction into the prison as part of this local systems change programme, allowed for an early 
and unique quantitative (Chi squared and Student t) insight into the levels of harm reported by those 
relapsing to prison, compared to those more established on their recovery journeys, and is therefore 
worthy of note. 
The TOP system collects twenty data items which are grouped into four domains namely: 
substance misuse, injecting risk, crime and health/social functioning, and reports these outcomes at 
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both the individual and cohort levels. The self-completed TOP form is administered at treatment 
baseline, at the point of recovery care plan review and upon treatment completion. 
 
3.13 Missing data 
Missing data because of attrition has been dealt with earlier, and whilst every effort to reduce 
missing data within the analytical phase of the research was made, several records were excluded 
from the descriptive analysis of the system level cohort.  Specifically, the ethnicity status of n = 31 (n 
= 30, HMP other and n = 1, InsideOut) could not be identified.  No attempt to impute these records 
was made.  
 
3.14 Bias 
Whilst an attempt to limit study bias was made via a comparison of the ‘system’ cohort with the 
national and regional level demographical profiles, this study’s non-random design has inherently 
led to biases both known and unknown. As examples, the proportion of OCU clients engaging with 
continuity of care increased over time, and the number of people leaving prison drug free, in other 
words not requiring the services of the community drug treatment system, could not be accounted 
for.  In the first instance, increased rates of OCU penetration might reflect a maturing system as the 
InsideOut intervention progressively adopted DIP overarching policy/guidelines, and might be 
argued pragmatically as a ‘good’ bias, whilst in the second, the unknown status of some of the prison 
leavers has detracted from the validity of this study’s findings.  Future work in this area will need to 
factor this source of bias into its design protocol. 
To clarify, when the client attributers and associated date information were not aligned 
within and across the DIRWeb and NDTMS/TOP systems, then those data were ‘lost’ to the system, 
and as such were excluded from the statutory and study counting mechanisms. In response to 
operational need, a regime of data monitoring and auditing exercises was introduced by the 
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commissioning team with the treatment providers, as a substantive element of their performance 
and contractual obligation; however, this proved to be of little value to the needs of the research 
analysis for several reasons. 
First, the quality control mechanisms introduced at that juncture were mainly targeted 
towards the current and future data collections, and so some of the data required for the research 
analysis would not have benefitted from that attention. Second, although improving the quality of 
the data would be positively reflected within the real time national reporting outputs, it would have 
little effect on the historical reports, even in those cases where older data could be included within 
the quality exercises, because those reports are not rerun. In other words, the statutory reports, 
especially those managed by the DIMIS/DIRWeb system, are fixed; refreshing the data would not 
have generated the outputs required to satisfy research and evaluation expectations. Third, a key 
factor taken into consideration when planning for the analytical phase was that the level of 
stringency applied to the data regarding the statutory reporting parameters, might prejudice records 
that might otherwise be included. 
 
3.15 Summary 
Chapter 3 has focussed on the methods employed in this research. It has detailed the nature of the 
intervention; the timeline of key events and project milestones; the groundwork undertaken to 
ensure the legal sharing of data; the audit process used to maximise the ‘cleanliness’ and volume for 
the purposes of this research; the principles of relational or entity data modelling, supporting the 
development of the care pathway data flow or process model; the sampling and analytical strategies 
including which variables were selected for analysis; the choice of statistical tests to be applied, and 
an innovative way of collecting and describing the TOP outcomes data operational at the time. 
Chapter 4 explains the descriptive and statistical analyses of the primary process and secondary 
outcome outputs. 
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Chapter 4 - Results 
4.0 Introduction 
This study’s results are presented in seven sections.  Firstly, this research is contextualised by 
describing the Essex Drug Recovery Partnership in terms of age, ethnicity and drugs misuse status as 
compared to the regional and national profiles (table 4.1, p. 102).  In the second section, the 
‘system’ cohort, comprised of people engaged with the CARAT, InsideOut, and people returning to 
the Partnership via externally located prisons (HMP Other), (figure 3.10, p. 95) is described as per 
the profiles detailed in section one (table 4.2, p. 104).  It is important to reiterate that the HMP 
Other organisational activities were included simply to strengthen the ‘system’ level process and 
outcome metrics relating to the study’s research questions, and as such are excluded from the 
hypothesis testing stage. 
 Utilising univariate/covariate statistical techniques, supported with effect size calculations 
where possible, section three is devoted to answering the study research questions, namely: 
Is (CC) associated with increased rates of drug treatment engagement? (table 4.3.1, p. 104) 
Is CC associated with reduced waiting times to drug treatment? (table 4.3.2, p. 105) 
Is CC associated with increased length of time in drug treatment? (table 4.3.3, p. 107) 
Is CC associated with reduced rates of return to prison (RTP)? (table 4.3.4, p. 109) 
Is drug treatment engagement associated with reduced rates of RTP? (table 4.3.5, p. 109) 
Is CC and drug treatment engagement associated with reduced rates of RTP? (table 4.3.6, p. 111) 
And in section four analyses some of the possible confounding variables (tables 4.4.1, 4.4.2 & 4.4.3, 
pages 112, 116 & 117 respectively). 
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Section five tests the study hypotheses, which are threefold. Firstly, that the InsideOut 
service was associated with increased rates of continuity of care within the first twelve months of 
first release from prison (table 4.5.1, p. 119).  Secondly, that the InsideOut service was associated 
with increased the rates of community drug treatment engagement within twelve months of the 
first release from prison (table 4.5.1, p. 119).  Thirdly, that the InsideOut service reduced the waiting 
times for ex-prisoners engaging with the community drug treatment system within the first twelve 
months of their first release from prison (table 4.5.2, p. 120).  And fourthly, the InsideOut service 
was associated with reduced rates of return-to-prison. The first, second and fourth hypotheses were 
described by way of percentage rates, supported with chi-squared (contingency table) computations 
and the mean waiting times to community drug treatment, as recorded by the CARAT and InsideOut 
teams, are compared by way of Kaplan Meier survival curves complemented with a Log Rank 
(Mantel Cox) test for statistical significance.  The rates of return to prison are included within the 
hypothesis testing section to help inform this element of the discussion (Chapter 5), and with a view 
to developing further investigations. 
 Section six locates the continuity of care performance outputs generated by this research 
within the context of the national performance reporting systems.  In the first instance, tier two 
(prison DIRWeb to community DIRWeb) outputs covering the four-year period 2008-12 are 
described (table 4.6.1, p. 122).  Secondly, tier three (prison NDTMS to community NDTMS) outputs 
covering the two-year period 2014-16 are described (table 4.6.2, p. 123).  It is important to note 
that, due to a period of reconfiguration and systems testing, nationally collated continuity of care 
performance reports were not available for the two-year period 2012-14.  The chapter is finalised, 
section 7, with ad hoc analysis of the local prison TOP data that became available during the later 
stages of this research (tables 4.7.1, 4.7.2, pages 126 and 128 respectively).  These data have been 
included mainly for the purposes of interest and discussion, and its claims are neither definitive nor 
scientifically robust. 
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4.1 The Essex Partnership described 
Census 2015 estimates that in the region of 850,000 adults aged between 18 to 64 years of age are 
resident within the county of Essex (ESSEX County 2016), (Table 4.1).  Compared to the National 
estimates, the Essex adult population is slightly older, especially in the 35 to 64 age groups (63% and 
67%, National and Essex, respectively).  The proportion of people identifying themselves as being 
from a Black Minority or other Ethnic backgrounds (BME) is slightly under-represented (14% and 
12%, National and Essex, respectively).  As per the last available Opiate Cocaine Use (OCU) 
prevalence estimates, the mean number of OCUs resident within the county stands at approximately 
4,329, which, expressed as a percentage, represents 0.5% of the total adult population. This suggests 
that when compared with the National profile (0.9%), the County may be relatively less affected by 
the harms associated with opiate and crack cocaine misuse. 
Table 4.1:  Contextual demographic information.   
Note: Age and ethnicity data were drawn from the ONS census 2015 and 2011 outputs, respectively (Office of 
National Statistics, 2015).  Estimated mean OCU counts as per the Glasgow 2012 prevalence estimates (Public 
Health England, 2016) 
 
Demographic England East of England Essex 
N % total n % total n % total 
Age band       
18 - 24 4,920,128 15 487,927 14 113,368 13 
25 - 34 7,485,996 22 764,386 21 168,923 20 
35 - 64 20,990,775 63 2,360,286 65 566,597 67 
Total 33396899 100 3612599 100 848888 100 
       
Ethnicity       
White British 28721333 86 3076851 85 743286 88 
BME 4675566 14 535748 15 105602 12 
Total 33396899 100 3612599 100 848888 100 
        
Drug profile *  % population  % population  % population 
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OCU 293,879 0.9 21,952 0.6 4,329 0.5 
 
4.2 The study ‘system’ described 
For the purposes of this research, the ‘system’ cohort (N = 808) was comprised of three groups of 
clients: 
(1) People receiving care from the CARAT team within HMP Chelmsford between April 1st, 
2008 and March 31st, 2010 (n = 255, 32%). 
(2) People transferring back to the county from prisons located elsewhere between April 1st, 
2008 and March 31st, 2012 via the community DIP team (HMP Other, n = 275, 34%). 
(3) People receiving care from the InsideOut service between April 1st, 2010 and March 31st, 
2012 (n = 278, 34%) see Table 4.2.  
 People transferring back to the county drug recovery system from HMP Other tended to be 
older, particularly within the 25 to 34 age range (50% HMP Other compared to 40% and 41%, CARAT 
and InsideOut, respectively).  Furthermore, individuals within the InsideOut cohort were older in 
general (42% aged 35 to 64 compared to 30% and 31%, CARAT and HMP Other respectively).  In 
total, the BME groups were slightly under-represented (9%), but less so within the InsideOut group 
(11%).  The total number of OCUs (n = 602, 75%) were disproportionately represented in favour of 
the InsideOut service both in terms of organisational representation (88% compared to 69% and 
67%, CARAT and HMP Other, respectively) and as a proportion of the system cohort (41%, 29% and 
30%, InsideOut, CARAT and HMP Other, respectively). 
Table 4.2:  Study cohort described by age, ethnicity, and drug use profile.   
 
Demographic CARAT HMP Other InsideOut Total  
 n % org 
total 
% row 
total 
n % org 
total 
% row 
total 
n % org 
total 
% row 
total 
n % cohort 
total 
Age band            
18 - 24 76 30 42 53 19 29 51 18 28 180 22 
25 - 34 103 40 29 138 50 39 113 41 32 354 44 
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35 - 64 76 30 28 84 31 31 114 41 42 274 34 
Total 255 100 32 275 100 34 278 100 34 808 100 
            
Ethnicity *            
White British 236 93 33 224 91 32 247 89 35 707 91 
BME 19 7 27 21 9 30 30 11 43 70 9 
Total 255 100 33 245 100 32 277 100 36 777 100 
            
Drug profile            
OCU 175 69 29 183 67 30 244 88 41 602 75 
Non-OCU 80 31 39 92 33 45 34 12 17 206 25 
Total 255 100 32 275 100 34 278 100 34 808 100 
Note: * 31 BME cases missing (30 HMP Other and 1 InsideOut) 
 
4.3 ‘System’ level activities 
This section sets the context within which the study’s central hypothesis is tested.   An analysis of 
the whole system data is undertaken to answer the study’s research questions and to address 
potential confounding. 
 
4.3.1 Is CC associated with increased rates of drug treatment engagement? 
Descriptive and chi-squared (2*2 contingency table) analysis of the study cohort determined that of 
the 363 (45%) people having received continuity of care, 100 (28%) subsequently engaged with the 
community drug treatment system within 12 months of their first release from prison.  Of those not 
having received continuity of care (n = 445), 11% (n = 51) subsequently engaged with drug treatment 
within twelve months of their first release from prison (Table 4.3.1). The conclusion is that the null 
hypothesis was rejected at the 0.01 level of significance (χ2 = 34.94, p < 0.01) and that there was a 
statistically significant association between receiving continuity care and rates of treatment 
engagement within twelve months of the first release from prison event.   
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Table 4.3.1:  Continuity of care cross-tabulated with engagement with structured drug treatment 
 
 
 
 
 
 
4.3.2 Is CC associated with reduced waiting times to drug treatment? 
A Kaplan Meier survival analysis (SA) was conducted by entering the following variables:  
1. Time: Time to treatment 
2. Status: Engaged with treatment 
3. Factor: Continuity of care 
The descriptive statistics are summarised in Table 4.3.2.  The cumulative longest estimated mean 
waiting times for people engaging with treatment within twelve months of their first release from 
prison were recorded by those not receiving continuity of care (n = 51, mean = 337 days, 95% CI 
[329, 345]). The cumulative shortest estimated waiting times for people engaging with treatment 
within twelve months of their first release from prison were recorded by those receiving continuity 
of care (n = 100, mean = 280 days, 95% CI [265, 295]). 
 
Table 4.3.2:  Survival times to treatment, with and without continuity of care 
Summary Means 
Continuity of 
care N 
n of 
Events 
Censored Estimate SE 95% CI 
n % 
  
Lower Bound 
Upper 
Bound 
No 445 51 394 89 337 4.1 329 345 
Yes 363 100 263 73 280 7.7 265 295 
Overall 808 151 657 81 311 4.2 303 320 
 
Outcome 
Engaged with 
treatment 
Continuity of care Statistical test 
Yes No Total 2 *2 Contingency  
n Column % N Column % n 
 
 
Yes 100 28 51 11 151 χ2 = 34.94 
No 263 72 394 89 657 p < 0.01 
Total 363  445  808  
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A Log Rank (Mantel Cox) test indicated that there was a statistical difference at the 0.01 
level between the cumulative longest estimated mean waiting times of people not receiving 
continuity of care and the cumulative shortest estimated mean waiting times of people receiving 
continuity of care (χ2 = 37.4, p < 0.01).  This analysis concludes, therefore, that continuity of care was 
associated with shorter waiting times to treatment within twelve months of first release from prison 
and that the null hypothesis can be rejected (see figure 4.3.2 below).  Interrogation of the mean 
waiting times to treatment (see supplementary table 3.0) via Hedges’ test for effect size (g = 0.65) 
suggests that there are medium to strong, perhaps ‘observable’ differences between the two 
groups. 
 
 
Figure 4.3.2:  Kaplan Meier SA for time to treatment, with and without continuity of care 
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4.3.3 Is CC associated with increased length of time in drug treatment? 
A Kaplan Meier survival analysis (SA) was conducted by entering the following variables:  
1. Time: Time in treatment 
2. Status: Engaged with treatment 
3. Factor: Continuity of care 
The descriptive statistics are summarised in Table 4.3.3.  The cumulative longest estimated mean 
times spent in treatment were reported by those people receiving continuity of care (n = 363, mean 
= 194 days, 95% CI [171, 220]) and the cumulative shortest estimated mean times spent in treatment 
were recorded by those not receiving continuity of care (n = 445, mean = 146 days, 95% CI [114, 
179]). 
 
Table 4.3.3:  Survival times in treatment, with and without continuity of care 
Summary Means 
Continuity of 
care N 
n of 
Events 
Censored Estimate SE 95% CI 
n % 
  
Lower Bound 
Upper 
Bound 
No 445 51 394 89 146 16.7 114 179 
Yes 363 100 263 73 195 12.6 171 220 
Overall 808 151 657 81 179 19.2 159 199 
 
However, the 95% confidence intervals overlapped and a Log Rank (Mantel Cox) test 
indicated that there was no statistically significant difference at the 0.01 level between the 
cumulative treatment times of people not receiving continuity of care and the cumulative treatment 
times of people receiving continuity of care (χ2 = 3.74, p > 0.01).  This analysis concludes, therefore, 
that continuity of care was not associated with increased times in treatment and that the null 
hypothesis is accepted (see figure 4.3.3 below).  Interrogation of the means length of times in 
treatment (see supplementary table 4.0) via Hedges’ test for effect size (g = 0.31) suggests that there 
may be weak but ‘unobservable’ differences between the two groups. 
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Figure 4.3.3:  Kaplan Meier SA for time in treatment, with and without continuity of care 
 
4.3.4 Is CC associated with reduced rates of RTP?  
Descriptive and chi-squared (2*2 contingency table) analysis of the study cohort determined that of 
the 363 (45%) people having received continuity of care, 69 (19%) subsequently returned to prison 
within 12 months of their first release from prison.  Of those not having received continuity of care 
(n = 445), 25% (n = 110) were subsequently returned to prison within the first twelve months of their 
first release (Table 4.3.1).  The conclusion is that the null hypothesis was accepted at the 0.01 level 
of significance (χ2 = 3.78, p > 0.01). There was no statistically significant association between the 
proportions of participants who were returned to prison within 12 months of their first release, with 
or without continuity of care. 
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Table 4.3.4:  Rates of return to prison, with and without continuity of care 
 
Outcome 
Returned 
to prison 
Continuity of care Statistical test 
Yes No Total 2 * 2 
Contingency 
n % column 
total 
% row 
total 
n % column 
total 
% row 
total 
n % column 
total 
 
Yes 69 19 39 110 25 61 179 22 χ2 = 3.78 
No 294 81 47 335 75 53 629 78 p > 0.01 
Total 363  45 445  55 808   
 
 
 
4.3.5 Is drug treatment engagement associated with reduced rates of RTP? 
A Kaplan Meier survival analysis (SA) was conducted by entering the following variables:  
1. Time: Time to RTP 
2. Status: RTP 
3. Factor: Engaged with treatment   
The descriptive statistics are summarised in Table 4.3.5.  The cumulative longest estimated mean 
survival times for people returning to prison within twelve months of their first release from prison 
were recorded by those in treatment (n = 151, mean = 334 days, 95% CI [323, 346]). The cumulative 
shortest estimated mean survival times for people returning to prison within twelve months of their 
first release from prison were recorded by those not in treatment (n = 657, mean = 312 days, 95% CI 
[304, 320]). 
Table 4.3.5:  Survival times to return to prison, with and without treatment 
Summary Means 
Engaged with 
Treatment N 
n of 
Events 
Censored Estimate SE 95% CI 
n % 
  
Lower Bound 
Upper 
Bound 
No 657 147 510 78 312 4.3 304 320 
Yes 151 32 119 79 334 6.0 323 346 
Overall 808 179 629 78 316 3.7 309 324 
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Although the 95% CIs did not overlap, a Log Rank (Mantel Cox) test indicated that there was 
no statistically significant difference at the 0.01 level between the cumulative estimated survival of 
people returning to prison in treatment and the cumulative estimated survival of people not in 
treatment (χ2 = 0.38 and p > 0.01).  This analysis concludes, therefore, that treatment was not 
statistically significantly associated with increased survival times of those returned to prison within 
twelve months of their first release from prison.  However, interrogation of the mean length of times 
of return to prison (see supplementary table 5.0) via Hedges’ test for effect size (g = 0.92) suggests 
that there may be a strong and observable differences between the two groups. 
 
Figure 4.3.5:  Kaplan Meier SA for those RTP, with and without treatment 
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4.3.6 Is CC and treatment engagement associated with reduced rates of RTP? 
A Kaplan Meier analysis was conducted by entering the following variables:  
1. Time: Time to RTP 
2. Status: RTP 
3. Factor: CC or not, with and without treatment 
The descriptive statistics are summarised in Table 4.3.6. Individuals receiving continuity of care and 
engaging with treatment within the first twelve months of their first release recorded the cumulative 
longest estimated survival times before being returned to prison within the first twelve months of 
their first release (n = 14, mean = 346, 95% CI [335, 357]).  The shortest cumulative estimated 
survival times were recorded by those has having received continuity of car but did not engage with 
treatment within the first twelve months of their first release from prison (n = 55, mean = 310 days, 
95% CI [296, 324]). 
Table 4.3.6:  Survival times to return to prison, with CC or not, with and without treatment 
Summary Means 
Engaged with Treatment N n of Events 
Censored Estimate SE 95% CI 
n %   
Lower 
Bound 
Upper 
Bound 
CC with treatment 100 14 86 86 346 5.6 335 357 
CC no treatment 263 55 208 79 310 7.1 296 324 
No CC with treatment 51 18 33 65 311 13.3 285 337 
No CC no treatment 394 92 302 77 313 5.3 303 324 
Overall 808 179 629 78 316 3.7 309 324 
 
Except for the ‘CC with treatment’ group, the 95% CIs of the remaining groups overlapped and 
Log Rank (Mantel Cox) test indicated that there was no statistically significant association at the 0.01 
level between the cumulative estimated survival times of people returning to prison, receiving CC 
with and without treatment, and those not receiving CC with and without treatment (χ2 = 8.67 and p 
> 0.01). Thus, it can be concluded that continuity of care and treatment did not increase the 
cumulative survival times of those returned to prison. 
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Figure 4.3.6:  Kaplan Meier SA those RTP, with and without CC, with and without treatment 
 
4.4 Confounding (predictors) 
The study’s primary process and outcomes, namely CC, engagement with drug treatment, and RTP, 
were cross-tabulated with the potential confounders of age, ethnicity, and drug using profiles. 
 
4.4.1 Age 
The mean ages were elevated for people receiving CC, engaging with treatment, and RTP.  People 
were statistically significantly older within the engaged with treatment cohort (t = 3.33, p < 0.01), as 
demonstrated in Table 4.4.1. 
 
Table 4.4.1:  Age as a predictor of receiving CC, engaging with treatment and RTP 
 
Process Outcome Age 
Statistical 
Significance 
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test 
n M min max SD Student t 
Continuity 
of care 
Y 363 31.2 18.3 49.9 7.3 
‡
t = 0.98 p > 0.01 N 445 30.7 18.0 50.4 7.9 
Total 808 30.9 18.0 50.4 7.6 
Engaged 
in drug 
treatment 
Y 151 32.6 18.7 49.1 6.7 
‡
t = 3.33 p < 0.01 N 657 30.5 18.0 50.4 7.8 
Total 808 30.9 18.0 50.4 7.6 
Returned 
to prison 
Y 179 31.2 18.4 50.1 7.1 
t = 0.61 p > 0.01 N 629 30.9 18.0 50.4 7.8 
Total 808 30.9 18.0 50.4 7.6 
Note: ‡ = adjusted for Levene’s test of equality of variances 
 
 
Figure 4.4.2a: Frequency distribution age vs receiving continuity of care 
Note: Both distributions displaying right skewness and the group not receiving continuity of care 
displaying bimodality 
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Figure 4.4.3b: Frequency distribution age vs engaged with treatment 
Note: Both distributions displaying right skewness and bimodality 
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Figure 4.4.4c: Frequency distribution age vs returned to prison 
Note: Both distributions displaying right skewness bimodality 
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4.4.2 Ethnicity 
People recorded as ‘White British’ were associated with higher rates of treatment engagement and 
RTP, compared to those recorded as BME.  Specifically, as a proportion of the entire group that were 
receiving and not receiving treatment, 21% of the White British group engaged with drug treatment 
compared to 7% of the BME group.  This finding was found to be statistically significant at the 0.01 
level (χ2 = 15.06, p < 0.01), as seen in Table 4.4.2.  Those in the White British group also reported to 
be associated higher rates of RTP than individuals from the BME group.  Indeed, 24% of the White 
British group were RTP within twelve months of their first release from prison compared to 17% 
BME, and this finding was statistically significant at the 0.01 level (χ2 = 10.73, p < 0.01). 
 
Table 4.4.2:  Ethnicity as a predictor of receiving CC, engaging with treatment, and RTP 
 
Process Outcome 
Ethnic profile Statistical test 
Significance 
White 
British 
% 
column BME 
% 
column Missing 
% 
column 
2*3 
Contingency 
Continuity 
of care 
Y 327 46 26 37 10 32 
χ2 = 4.23  p > 0.01 N 380 54 44 63 21 68 
Total 707  70  31  
Engaged 
in drug 
treatment 
Y 146 21 5 7 0 0 
χ2 = 15.06 p < 0.01 N 561 79 65 93 31 100 
Total 707  70  31  
Returned 
to prison 
Y 167 24 12 17 0 0 
χ2 = 10.73 p < 0.01 N 540 76 58 83 31 100 
Total 707  70  31  
 
4.4.3 Drug profile 
People recorded as OCU were associated with higher rates of treatment engagement and RTP 
compared to those recorded as BME.  As a proportion of the group total engaging or not engaging 
with treatment, 28% of the OCU group were engaged with treatment compared to 2% of the non-
OCU group, and this finding was statistically significant at the 0.01 level (χ2 = 48.11, p < 0.01), as 
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seen in Table 4.4.3.  Individuals in the OCU group also reported higher rates of RTP than those from 
the BME group.  Specifically, 28% of the OCU group were RTP within twelve months of their first 
release from prison, compared to 6% non-OCU group, and this finding was statistically significant at 
the 0.01 level (χ2 = 42.74, p < 0.01). 
 
Table 4.4.3:  Drug profile as a predictor of receiving CC, engaging with treatment and RTP 
 
Process Outcome 
Drug profile Statistical test 
Significance 
OCU % column Non-OCU % column 2*2 Contingency 
Continuity 
of care 
Y 278 46 85 41 
χ2 = 1.50 p > 0.01 N 324 54 121 59 
Total 602  206  
Engaged in 
drug 
treatment 
Y 146 24 5 2 
χ2 = 48.11 p < 0.01 N 456 76 201 98 
Total 602  206  
Returned 
to prison 
Y 167 28 12 6 
χ2 = 42.74 p < 0.01 N 435 72 194 94 
Total 602  206  
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4.5 Testing the study hypothesis - CARAT vs. InsideOut service delivery models 
 
4.5.1 Rates of continuity of care, treatment engagement, and return to prison 
During the 4-year period between April 1st, 2008 and March 31st, 2012 inclusive, 533 drug affected 
clients were referred to the Essex community drug treatment system via HMP Chelmsford (Table 
4.5.1).  Between April 1st, 2008 and March 31st, 2010, 255 (48%) people were released via the CARAT 
team, and between April 1st, 2010 and March 31st, 2012, 278 (42%) people were released via the 
InsideOut team.   
 
Continuity of care 
Applying descriptive and chi-squared 2 * 2 contingency tables determined that, of those released, 
186 (35%), and 347 (65%), were recorded as having received and not received continuity of care, 
respectively.  Of those having received the continuity of care intervention, 70 people (27% within 
and 38% of the total), were managed by the CARAT team and 116 people (42% within and 62% of 
the total), were managed by the InsideOut team.  Of those having not received the continuity of care 
intervention, (n = 347, 65%), 185 people, (73% within, 53% of the total), were released during the 
CARAT tenure and 162 people (58% within, 47% of the total), were released during within the first 
two years of the InsideOut service delivery.  These findings indicated that there was a statistically 
significant association between the different rates of continuity of care delivered via the two 
services (χ2 = 17.52, p < 0.01), (Table 4.5.1).  
 
Treatment engagement 
With and without continuity of care, 82 people (15%) were found to have engaged in community 
drug treatment (Table 4.5.1).  Out of these 82 individuals, 26 were engaged in treatment during the 
CARAT tenure (10% within, 32% of the total), and 56 people were engaged with treatment during 
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the InsideOut tenure (20% within, 68% of the total).  These findings indicated that the rates of 
treatment engagement were statistically significantly associated with type of service delivery (χ2 = 
15.44, p < 0.01), (Table 4.5.1). 
 
Return to prison 
Applying a two-tailed chi-squared 2 * 2 contingency test determined that the rate people returned 
to prison was 29% (n = 152).  Of those who returned to prison, 93 people (36% within, 61% of the 
total) were released during the CARAT tenure, and 59 (21% within, 39% of the total) were released 
during the InsideOut service tenure.  Of those not returned to prison (n = 381, 71%), 162 people 
were released during the CARAT tenure (64% within, 43% of the total), and 219 people (79% within, 
57% of the total), were released within the first two years of implementation of the InsideOut 
service.  These findings indicate that the rates of returns to prison within the first twelve months of 
release were statistically significantly associated with type of service delivery (χ2 = 21.14, p < 0.01), 
(Table 4.5.1). 
Table 4.5.1:  CARAT vs. InsideOut HMP Chelmsford activities.   
Organisational level activities 
Count of people released to the Essex County Drug Recover Partnership from HMP Chelmsford 
via the CARAT & InsideOut Teams between 01/04/2008 & 31/03/2012 
 n   
 % activity Test 
Within organisation Of the total 2 *2 Contingency 
 CARAT  InsideOut Total CARAT InsideOut CARAT InsideOut a vs. b 
Total people released 255 278 533 n/a n/a 48 52 n/a 
With continuity of care (a) 70 116 186 27 42 38 62 χ2 = 17.52 
No continuity of care (b) 185 162 347 73 58 53 47 p < 0.01 
Into treatment (a) 26 56 82 10 20 32 68 χ2 = 15.44 
Not into treatment (b) 229 222 451 90 80 51 49 p < 0.01 
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Return to prison (a) 93 59 152 36 21 61 39 χ2 = 21.14 
Not return to prison (b) 162 219 381 64 79 43 57 p < 0.01 
 
Note: Process and outcome activities reported as; (1) within, as a % proportion of the total number of people 
released by each organisation, and (2) between, as a % proportion of the total number of events per activity 
i.e. the row total. 
  
4.5.2 Waiting times  
A Kaplan Meier analysis was conducted by entering the following variables:  
1. Time: Waiting Time to Treatment 
2. Status: Engaged with Treatment 
3. Factor: Service Delivery Model 
The descriptive statistics are summarised in Table 4.5.2.  The cumulative longest estimated mean 
survival (waiting) times for drug treatment were recorded by prisoners managed by the CARAT 
service (n = 26, mean = 143 days 95% CI [87, 181]) and the cumulative shortest estimated mean 
(waiting) times for treatment were recorded by prisoners managed by the InsideOut service (n = 56, 
m = 99 days, 95% CI [68, 130). 
However, the 95% CI overlapped and a Log Rank (Mantel Cox) test indicated that there was no 
statistically significant association at the .01 level between the cumulative estimated survival 
(waiting) times for drug treatment within the first twelve months of release from prison and type of 
service delivery (χ2 = 3.04, p > 0.01).  The conclusion that can be drawn from this analysis is that the 
InsideOut service model did not reduce waiting times to community drug treatment when compared 
to the CARAT service model. However, an interrogation of the mean length of waiting times (see 
supplementary table 6.0) via Hedges’ test (d = 0.28) suggests there may be a weak or ‘unobservable’ 
difference between the two groups. 
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Table 4.5.2:  Waiting times to drug treatment 
Summary Means 
Service delivery 
model N 
n of 
Events 
Censored Estimate SE 95% CI 
n % 
  
Lower Bound 
Upper 
Bound 
 
CARAT 
 
255 
 
26 
 
229 
 
90 
 
134 
 
24.1 
 
87 
 
181 
InsideOut 278 56 222 80 99 15.8 68 130 
Overall 533 82 451 85 111 13.3 84 137 
 
 
 
 
 
Figure 4.5.2:  Kaplan Meier SA for waiting times to treatment, CARAT and InsideOut compared.  
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4.6 CARAT and InsideOut continuity of care performance within the national context 
In this section, the study and subsequent continuity of care performance outputs are contextualised 
within the national performance frameworks.  During the period of study data collection period, the 
prison to community continuity of care transition was measured as a tier 2 (prison DIRWeb to 
community DIRWeb) transition, and during the full two-year period prior to thesis submission date, 
the transition was recorded as a tier 3 (structured) treatment journey. 
 
4.6.1 2008-12 Home Office DIMIS/DIRWeb reports 
The Essex Partnership’s continuity of care performance returns improved year on year.  Between 
April 1st 2008 and 31st March 2009, 113 people (27% of the total) leaving prison were recorded as 
having engaged with the community DIP team within twenty-eight days of release.  This rate of 
engagement improved on a yearly basis so that by 2012, 68% (n = 169) of those released were 
involved with the community system, as seen in Table 4.6.1.   
A similar pattern was reported by the Leicester/Leicestershire drug recovery partnership 
who, having also introduced a single service delivery model by 2012, could report that 77% (n = 95) 
of people released were engaged with the community DIP team.  Higher levels of engagement with 
these respective programmes is linked to the work of five of the seven Drug System Change Pilot 
areas (Essex and Leicester included), which submitted bids detailing a focus on their criminal justice 
drug treatment care pathways.  Combined, the continuity care performance returns improved from 
23% (n = 265) during 2008 to 74% (n = 405) during 2012.  In comparison, their matched control areas 
reported an improvement to 45% (n = 197) in 2012 from 24% (n = 295) by 2012 and in line with 
national returns of 24% and 47%, respectively. 
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Table 4.6.1:  Tier 2 continuity of care performance rate returns.   
Prison to community continuity of care tier 2 (DIR to DIR) activity between 2008 and 2012. Performance activities of the two systems change areas testing integrated service provision, five 
of the seven Drug System Change Pilots focussed towards criminal justice care pathways and their matched controls, within the context of the national returns as reported by the UK 
Home Office DIMIS (DIRWeb) reporting system. 
Area/status 
2008 - 09 2009 - 10 2010 - 11 2011 - 12 
Prison 
referrals 
Community 
engagements 
% 
Prison 
referrals 
Community 
engagements 
% 
Prison 
referrals 
Community 
engagements 
% 
Prison 
referrals 
Community 
engagements 
% 
Essex 416 113 27 377 171 45 403 238 59 248 169 68 
Leicester 327 99 30 337 73 22 267 161 60 123 95 77 
DSCP areas (n = 5) 1143 265 23 1088 310 28 1009 594 59 547 405 74 
Control areas (n = 5) 1223 295 24 1054 388 37 986 478 48 437 196 45 
National returns (n = 149) 26926 6544 24 23052 7894 34 24162 10159 42 13722 6396 47 
 
Note: quarter 4, the year 2011-12 missing. 
 
4.6.2 2014-16 Public Health England NDEC/NDTMS reports 
After a two-year hiatus between 2012 and 2014, during which time the NDTMS replaced the prison 
DIRWeb data collection system, responsibility for the reporting of the prison to continuity of care 
transition was transferred to Public Health England.  Whilst the national, role and regional continuity 
of care performance has remained steady at approximately 25%, the InsideOut service has delivered 
year on year performance rate improvements of 37% (n = 162) and 55% (n = 250) in 2015 and 2016, 
respectively. 
Table 4.6.2:  Tier 3 continuity of care performance rate returns 
 
 
 
4.7 Treatment outcome profile 
This section of the data analysis compares and reports the outcomes data of those people 
recovering and relapsing (to prison).   
 
Performance contexts 
% prisoners released commencing a treatment episode in 
the community within 3 weeks of release 
2014 - 15 2015 - 16 
Engaged % Engaged % 
National 7385 25 7114 24 
Local (role) 6240 26 5965 24 
Midlands & East of England (region) 2407 25 2950 24 
HMP Chelmsford (establishment) 162 37 250 55 
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4.7.1 TOP alcohol consumption and drug use 
In the community treatment system (the ‘recovered’ group for the purposes of this study), 3,691 
Essex residents were reported to have exited the Partnership’s drug and alcohol treatment system 
as recovered.  In the prison treatment system (the ‘relapsed’ group), 1,628 people were reported to 
have engaged (Table 4.7.1).  Consumption of alcohol was reported by 47% of those recovered and 
42% of those relapsed at a statistically significant level (p < 0.01), and mean daily consumption was 
11.0 and 18.2 days, recovered and relapsed, respectively (t = 17.72, p < 0.01).   
Opiate use was reported by 22 (1%) of people recovered and by 667 (41%) of those relapsed 
(p < 0.01), with means daily use reported as 11.8 and 18.9 days, recovered and relapsed, respectively 
(t = 3.39, p < 0.01).  Crack cocaine use was reported by 23 (1%) of individuals in the recovered group 
and by 614 (38%) of those who had relapsed (p < 0.01), with mean daily use reported as 8.4 and 16.5 
days, recovered and relapsed, respectively (t = 3.79, p < 0.01).  Powder cocaine use was reported by 
206 (6%) of recovered people and by 318 (20%) of those who had relapsed (p < 0.01), with mean 
daily use reported as 5.5 and 13.2 days, recovered and relapsed, respectively (t = 9.73, p < 0.01).  
Amphetamine use was reported by 32 (1%) of those who had recovered and by 50 (3%), of those 
who had relapsed (p < 0.01), with mean daily use reported as 9.0 and 10.5 days, recovered and 
relapsed, respectively (t = 0.68, p > 0.01).  Cannabis use was reported by 710 (19%), of people who 
had recovered and by 564 (35%) of those who had relapsed (p < 0.01), with mean daily use reported 
as 14.7 and 19.5 days, recovered and relapsed, respectively (t = 8.89, p < 0.01).  Use of other drugs 
was reported by 74 (2%) of people recovered and by 249 (15%) of those relapsed (p < 0.01), with 
mean daily use reported as 12.4 and 18.5 days, recovered and relapsed, respectively (t = 4.61, p < 
0.01). 
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4.7.2 TOP offending 
As illustrated in Table 4.7.1, shoplifting activity was reported by 13 (< 1%) people recovered and by 
317 (19%) of those relapsed (p < 0.01), with mean daily activity reported as 4.2 and 13.9 days 
recovered and relapsed, respectively (t = 3.28, p < 0.01).  The dealing of illicit drugs was reported by 
8 (< 1%) people recovered and by 84 (5%) of those relapsed (p < 0.01), with mean daily use reported 
as 6.3 and 17.9 days, recovered and relapsed, respectively (t = 3.48, p < 0.01).  Other acquisitive 
crime was reported by 21 (1%) individuals who had recovered and by 375 (23%) of those who had 
relapsed (p < 0.01).  Furthermore, instances of assault were reported by 26 (1%) people and by 223 
(14%) of those who had recovered and relapsed, respectively (p < 0.01). 
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Table 4.7.1:  Self-reported drug use and criminal activity  
 
TOP  System data collected from NDTMS/TOP between 01/04/2008 & 31/03/2013      
  Recovered (n = 3691)    Relapsed (n = 1628)    Statistical test 
Domain Item n % M Range  SD n % M Range  SD Student's t Fisher's 
exact (two 
tailed) 
     Min Max     Min Max     
Drug use Alcohol 1731 47 11 1 28 8.7 684 42 18.2 1 28 9.7 t = 17.72       
p < 0.01 
p < 0.01 
                 
 Opiate 22 1 11.8 1 28 11.4 667 41 18.9 1 28 9.6 t = 3.39         
p < 0.01 
p < 0.01 
                 
 Crack 23 1 8.4 1 28 10.7 614 38 16.5 1 28 10.1 t = 3.79         
p < 0.01 
p < 0.01 
                 
 Cocaine 206 6 5.5 1 28 6.2 318 20 13.2 1 28 10.2 t = 9.73         
p < 0.01 
p < 0.01 
                 
 Amphetami
ne 
32  9 1 28 9 50 3 10.5 1 28 10.1 t = 0.68         
p > 0.01 
p < 0.01 
   1              
 Cannabis 710 19 14.7 1 28 9.7 564 35 19.5 1 28 9.4 t = 8.89         
p < 0.01 
p < 0.01 
                 
 Other drug 74 2 12.5 1 28 10.5 249 15 18.4 1 28 9.4 t = 4.61         
p < 0.01 
p < 0.01 
                 
Crime Shop lifting 13 0 4.2 1 20 5.2 317 19 13.9 1 28 10.6 t = 3.28         
p < 0.01 
p < 0.01 
                 
 Dealing 8 0 6.3 1 20 6.5 84 5 17.9 1 28 9.2 t = 3.47         
p < 0.01 
p < 0.01 
                 
 Other theft 21 1 n/a n/a n/a n/a 375 23 n/a n/a n/a n/a n/a  p < 0.01 
                 
 Assault 26 1 n/a n/a n/a n/a 223 14 n/a n/a n/a n/a n/a  p < 0.01 
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4.7.3 TOP risky health behaviours 
Injecting behaviour, as seen in Table 4.7.2, was reported by 12 (< 1%) people who were recovered 
and by 283 (17%), of those who had relapsed (p < 0.01), with mean daily activity reported as 8.5 and 
18.2 days, recovered and relapsed, respectively (t = 3.48, p < 0.01).  Sharing of equipment was 
reported by 5 (< 1%) individuals who were in the recovered group, and by 42 (3%) of those in the 
relapsed group (p < 0.01). 
 
4.7.4 TOP health and social functioning 
Those who had recovered reported an average psychological wellbeing score of 14.3 (range = 0 to 
20), and people who had relapsed reported a mean score of 11.3 (t = 23.67, p < 0.01), (Table 4.7.2).  
The mean number of days worked for those recovered (n = 1232, 33%) was higher at 17.9 days than 
for those who had relapsed, 15.9 days (n = 179, 11%), (t = 4.35, p < 0.01).  The mean number of days 
spent in education was 13.0 and 15.5, recovered (n = 25, 7%) and relapsed (25, (2%), p < 0.01), 
respectively (t = 1.88, p = 0.06).  The presence of an acute housing need was reported by 139 (4%), 
of people who had recovered, but this need was significantly higher at 681 (42%) for those who had 
relapsed (p < 0.01).  Furthermore, 75 of those recovered (2%), and 208 (13%) of those relapsing 
reported their housing situation was at risk (p < 0.01).  In terms of overall health, the mean physical 
health scores reported by both groups were 14.9 and 13.0 days, recovered and relapsed, 
respectively (t = 15.89, p < 0.01), and the mean quality of life scores were 14.8 and 11.7 days, 
recovered and relapsed, respectively (t = 23.73, p < 0.01). 
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Table 4.7.2:  Self-reported risk behaviours and health and social functioning 
 
TOP  System data collected from NDTMS/TOP between 01/04/2008 & 31/03/2013      
  Recovered (N = 3691)    Relapsed (N = 1628)    Statistical 
test 
 
Domain Item n % M Range  SD n % M Range  SD Student's t Fisher's 
exact (two 
tailed) 
     Min Max     Min Max    
Risk 
behaviours 
Injecting 12 0 8.5 1 28 10.7 283 17 18.2 1 28 9.4 t = 3.48         
p < 0.01 
p < 0.01 
                
 Sharing 
equipment 
5 0     42 3      p < 0.01 
                
Health & 
social 
functioning 
Psychological 
wellbeing 
3669 99 14.3 1 20 3.9 1598 98 11.3 1 20 4.9 t = 23.67         p < 0.01 
                
 Paid work 1232 33 17.9 1 28 5.5 179 11 15.9 1 28 7.2 t = 4.35         
p < 0.01 
p < 0.01 
                
 Education 254 7 13 1 28 6.1 25 2 15.5 2 28 8.5 t = 1.88         
p > 0.01 
p > 0.01 
                
 Acute housing 
need 
139 4     681 42      p < 0.01 
                
 Housing at risk 75 2     208 13      p < 0.01 
                
 Physical health 3670 99 14.9 1 20 3.7 1606 99 13 1 20 4.6 t = 15.89         p < 0.01 
                
 Quality of life 3671 99 14.8 1 20 3.9 1569 96 11.7 1 20 5.2 t = 23.73         p < 0.01 
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Chapter 5 – Discussion 
5.1 Key findings 
In categorical terms, at both the system and organisational levels of enquiry, the findings presented here 
are mainly supportive of the study’s assumptions/primary hypotheses and justify the strategic 
commissioning decision to restructure service delivery around the prison-to-community continuity of care 
key transition point.  However, the findings generated from the continuous data reported here are less 
convincing, especially regarding the waiting times to treatment recorded at the organisational level.  
Importantly, unexplored confounding factors are likely to be affecting these initial interpretations (see fig 
5.1 below). 
Figure 5.1:  Study findings tabulated 
Research questions/hypotheses 
Strength of study findings 
System level (study assumptions) Organisational level (hypothesis testing) 
Positive Negative Positive Negative 
Continuity of carea & engagement with drug treatmentb (1)   
ab 
Continuity of care & waiting times to drug treatment (2) ‡   
†
Continuity of care & length of time in drug treatment (2) 
 
†   
Continuity of care & relapse to prisonc (1) 
 
 c 
Drug treatment & relapse to prison (2) 
 
‡   
Continuity of care/treatment & relapse to prisond (2) 
 
 d
 
 
Note: (alpha) = discrete measurement, (1) = categorical, (2) = continuous, † = weak effect & ‡= strong effect 
 
At the system level, continuity of care was shown to be significantly associated with improved 
rates of treatment engagement (table 4.3.1, p 105) and reduced estimated mean waiting times for 
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treatment (figure 4.3.2, p 107).  Individuals in contact with the prison-to-community continuity of care 
pathway were almost three times more likely to receive drug treatment and waited for more than half as 
long to do so compared to those outside of the care pathway.  Those receiving continuity of care reported 
longer estimated mean times in treatment (table 4.3.3, p 108), and in terms of percentage rates, were less 
likely to be returned to prison (table 4.3.4, p 110), but in both instances, not statistically significantly so.  
Although this study could not demonstrate that drug treatment was significantly associated with longer 
survival times in respect of returns to prison (table 4.3.5, p 110), a calculation of effect size is suggestive of 
a small but unobservable treatment effect (p 110).   And although people engaging with treatment via 
continuity of care reported longer stays in treatment, there was no evidence to support that the effect 
was statistically significant (table 4.3.6, p 112). 
 This study has demonstrated that single service delivery (InsideOut)-directed prison-to-
community continuity of care was significantly associated with improved rates of continuity of care, 
treatment engagements and reduced rates of returns to prison when compared to the twin service 
(CARAT to Community DIP) delivery model (table 4.5.1, p 120).  In relative terms, and against a backdrop 
of increased system activity, people managed by the InsideOut team were more likely to receive 
continuity of care and more than twice as likely to engage with community treatment.  People managed 
by the InsideOut service were almost half as likely to be returned to prison within the first twelve months 
of their first recorded release. However, whilst reduced estimated mean waiting times to treatment were 
recorded by people managed by the InsideOut service, this finding was not statistically significant (table 
4.5.2, p 121). 
 Confounding factors likely to be affecting this study’s findings include; selection bias and differing 
baseline characteristics between the comparison groups e.g. drug profile, age.  For example, this study 
could not account for all the people returning to prison (selection bias) due to cross boundary information 
sharing limitations. At the organisational level, due to limited sample size, the type of drugs misuse and 
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the increasing age of the OCU cohort has clouded this study’s interpretations of the intervention’s effects 
because the effects of these base line characteristics were not factored into the comparative analyses.  
This study’s attention to quality control (QC) of the data has undoubtedly contributed towards the 
reported elevated rates of prison-to-community community of care, especially within the context of the 
national reporting frameworks.  Increasing the number of matched statistical entities within the local 
environment will have artificially improved the rates of CC in comparison to other localities, simply 
because other partnerships will most likely not have undertaken similar QC exercises.  In other words, the 
performance environments were not equal. 
The introduction and use of volunteers at an unrecorded point within the study’s time frame, 
perhaps represents this study’s main concern, especially in respect of its findings and interpretations of 
the effect of the InsideOut intervention.  The ‘chaperoning’ of people upon their release from prison to 
their first community drug treatment appointment was not factored into the study design and is likely to 
have contributed markedly towards the reported improvement in the rates of treatment engagement.  
This development warrants further investigation because it may conceivably emerge that commissioning 
models that utilise volunteers in this way might prove to be a better use of resource as compared to the 
wholesale change of service delivery models as researched by this study. 
   
5.1.1 Prison-to-community continuity of care 
Treatments and therapies in both the prison and community settings continue to demonstrate an 
important role in achieving positive health and crime outcomes (Aspinall et al., 2016; Evans et al., 2016; 
Garnick et al., 2014; Yang et al., 2013).  Nevertheless, connecting the two systems by way of delivering 
effective prison-to-community continuity of care journeys remains problematic and shows little sign of 
improving (HM Inspectorate of Probation, 2016).  With the effects of austerity now being realised, 
particularly within the prison system (Chief Inspector of Prisons, 2015; The Full Fact Organisation, 2017), 
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and with attentions in part focussed towards other priorities within the prison service (BBC, 2017) and the 
NHS (Cambell, 2016), the opportunities and incentives to promote further development and testing of the 
service delivery model reported here may be limited.   
National policy strategists and commissioners remain focussed on encouraging integrated 
commissioning models (Bailie & Elliot, 2016).  From the local perspective, however, pressures associated 
with the reductions in the Public Health grant (A. Davies, 2015) may mean that prison-to-community 
initiatives, and offender health issues in general, become increasingly deprioritised.  This is unfortunate 
because, given current economic restraints and the recent focus on ‘transforming rehabilitation’ (UK 
Government, 2013), it could be argued that now is an opportune moment to further explore the 
feasibility of the single service delivery model presented here.  This is important, because this research 
would call into question the developing clinical trend described below if it were given the opportunity to 
set a precedent.   
Driven by persistently high rates of relapse from treatment and recidivism, certain recent 
research is focussed towards developing and testing mechanisms of drug delivery amongst the criminal 
justice population in order to improve treatment compliance, vis-a-vis prisoner continuity of care (Lee et 
al., 2015; Lee et al., 2016).  Prima facie, the results reported by this research are encouraging.  
Nevertheless, whilst this study makes no moral judgement with respect to substance misuse and wholly 
supports developments that aim to improve the health and crime outcomes associated with this complex 
and vulnerable demographic, it does subscribe to the notion that avenues of non-clinical intervention 
ought to be pursued in order to support cases where the primary goal for full recovery from substance 
misuse is abstinence.  Otherwise it is foreseeable that, albeit in a distant scenario, the solutions that are 
presently being promoted have the potential to lead to instances of ‘approved chemical dependence’. 
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5.1.2 Return to prison 
During the early stages of this study, particularly at the data modelling stage, there was a temptation to 
view the relapse to prison (RTP) measure as a local proxy for rates of reoffending.  In light of examiner 
feedback, however, and with a better understanding of the causes and reasons for the event, RTP within 
the context of this research is treated as a local ‘system’ outcome.  Such a view does not set a precedent, 
and may be of use.  Within the national reporting structure, a comparable outcome measure is the ‘in 
treatment’ count, as per the DOMES outputs, and as per client engagement via the Drug Testing on Arrest 
intervention.  This is a useful measure because, to some extent, it provides an insight into how effective 
the community drug treatment system is with regard to crime reduction.  A possible performance line of 
enquiry might be, “If drug treatment reduces crime, why are people in treatment appearing on the police 
Drug Test Recording (DTR)?”.  As a standalone challenge, this line of enquiry is not particularly helpful; 
nevertheless, when asked about a drug recovery system that reports static or increasing rates of the 
event in question, and particularly if re-offending continues to take place with the same individuals, then 
it can be argued that it begins to gain credence.  With that view in mind, this study advocates for the 
future inclusion of RTP count in the DOMES reporting mechanism. 
 
5.1.3 TOP 
The ad hoc analysis of the prison TOP data has raised some interesting points.  Within the context of this 
study, the findings were interesting for two reasons.  Firstly, they appear to confirm our experiential 
(perhaps obvious) understandings about the levels of ‘chaos’ in people’s lives (within 28 days of 
incarceration). And secondly, this study would suggest that the TOP data in prison might be 
operationalised, if it is not already the case, in order to more fully describe the drug recovery journey.  As 
previously emphasised, no claims are made re the scientific rigour of this analysis but this study would 
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suggest that if the findings reported here might be replicated via a more robust approach (Marsden et al., 
2011) and an interesting line of research might be developed.   
For example, if we are able to ‘connect’ the recovery journey, especially regarding those returning 
to prison (relapsing) within twelve months of their release, we might more formally (quantitatively) test 
assumptions/hypotheses.  For example, aside from testing the obvious assumption that failure to engage 
with the drug treatment (recovery) system upon release leads to relapsing behaviours, we might sensitise 
the analyses of the post release TOP to explore and approximate the cause and extent of the 
deteriorations prior to reincarceration so that the extent of the deterioration might be quantified.  Again, 
a somewhat obvious hypothesis to test would be that changes in circumstances, e.g. loss of stable 
accommodation, leads to increased criminal activity and increased likelihood of incarceration. 
Such an approach may produce secondary, ‘real time’, benefits.  For example, it might encourage 
the incorporation of the TOP fields into locality case management systems to act as ‘early warning’ 
markers thereby assisting care and case managers with their client management strategies thereby 
helping people to stay healthier and crime free. Operationalisation of the TOP in such a way presents 
many opportunities and this study advocates for such developments.  
 
5.2 Study limitations. 
 
This study was subject to several limitations.  It was relatively small, non-randomised, confined to a single 
locality and reported adult male prison-to-community process and outcomes only.  Importantly, the 
univariate approach appears to have confounded the interpretation of the outcome analyses re continuity 
of care at the system level which, due to limited sample size, was not investigated during the hypothesis 
(CARAT vs InsideOut) testing stage.  Importantly, the differences between the groups re baseline drug 
profile (OCU status) may have biased the findings in favour of continuity of care irrespective of the 
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commission intervention reported here.  Future investigations might target survival analyses towards 
discrete groups e.g. OCU only in order to address this issue.   
 For pragmatic reasons associated with audience type (in this case commissioners) a univariate 
approach was initially adopted. However, upon reflection the application of survival analyses combined 
with cox regression statistics throughout this study would have been more appropriate and made the 
study scientifically more robust in that much of the confounding may have been better understood. Also, 
where t tests have been reported re the TOP data, underlying assumptions associated with normal 
distributions were not investigated and the likelihood is that these data are bi-modal and left skewed 
requiring that other types of statistics be applied.  Finally, the underlying comparative analytical strategy 
re the TOP data is flawed given that it will be subject to selection biased. In other words, offending 
behaviour leads to incarceration whilst successfully recovering tends not to. 
 
5.2.1 Sample size  
Although a relatively small sample for quantitative analyses and comparisons (N = 533, CARAT (n = 255) 
vs. InsideOut (n = 278), a post-hoc power calculation (ClinCalc, 2017) determined that the study findings 
were reasonably powerful when setting alpha to 0.05, but less so when alpha was set to 0.01 (see 
supplementary table 1.0). 
 
5.2.2 Randomisation 
Whilst random sampling to minimise bias would have been the preferred strategy prior to analysis, the 
known and experientially expected low number of study outputs directed that this was not practicable.  A 
preliminary interrogation of the continuity of care tier 2 performance data indicated that the 
approximately 10% (n= 20 or so) of the CARAT sample might engage with community drug treatment, and 
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the best hoped for ‘expected’ effect of delivering continuity of care via the InsideOut service might have 
increased this rate to approximately 50% (n = 130 or so). It can be argued that because this study is the 
first of its type, it can be viewed as a ‘pilot’, and as such, random sampling may have diluted its findings 
thereby undermining or weakening the case for future investigations. A retrospective interrogation of the 
regional or national datasets might accommodate a random sampling strategy, and access to the wider 
network of drug recovery partnerships might allow for a prospective randomised intervention design to 
be tested.   
 
5.2.3 Low crime area 
Essex reports below national average overall acquisitive and drugs-related rates of crime, and is 
reasonably affluent (sourced from (Flatley, 2017)).  This study cannot provide definitive insights as to how 
these conditions may have influenced the findings presented here, but might speculate that people 
returning to this type of environment might be at reduced risk of relapse and recidivism.  Following that 
line of reasoning, it is worth considering given that the InsideOut intervention (or the prison-to-
community continuity of care process in general) might yield different results in areas with less conducive 
environments.  
 
5.2.4 Study demographic 
This study was limited to adult males released from a local prison, but given that adult female prison 
leavers are reported to relapse and recidivate in 45% of cases, there is little to suggest that the InsideOut 
intervention, tailored to women’s needs, would be less effective with that group.  Perhaps the location of 
the prison, i.e. logistical challenges, might be a more significant factor in success rates than gender per se.  
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5.2.5 Weak study design 
An important oversight during the design phase of this research was the failure to take more account of 
potentially confounding factors. For example, the use of volunteers at an (unknown) point during the 
implementation of the InsideOut intervention.  This has two possible consequences.  From a quantitative 
perspective, there was an early assumption that we were testing like-for-like in terms of general care, but 
the introduction of volunteers to meet ex-prisoners at the gate upon their release has more than likely 
(positively) influenced the improved rates of continuity of care. From the care perspective, this is 
obviously a good thing; however, not being able to measure the impact of such an intervention during the 
CARAT period of operations may somewhat dilute the study’s findings in terms of its assertion that single 
service provision was preferred to a twin service delivery model. Future research into service delivery 
models will need to take this into consideration.  
 
5.2.6 Sources of potential bias or imprecision 
An early concern, realised during the development of the ethical approval document, was the proximity of 
the quantitative researcher to the commissioning and performance team who had oversight of the 
InsideOut service, and this might have influenced the results reported in this study.  In other words, there 
may have been a vested interest to report the evaluation of the intervention in a favourable light, given 
the quantitative researchers’ inputs during the early design and commissioning phase of the InsideOut 
service. 
 Of course, from a performance perspective, the desire to see the new service succeeding was 
paramount. However, my own responsibilities with regard to the design and operation of InsideOut were 
devolved upon the ‘go live’ date of April 1st, 2010, and from that point on, the research activities reported 
here took precedence. At no point was I involved in the delivery of the service.  Furthermore, during the 
early stages of the study design it was made clear, via lengthy discussions conducted with the lead 
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recovery commissioner, that the evaluation might report that the introduction of InsideOut had no 
positive impact on the delivery of continuity of care. 
 
5.2.7 Direction and magnitude of any potential bias 
As well as the possibility of subjective (researcher) bias influencing the findings reported here, the 
number of matched statistical entities generated for study counting purposes was maximised via the data 
audit which has undoubtedly biased this research (and the performance) outputs in its favour.  The audit 
reduced the number of statistical entities in both the prison and community DIRWeb systems, and 
consequently improved the number of matched records at the system level by as much as 29% in one 
direction.  An exact percentage improvement figure caused by the audit in relation to this research cannot 
be provided, but a cautious estimate of the impact of the quality control exercise would be in the region 
of a 10% to 20% increase in the number of matches. 
 
5.3 Context 
In order to contextualise this study, three demographic variables were selected for comparison with the 
local, regional and national profiles. 
 
5.3.1 Age 
The study variable age was grouped into three bands, namely 18–24, 25–34 and 35–64 years of age.  
Although not coterminous, these groupings best fit the published ONS, OCU prevalence, and prison 
population statistical outputs, and were sufficiently comparable to allow an interpretation of trends in 
broad terms.  In terms of age, the Essex population was broadly representative in comparison to the 
regional and national profiles, albeit slightly older; however, the study group was not. Compared to the 
general population, individuals in the study group tended to be younger and were indicative of the prison 
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population during the period of data collection (2008/9 – 2011/12) (Ministry of Justice, 2016).  However, 
there was considerable variation within the study group.  For instance, people cared for by the CARAT 
team tended to be younger than those cared for by the InsideOut team (see table 4.2) and the mid-age 
range group was over-represented within ‘HMP Other’ population.   
There are several possible interpretations. Firstly, when comparing the CARAT and InsideOut 
groups, the differing age profiles might be explained by way of the standardised introduction of the Home 
Office’s DIP policy and guidelines (Home Office, 2007a, 2011).  Prior to the InsideOut intervention, the 
local prison CARAT team appears to have operated within an ‘assess all’ (OCU and non-OCU) process-
driven management model, as perhaps evidenced by the drug profiling section discussed later; whereas 
the InsideOut team, which was experienced in a targeted, outcomes-orientated approach, primarily 
focussed their attention on prisoners with OCU drug profiles, who tended to be older than the non-OCU 
group (see table 4.2).  Secondly, the local sentencing policy may have directed that younger people were 
less likely to be sent to prison.  According to a senior commissioner in private correspondence, this was 
not the case, and given that during the data collection period the prisoner age profile remained fairly 
constant (Ministry of Justice, 2016), it seems unlikely. However, this latter scenario cannot be ruled out 
because – certainly at the national level – a trend for fewer sentences for younger people appears to have 
emerged  (Ministry of Justice, 2016). 
 
5.3.2 Ethnicity 
According to the ONS outputs, the BME communities were slightly under-represented within the general 
population, and also within the study group; but as with the age profiling, there was a noticeable within-
cohort variation (see table 4.2).  In terms of comparison with the Essex demographic, the BME groups 
were more fairly represented by the InsideOut team than by the CARAT intervention, with the ‘HMP 
Other’ group falling roughly in-between. This may be largely explained as a reflection of the Essex 
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Partnership’s emerging diversity (EssexInsight, 2012) and suggests that the InsideOut intervention might 
readily transfer to other ethnically diverse areas. 
 
5.3.3 Drug profile 
In terms of percentage representation (mean number of estimated OCUs/adult population estimate), the 
Essex Partnership is not representative (almost half) of the national picture, but it is broadly in line with 
regional estimates.  This is reflected by the observation that the Partnership was not included within the 
first three waves of the UK Home Office’s Drug Testing on Arrest (DToA) initiative, because it was not 
viewed as a ‘high crime’ area (Public Health Institute, 2003). 
However, there was considerable disparity within the study group.  Almost nine out of ten people 
cared for by the InsideOut team reported OCU misuse, compared to almost seven out of ten people seen 
by the CARAT and community DIP teams (HMP Other). Whilst the disparity reported within ‘HMP Other’ 
group is not fully explained by this research, in terms of the ‘success’ associated with the introduction of 
the InsideOut intervention, the rebalancing of the drug profile in favour of those people seeking 
treatment for OCU misuse is perhaps second only to the reportedly improved rates of continuity of care 
and the associated reduction in waiting times, which warrants special mention. 
 Throughout the course of this study and within a ‘commissioning for outcomes’ framework, 
prioritising the OCU-misusing cohort was of paramount importance.  This complex and high-risk group of 
people has been (and to some extent remains) a focus of attention since the earliest anti-drug policy 
outputs.  While leaving for later discussion the significant cost benefits to be realised from targeting the 
harms associated with OCU misuse, the InsideOut’s intervention has facilitated an increase of more than 
double the number of ex-prisoner OCUs into drug treatment, and this alone is a significant achievement in 
light of the greater complexity and vulnerability associated with this high-risk group. 
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5.4 Confounding (or predicting) variables 
 
5.4.1 Considered within study design 
This study is primarily concerned with transitioning people from the prison to community drug recovery 
within a systems orientated (‘whole’ person) and non-reductionist paradigm.  And from that perspective 
issues such as age, ethnic and drug profiling, and their possible influences were a secondary concern. 
However, that said, an analysis of the age of people engaging with treatment found that older 
people were statistically significantly more likely to engage with community drug treatment and this is 
important strategically delivery perspective.   The opiate-misusing cohort is ageing  and as they older they 
present with increasingly complex needs, and recent research has voiced concerns that the drug recovery 
and wider healthcare systems are properly prepared (Pirona, Guarita, Montanari, & Noor, 2014). 
 
5.4.2 Not explored 
Other confounders not explored fell into one of two categories: those that can be addressed via an 
interrogation of the national datasets, and those that may be investigated in further research via 
improved study designs.  Firstly, of the people re-entering the community drug recovery system (from all 
prisons), it was not known how many were returned to prisons external to the partnership.  As mentioned 
previously, it was thought that sentencing policy remained standard throughout the study period; 
however, an analysis of the wider datasets will be required to improve our understanding in that area. 
 Perhaps of greater importance in terms of the veracity of this study’s findings, were the two 
observations that emerged (one ‘positive’ and the other not) regarding the completion of the data 
collection phase. From the data reported here, it is not possible to estimate the number of people who 
left the prison drug-free and fully rehabilitated.  Within the context of this study, this may potentially be 
viewed as a positive finding, since knowing such information may have led to an adjusted (lowered) 
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denominator regarding the rate of return prison metric, with and without continuity of care, thereby 
producing a statistically significant difference for that research question (currently reported as p > 0.01). 
 
5.5 Significance 
This study’s findings have both clinical and non-clinical significance, and whilst the work reported here 
was predominantly focused on non-clinical/administrative aspects, the clinical relevance is discussed first 
because the overarching aim of the intervention was to contribute to improving the negative health and 
crime outcomes associated with this complex and vulnerable group of people. 
 
5.5.1 Clinical 
Relapse to substance misuse, overdose, and mortality 
Although this study did not directly concern itself the with high mortality rates associated with substance-
misusing prisoners shortly after their release (Binswanger, Blatchford, Mueller, & Stern, 2013), recent 
research indicates that the risk of early death for ex-prisoners is acute, and persists long after release 
(Chang, Lichtenstein, Larsson, & Fazel, 2015; Pierce et al., 2016).  This research stresses the importance of 
prison-to-community transitional arrangements and, in addition, highlighted that the substance misuse 
treatment itself might benefit from a shift in focus from the acute to a chronic disease management 
model.  Interestingly, the Scottish Naxelone project has recently published findings suggesting that the 
mortality rate of injecting drug-misusing prisoners decreased during the first two years of their 
intervention (Bird, McAuley, Perry, & Hunter, 2016).   
A persuasive case for targeting prisoners at the point of their release in order to minimise their 
risk of death has been put forward by Zhlodre and Fazel (2012), who highlighted that almost one in five 
reported ex-prisoner deaths can be attributed directly to substance misuse.  From this study’s 
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perspective, it would be interesting to reframe the research questions presented here with mortality rates 
in mind.  For example, how do waiting times, engagement with/duration of treatment (type), and 
access/lack of access to prison-to-community continuity of care, impact on the rates of mortality within 
the ex-prisoner population in both the short and long term? 
 
Infectious diseases 
Prison-to-community continuity of care is important in terms of other, not unrelated, treatment contexts.  
Binswanger et al. (2013) have reported that post-release prisoners that report infectious diseases may 
have up to four times greater risk of death than the general population. 
Although new incidences of HIV have stabilised, and there is a trend towards decreasing infection rates 
(Kirwanm, Chau, Brown, Gill, & Delpech, 2016), HIV prevalence within the prison population remains 
problematic, especially within the injecting drug-using cohort (Dolan et al., 2015). 
For instance, a recent Scottish study, comparing prison to community HCV treatment outcomes, observed 
that because outcomes were negatively impacted by transfer and release policies within the prison 
system, people should be placed on medical hold rather than have their treatment interrupted (Aspinall 
et al., 2016). 
 
5.5.2 Non-clinical 
Care 
Whilst not statistically significant, there is a trend suggesting continuity of care, independent of 
treatment, may be associated with length of time in treatment and return to prison (p = 0.070 and 0.052, 
respectively). Whilst somewhat speculative at this stage, this may suggest the presence of a qualitative 
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dimension not envisaged within the original PTORS design. As mentioned earlier, the use of volunteers 
(Foundation66, 2017) to assist with prison leavers, especially at the point of release, evolved during the 
latter stages of the data collection phase (2011) and this study was unable to quantify its effect. However, 
this highlights another area of interesting research with a view to investigating exactly which types of non-
clinical care are delivered by the voluntary sector involved with prison-to-community transitions. 
 
Systems thinking within the healthcare context 
At the time, this study was conceived (2008-9), whilst the language of systems appeared to be ubiquitous 
within the health and criminal justice domains, the theoretical drivers underpinning this type of thinking 
when applied to problem-solving or ‘untangling messes’ were perhaps less evident.   During the 
intervening period, this type of problem-solving approach, which is geared toward individual- (Daddow & 
Broome, 2010) and place-based situations (Ham & Alderwick, 2015), has emerged and continues to gain 
traction (Adam, 2014; Cordon, 2013).   
By making certain assumptions – for example, that drug treatment works in the sense that it 
improves health and reduces crime – this study adopted a person-centred system thinking approach 
(Kabir Sheikh, George, & Gilson, 2014; K. Sheikh et al., 2011), and located the point of release from prison 
as the crucial ‘pinch point’ within a process-linked-to-outcomes systems conceptual framework.  This type 
of ‘harder’ problem-solving approach, which tends to appeal to those with of a more positivistic 
epistemological outlook, may have particular use within the field of public health, where lines of enquiry 
involve the use of data-driven policy and decision making (Carey et al., 2015). 
In an environment of increasing demand and shrinking resources (The KingsFund, 2017), the 
systems thinking (hard and soft) approach, which is targeted towards integrated service delivery, may 
contribute to the desired health outcomes linked to expenditure policy outcomes currently in focus (The 
Telegraph, 2017). 
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Integrated commissioning 
Locally, the integrated prison and community care offender health care pathways have been further 
integrated to incorporate people with mental health issues, learning difficulties, etc. into a new service 
provision called Full Circle (Pheonix Futures, 2016). In other words, all complex and vulnerable individuals 
in contact with the local criminal justice system (irrespective of substance misuse) will potentially benefit 
from contact with this service.  Also, the introduction of the Drug Testing on Arrest (DToA) scheme into 
the partnership (Office of the Police and Crime Commissioner for Essex, 2014) may have uncovered a 
group of ‘hidden’ or treatment-naive substance-misusing offenders (report pending), who will fall within 
the remit of the Full Circle provision. This suggests that, from a value-for-money standpoint alone, this 
type of strategic commissioning model is effectively delivering service.   
 
Performance 
Viewed through the (local) lenses of strategic commissioning, data and performance management, the 
findings presented here have vindicated our a priori decision to reconfigure (integrate) service delivery 
around the prison-to-community continuity of care transition point. However, as emphasised earlier, 
without being able to definitively attribute cause and effect, we have been cautious with our 
interpretations, and recommend that future research should investigate the qualitative aspects 
associated with the transition point within this care pathway. With that said, and applying the caveats 
associated with system maturation and ‘machine learning’, from the performance perspective it is 
gratifying to report that by the NHS year end in 2016, the InsideOut team recorded a 55% (tier 3) prison-
to-community continuity of care performance rate. At that point in the reporting cycle, excluding a return 
of 100% (n = 1), the InsideOut team had reached the pinnacle of the prison-to-community continuity of 
care performance tables within the England/Wales context. 
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Cost benefit and value for money considerations 
Aside from the beneficial individual and societal harm reductions associated with treatment engagement 
amongst drug misusers, there are significant short- and long-term economic implications. The annual and 
lifetime costs associated with an out-of-treatment OCU misuser range from £37K to £65K and from £550 
to £956K respectively (Frontier Economics, 2009).  In addition, the costs of housing people in prison are 
estimated to be £33,102 per person, per year (UK Government, 2014). Whilst a detailed unit-costing 
exercise was beyond the scope of this research, we can draw some tentative conclusions, especially in 
respect of value for money, about the financial impact associated with the introduction of the InsideOut 
service. 
For instance, for the same contract value, and in actual terms, the InsideOut team placed more 
than twice as many people into structured treatment compared with the CARAT team, and contributed 
towards an approximate 30% reduction in the numbers of people being returned to prison within the first 
twelve months of their first release. In other words, for no extra investment (apart from the resources 
required to manage the recommissioning exercise and fund this research), the single service delivery 
model appears to be a more productive (in terms of value for money) commissioning arrangement.  
Without knowing the exact amount of treatment time and time spent in prison after first recall, it is 
difficult to be exact. Nevertheless, according to this study’s findings, there appears to be some quite 
significant cost benefits and value for money gains associated with this particular intervention. 
 
5.6 Generalisability 
To what extent might the findings reported here be applicable to other groups and other settings? If the 
intervention had been targeted towards adult female substance misusers, as previously discussed, there is 
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a reasonable level of confidence that the improved rates of prison-to-community continuity of care, 
structured treatment engagements and reduced rates of return to prison reported here would have been 
observed with that group also. However, we are less confident that this type of intervention is applicable 
to the Young Offender (<18 years) age group and institutional setting, having limited operational 
experience with that group.  In terms of different settings, we are reasonably confident that this type of 
intervention could be replicated within Partnerships that host local category B prisons.  This assertion is 
supported with the knowledge that, having influenced their commissioning strategy to adopt a single 
service delivery model, the Leicester/Leicestershire/Rutland Drug Recovery Partnership made similar 
prison-to-community continuity of care gains (National Treatment Agency, 2009e), as per the tier 2 
statutory reporting mechanism.  If the system-level findings reported here can be verified and 
strengthened by an interrogation of the national datasets, there is no reason to suppose that this 
intervention would not transfer. The problem may be that, given the diminishing influence of the 
commissioning and performance frameworks originally introduced by the NTA, the opportunity to further 
integrate commissioning streams to support these types of interventions may have been missed (Jones, 
Donmall, & Millar, 2015). 
 
5.7 Conclusions and future research 
Viewed in the round, the conclusion is drawn that the Essex Partnership was correct to reconfigure the 
prison-to-community continuity of care pathway by introducing the InsideOut intervention. Furthermore, 
this research would argue that a case is developing for introducing the rate of relapse to prison as a 
system measure of performance. Extending this research to incorporate an analysis of the factors 
contributing to the RTP event might strengthen this case and contribute to our understanding of the rates 
of reoffending. And, whilst the findings presented by this research are generally supportive of the single 
service delivery model, more work is required if the confounding influences are to be apportioned and 
 
 
148 
 
fully understood, particularly in respect of the use of peer mentors at the point of release as ‘chaperones’ 
to the community drug recovery system.   
Outside of these confounding factors, at the system level there appears to be a relationship 
between prison-to-community continuity of care and improved rates of and reduced waiting times to 
community drug treatment engagement. And whilst the evidence is less convincing with regards to the 
relationship between treatment engagement and return-to-prison, this study suggests that there is 
enough of an effect to warrant further investigations.  Perhaps initially, the research challenge is to 
generate more robust ‘scientific’ evidence that supports the importance of prison-to-community 
continuity of care and its relationship with treatment engagement (and thus return-to-prison), and the 
role it plays in reducing health and crime harms associated with drugs misuse so that future strategic 
commissioning decisions might be influenced. 
 The introduction and consolidation of the NDTMS into the prison drug recovery system is an 
encouraging development and presents numerous opportunities.  From this study’s perspective, it would 
be interesting to discover if the system-level outcome and process trends reported here are replicated 
with the regional and national datasets and for longer (two and three-year) follow-up periods.  Also of 
interest would be a sampling exercise of the local area Public Health commissioning practices to 
determine whether possible associations exist between types of criminal justice care pathway 
commissioning models and prison-to-community performance.  
 Finally, the main concern throughout this period of study has been the notion that perhaps simply 
having ‘Drug System Change Pilot’ status conferred to the Partnership has driven up the rates of prison-
to-community continuity of care wholly outside of the InsideOut intervention.  And whilst this may be of 
concern from a research perspective, ultimately, and by whatever mechanism, more prison leavers were 
engaged with drug treatment, thereby improving their own health and facilitating their rehabilitation into 
the communities they return to.  Or put another way, we did no harm… 
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Appendices 
1.0 PTORS favourable ethical opinion 
  
  
  
NRES Committee East of England - Essex  
East of England Rec Office 1  
Victoria House  
Capital Park  
Fulbourn  
Cambridge  
CB21 5XB  
  
 Telephone: 01223 597693  
Facsimile: 01223 597645 27 April 2012  
  
Professor Gillian Green  
Director NIHR Research Design Service for the East of England  
University of Essex  
Room S2S.5.07   
School of Health & Human Sciences  
Wivenhoe Park, University of Essex  
CO4 3SQ  
  
  
Dear Professor Green  
  
Study title:  The impact of 'Inside Out' on crime and health outcomes 
and processes among substance misusing offenders: 
Essex drug & alcohol partnership (EDAP) prison 
treatment outcomes research study (PTORS)   
REC reference:  12/EE/0074  
  
Thank you for your letter of 26 March 2012, responding to the Committee’s request for further 
information on the above research and submitting revised documentation.  
  
The further information has been considered on behalf of the Committee by the Chair in 
consultation with the other reviewer for your study 
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Confirmation of ethical opinion 
  
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation [as 
revised], subject to the conditions specified below.  
  
Ethical review of research sites 
NHS sites  
  
The favourable opinion applies to all NHS sites taking part in the study, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
"Conditions of the favourable opinion" below).  
  
Non-NHS sites  
  
Conditions of the favourable opinion 
  
The favourable opinion is subject to the following conditions being met prior to the start of the 
study.  
  
Management permission or approval must be obtained from each host organisation prior to the start 
of the study at the site concerned.  
  
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements.  
  
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.    
  
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought 
from the R&D office on the information it requires to give permission for this activity.  
  
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.   
  
Sponsors are not required to notify the Committee of approvals from host organisations  
  
It is the responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable).  
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Approved documents 
  
The final list of documents reviewed and approved by the Committee is as follows:  
   
Document     Version     Date     
Evidence of insurance or indemnity      01 August 2011   
Interview Schedules/Topic Guides   1.0   07 February 2012   
Investigator CV      07 February 2012   
Letter from Sponsor      30 January 2012   
Letter of invitation to participant   1.0   07 February 2012   
Other: CV David Pevalin      07 February 2012   
Other: CV Frances Blumenfield      07 February 2012   
Other: CV Sarah Secker      07 February 2012   
Other: CV Marc Connor      07 February 2012   
Other: Key Worker Information Letter   1.0   07 February 2012   
Other: Instructions to Key Workers   1.0   26 March 2012   
Participant Consent Form   1.0   07 February 2012   
Participant Consent Form   2.0   26 March 2012   
Participant Information Sheet: Long   1.0   07 February 2012   
Participant Information Sheet: Short Prison   1.0   07 February 2012   
Participant Information Sheet: Short Community   1.0   07 February 2012   
Participant Information Sheet: Long PIS   2.0   26 March 2012   
Participant Information Sheet: Short Prison Cohort   2.0   26 March 2012   
Participant Information Sheet: Short Community Cohort   2.0   26 March 2012   
Protocol   1.0   07 February 2012   
Protocol (NOSA) 2.0   26 March 2012   
REC application   3.3   03 February 2012   
Referees or other scientific critique report      30 January 2012   
Response to Request for Further Information      26 March 2012   
Summary/Synopsis   1.0   07 February 2012   
  
Statement of compliance 
  
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics 
Committees and complies fully with the Standard Operating Procedures for Research Ethics 
Committees in the UK.  
After ethical review 
Reporting requirements  
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The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including:  
  
Notifying substantial amendments  
Adding new sites and investigators  
Notification of serious breaches of the protocol  
Progress and safety reports  
Notifying the end of the study  
  
The NRES website also provides guidance on these topics, which is updated in the light of changes in 
reporting requirements or procedures.  
  
Feedback  
  
You are invited to give your view of the service that you have received from the National Research 
Ethics Service and the application procedure.  If you wish to make your views known please use the 
feedback form available on the website.  
  
Further information is available at National Research Ethics Service website > After Review   
  
12/EE/0074  Please quote this number on all correspondence  
  
With the Committee’s best wishes for the success of this project  
  
Yours sincerely  
  
pp   
Dr Alan Lamont Chair 
  
Email: suzanne.emerton@eoe.nhs.uk  
  
Enclosures:  “After ethical review – guidance for researchers”   
Copy to:  Sarah Manning Press  
Marc Connor  
Sarah Senker 
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2.0 Confirmation from sponsor 
 
University of Essex Research and Enterprise Colchester Campus 
 Office Wivenhoe Park 
 T 01206 872922  Colchester C04 3SQ 
 F 01 206 873894 United Kingdom 
 E reo@essex.ac.uk 
wvvwessex.ac.uk/reo 
T 01206 873333 
F 01206 873598 
www.essexacuk 
30 January 2012 
Dr Alan Lamont 
Chair 
NRES Committee East of England - Essex 
Victoria House 
Capital Park 
Fulbourn 
Cambridge 
CB21 5XB 
Dear Dr Lamont 
The impact of 'Inside Out' on crime and health outcomes and processes among substance misusing offenders: Essex drug & 
alcohol partnership (EDAP) prison treatment outcomes research study (PTORS) (REC ref no: 12/EE/0074) 
I am pleased to confirm that the University of Essex, as employer of the Chief Investigator, will act as Sponsor under the 
Department of Health Research Governance Framework for Health and Social Care for the following research project: 
Chief Investigator: Professor Gill Green 
Department: Health and Human Sciences 
Project Title: 
The impact of 'Inside Out' on crime and health outcomes and processes among substance 
misusing offenders: Essex drug & alcohol partnership (EDAP) prison treatment 
outcomes research study (PTORS) 
Funding  Award to Professor Gill Green from the Essex Drug and Alcohol Action Team 
For the avoidance of doubt the University of Essex will not act as Sponsor for Clinical Trials of Medicinal Products which fall 
under The Medicines for Human Use (Clinical Trials) Regulations 2004. 
The University will provide indemnity against negligent harm caused as a direct result of our employees' actions. 
Yours sincerely 
 
Sarah Manning-Press 
Research Governance and Planning Manager 
THE QUEEN'S 
ANNIVERSARY PRIZES 
50% recycled Foe CURTHER Enuc:AT10N material 2009 
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3.0 Notice of substantial amendment – Research proposal (information governance) 
 Welcome to the Integrated Research Application System 
 NOTICE OF SUBSTANTIAL AMENDMENT 
Please use this form to notify the main REC of substantial amendments to all research other than clinical trials of 
investigational medicinal products (CTIMPs).   
The form should be completed by the Chief Investigator using language comprehensible to a lay person.   
  
Details of Chief Investigator:  
 Title   Forename/Initials  Surname 
  
 Professor Gillian  Green 
Work Address Room S2S.5.07  
  School of Health & Human Sciences 
  Wivenhoe Park, University of Essex 
PostCode CO4 3SQ 
Email gillgr@essex.ac.uk 
Telephone 01206874144 
Fax 
  
 
The impact of 'Inside Out' on crime and health outcomes and processes among  
Full title of study: substance misusing offenders: Essex drug & alcohol partnership (EDAP) prison treatment 
outcomes research study (PTORS)  
Lead sponsor: University of Essex 
Name of REC: NRES Committee East of England - Essex  
REC reference number: 12/EE/0074 
Name of lead R&D office: 
Date study commenced: 30/04/2012 
Protocol reference (if applicable), current version 12/EE/0074, 
Version 2, 26/03/2012 and date: 
Amendment number and date: 1, 01/05/2012 
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Type of amendment  
(a) Amendment to information previously given in IRAS Yes      No 
If yes, please refer to relevant sections of IRAS in the “summary of changes” below. 
  
(b) Amendment to the protocol 
  Yes       No 
If yes, please submit either the revised protocol with a new version number and date, highlighting changes in bold, or 
a document listing the changes and giving both the previous and revised text.  
  
(c) Amendment to the information sheet(s) and consent form(s) for participants, or to any other supporting  
documentation for the 
study 
documentation for the study  
Yes       No 
If yes, please submit all revised documents with new version numbers and dates, highlighting new text in bold. 
  
Is this a modified version of an amendment previously notified and not approved?  
  Yes       No 
  
Summary of changes  
Briefly summarise the main changes proposed in this amendment. Explain the purpose of the changes and their 
significance for the study.  
If this is a modified amendment, please explain how the modifications address the concerns raised previously by 
the ethics committee.  
If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific 
value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or 
not additional scientific critique has been obtained. 
In response to committee feedback we have further defined the aims and objectives chapter and expanded the 
sections "Quantitative data collection" and "Quantitative Data Analysis" within the research protocol, to provide a 
clearer account of the quantitative arm's objectives. To support these amendments and committee concerns 
regarding information sharing processes, governance and agreements, we have attached the Partnership and 
Inside Out client information sharing agreements, plus the NDTMS data set business definitions documents.   The 
TOPs form is also include for information  
  
Please note that this amendment does not alter the research design or methodology of the study but merely 
wishes to clarify the quantitative context and aspects.  
  
Any other relevant information  
Applicants may indicate any specific issues relating to the amendment, on which the opinion of a reviewing body is 
sought. 
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List of enclosed documents  
Document Version Date 
Research Proposal 4 01/05/2012 
Tops Form  01/05/2012 
NDTMS business definitions  01/05/2012 
DAAT Information Sharing Protocol  01/05/2012 
WDP (Inside Out) Information Sharing Protocol  01/05/2012 
HMP Chelmsford Information Sharing Protocol  01/05/2012 
 
 
 
 
 
173 
 
 
 
Declaration by Chief Investigator  
1. I confirm that the information in this form is accurate to the best of my knowledge and I take full responsibility  
for it.  
2. I consider that it would be reasonable for the proposed amendment to be implemented.  
  
  
This section was signed electronically by gill green on 01/06/2012 10:58.  
  
 Job Title/Post: Professor 
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Job Title/Post: Professor 
Organisation: University of Essex 
Email: gillgr@essex.ac.uk 
  
Declaration by the sponsor's representative  
I confirm the sponsor's support for this substantial amendment. 
  
  
This section was signed electronically by Sarah Manning-Press on 01/06/2012 14:51.  
  
 Job Title/Post: Research Governance and Planning Manager 
 Organisation: University of Essex 
 Email: sarahm@essex.ac.uk 
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Prison Treatment Outcomes and Processes 
Research Study (PTORS) 
 
Professor Gill Green, 
Marc Connor & Sarah Senker  
University of Essex 
 
On behalf of Essex Drug and Alcohol Partnership. 
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Summary 
In April 2009 the Essex Drug and Alcohol Partnership (EDAP) was awarded Drug 
Systems Change Pilot status (DSCP), a Central Government sponsored initiative which allowed 
for and encouraged the testing of new ways of delivering drug treatment. A combination of local 
commissioning and information strategic thinking led to the creation of an innovative new drug 
treatment service, called “Inside Out”.  This provision was designed to span both the prison and 
community domains with the primary aim of improving the continuity of care or recovery journey 
for those drug misusing offenders exiting the prison estate into the local community.   
Statutory reports published during the first year of operations indicated that the number of 
successful client transitions significantly increased and that more clients in general exited the 
criminal justice system free of drug dependency.  These early successes and their supporting 
rationales have directly influenced national policy.   
This study will employ a mixed methods approach to investigate whether the initial 
process gains delivered by “Inside Out” have lead to reduced criminal activities or fewer episodes 
of recidivism and improved the health outcomes for this highly vulnerable group. Quantitative 
analyses of the recently piloted national data sets will be complemented with a qualitative study of 
those recovering and relapsing, with a view to better understanding how this example of 
organisational restructuring has influenced the recovery journey.  
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Background and Purpose 
Drugs and crime 
The associations between drug abuse and criminal behaviours are complex but well 
documented (Bennett, Holloway & Williams, 2001; Gossop, Trakada, Stewart & Witton, 2005; 
Keene, 2005; Lord Patel, 2010; McIntosh et al., 2007).  In addition, research indicates that a small 
number of offenders are responsible for a disproportionate amount of crime (Dawson & 
Cuppleditch, 2007). Particularly active amongst this population are the heroin and crack cocaine 
users (OCUs) who are responsible for approximately 56% of all crimes, especially those of an 
acquisitive nature (McIntosh et al., 2007). More recently it has been suggested that crack users in 
particular display the greatest odds of offending (Bennett, Holloway & Farrington, 2008). The 
focus of this study will be on those OCUs who appear in the prison system. 
Drugs and prison 
It is reported that up to 50% of all prisoners have a history of problematic drug use (Lord 
Patel, 2010; Singleton et al., 1999). The best way to gauge drug misuse within a prison at a given 
time is the random mandatory drugs test (RMDT). Although nationally the percentage of those 
testing positive is below the target of 9.3%, male local prisons exceed this with 10% of those 
tested giving a positive result (Ministry of Justice, 2011). Such a finding is of particular relevance 
for this research as HMP Chelmsford, where the study will occur, is a male local prison. 
Treatment of substance misusing offenders 
For every £1 spent on drug treatment, £2.50 is realised in savings to society in terms of the 
effects on crime and health economies (Davies et al., 2009). Despite this, and findings indicating 
the success of drug treatment for individuals (e.g. Godfrey, Stewart & Gossop, 2004; Gossop, 
Marsden, Stewart & Rolfe, 2000; Gossop et al., 2005; Sidwell, Best & Strang, 1999), the Ministry 
of Justice report (2011) indicates that the number of drug treatment programmes being completed 
in prison decreased from 2009/10 to 2010/2011
2
. Being aware of this phenomenon provides the 
                                                          
2
 N.B. It is not clear if this is due to a decrease in available treatment within custody or a decrease in the number of 
substance misusing offenders entering prison. 
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impetus to enhance service delivery with the aims of cutting crime and improving health 
outcomes.  
In contrast to previous studies (e.g. Gordon et al., 2008; Maude-Griffin et al., 1998; Perry 
et al., 2006; Wexler et al., 1999), this study will not focus on specific treatment modalities per se 
but will instead consider the impact of structural alterations resulting in the re-commissioning of 
two single disparate drug services into a single unified system. It seeks to learn if and how these 
structural changes affect an individual’s recovery journey and whether health and offending 
outcomes are improved.  
Policy  
The UK Government’s Drugs Intervention Programme (DIP) has operated in England and 
Wales since 2003 (Skodbo et al., 2007). Its overarching aim is to target those offenders 
committing acquisitive crime to fund their drug habits (heroin and/or crack) (Home Office, 2011). 
In the community the DIP is delivered via the Criminal Justice Intervention Teams (CJITS) a 
substantive component of which is the Arrest Referral function, normally delivered by third sector 
organisations. In the prisons, DIP is delivered by the Counselling, Assessment, Referral, Advice 
and Through-Care Services (CARATS).  
Context  
In 2009 Essex Drug and Alcohol Partnership was awarded Drug Systems Change Pilot 
Status (DSCP) (National Treatment Agency, 2011). A partnership of representatives from various 
government departments including the Department of Health, Ministry of Justice, Home Office 
and Department for Works and Pensions sponsored this initiative to test new ways of delivering 
drug treatment. As part of DSCP status, a range of freedom and flexibilities were granted by the 
government partnership to facilitate alterations in the way that drug treatment is commissioned 
and monitored. EDAP elected to focus their attentions on the criminal justice setting with a view 
to commissioning and delivering a combined prison/community drug recovery provision (EDAP, 
2008). This decision resulted in a ‘merging’ of the CARAT and CJIT services and the creation of 
“Inside Out”.  
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At the core of this restructuring exercise was a desire to implement an enhanced continuity 
of care for service users. In particular it aimed to improve the transition from prison to the 
community for substance misusing offenders which has been identified as a time of risk and 
vulnerability (Lord Patel, 2010; Merrall et al., 2010). Part of the “Inside Out” initiative involved 
the introduction of the National Drug Treatment Monitoring System (NDTMS) (previously used 
in community settings only) into the prison environment with the aim of improving information 
sharing. As a result of this pioneering approach, all drug and alcohol Partnerships have direct 
access to the CARAT prison drug treatment funding streams and the NDTMS is to be deployed 
nationwide throughout the prison estate. 
“Inside Out”, based in Essex (Westminster Drug Project, 2010) became operational in 
April 2009 and will run in its current form for a total of three years. It is this innovative service 
that will form the central focus for this research.  Recent policy has moved away from a focus on 
engagement and process towards a focus on outcomes (reducing crime, improving health). In 
particular the quantitative arm of this study seeks to capitalise on this stance. 
Recovery 
Although the notion of recovery is at the core of the Government’s Drug Strategy (2010), 
there remains little clarity over the definition of this all important concept - a fact noted through 
the number of issues raised in government and academic papers discussing recovery-orientated 
practice and the field of addiction (Jacobson & Greenley, 2001; Laudet, 2007; White, 2007). 
Whilst the government drug strategy seeks primarily for individuals to live drug free lives, others 
are more liberal in their understanding and inclined to consider recovery as a more global concept 
extending beyond substance misuse (White, 2007) incorporating change not just abstinence 
(Laudet, 2007).  In light of this debate and paucity of a consensus around recovery, the qualitative 
arm of this study seeks to explore the client’s independent understanding of recovery and 
investigate how “Inside Out” has impacted on an individual’s recovery journey with a view to 
shed some light on this hotly contested concept. This is in line with White’s (2007) 
acknowledgement that those impacted by the definition of recovery should have a chance to define 
it themselves (p. 230). 
Aims and Objectives 
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The primary aim of this research is to investigate whether an integrated drug treatment 
journey reduces crime and improves health for those substance misusing clients engaged with the 
criminal justice system.  
Specifically, the quantitative objective will be to assess whether the reorganisation of 
service delivery has improved the outcomes being researched. A secondary objective will be to 
compare process statistics with national averages.  
The qualitative arm will investigate the perception of the reorganisation at ‘client level’ 
and will compare those ‘recovering’ with those ‘relapsing.’  
Both arms of the study will consider recidivism and the associated characteristics in this 
complex and vulnerable cohort in order to inform future best practice.  
The Plan of Work 
This study will deliver a mixed methods approach. The quantitative investigation will 
analyse existing data and provide the framework from which the qualitative cohort will be drawn. 
The study will explore which traits, characteristics, perceptions and experiences are associated 
with success or failure within this new and highly innovative service provision. Using both 
quantitative and qualitative investigations it will explore the impact of the re-organised system on 
service users considering the statistical outcomes and their subjective experiences (see appendix 1 
for diagrammatic representation of study design). 
The nature of the study dictates that both a fixed and flexible approach will be adopted. 
Because the quantitative arm is focused on outcomes and aggregate data, a fixed non-
experimental, longitudinal approach is optimal. For the qualitative arm a flexible, cross sectional 
approach will be adopted, with a focus on the subjective, individual client experience of the new 
integrated recovery journey facilitated by “Inside Out”. 
 
 
Data collection and sampling 
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Statutory data sets i.e. the national drug treatment monitoring system (NDTMS) and the 
treatment outcomes profile (TOP), both managed by Essex Drug and Alcohol Action Team 
(EDAAT) on behalf of the National Treatment Agency for substance misuse (NTA), will provide 
the quantitative data for analysis. All individuals whose data is captured by the NDTMS and TOPs 
systems will be within scope and selection for the interview cohort. Final selection will depend on 
the frequency of appearance within the NDTMS data set, which will indicate the number of times 
clients have relapsed. Fifteen clients who have relapsed two or more times will be approached for 
interview within the prison setting and fifteen clients who have ‘recovered’ i.e. have not been 
recalled to prison in the last 24 months following release.  However, the NDTMS only provides 
initials, date of birth and gender of clients therefore the key workers will be tasked to properly 
identify and subsequently approach candidates for interview on behalf of the qualitative 
researcher.  Key workers will be provided with an information pack to disseminate to potential 
interviewees (see appendix 3 for cover letter). Should clients be interested in participating, the key 
worker will notify the qualitative researcher and a convenient interview time and date will be 
arranged.  
Quantitative data collection 
The statutory data sets are collected as a matter of routine by the service provider and are 
managed by EDAAT. The NDTMS predominantly collects performance data related to the client 
treatment recovery journey and also includes public health markers such as injecting behaviour 
etc. The TOPs form collects outcome data in four domains; drug use, crime, health and well-being 
and social functioning, at the start, during and end of the treatment episode. The quantitative 
researcher has already sought permission from the EDAAT information team to analyse and 
describe these data. The quantitative analyses will focus on changes in the outcome measures.  
Qualitative data collection 
Qualitative data collection will be by way of one-to-one interviews with service users. Fifteen 
interviews will take place within HMP Chelmsford (those clients identified as ‘relapsing’) and 
twenty interviews will take place within the community (identified as ‘recovering’).  The use of 
different cohorts is in recognition of the different trajectories drug users can take (Hser et al., 
2007). Of particular relevance are findings from Scott et al. (2005) which indicates a lower 
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likelihood of sustaining recovery following more numerous treatment episodes. This consolidates 
the need to consider ‘frequent flyers’ (those returning to prison regularly) as well as successful 
clients; considering effective and ineffective treatment (Webb, 2011). Interviews will be semi-
structured and will intend to cover the individual’s history of substance misuse and offending, the 
journey up to the present day, drug treatment and offending work, their perception of “inside out”, 
their personal ideology surrounding addiction and recovery, some of the challenges they have 
faced, aspects that have helped facilitate recovery and their future goals. The format of the 
interview will be flexible to enable the focus to be on issues most pertinent to the individual 
participant. 
Quantitative data analysis 
The quantitative data analyses will include descriptive, chi squared, student t- tests, Kaplan 
Meier and effect size calcu;ators.  Comparative analyses covering the length of time in treatment 
and type of treatment received (e.g. methadone maintenance, psycho-social support) will be 
conducted. Chi squared analyses will be applied to describe risk factors associated with 
incarceration. T tests will involve the comparison of means between those relapsing and those 
recovering. The relationship between treatment length or type and outcomes will form the basis of 
the inferential analysis. The evidence base suggests that lengthier periods of treatment are 
associated with positive outcomes in terms of health and recidivism (NTA, 2010). Process and 
monitoring data will be used to describe continuity of care results.  
Qualitative data analysis 
Interviews will be recorded in their entirety to facilitate verbatim transcription. Narrative 
analysis is the chosen qualitative approach. With a focus on transitional and traumatic life events, 
sense making and self-exploration (Crossley, 2008), this method has been previously employed 
with ‘addict’ populations to explore recovery (Hänninen & Koski – Jännes, 1999; Taïeb et al., 
2008). Transcripts will be analysed with a view to identify emergent and re-occurring patterns as 
well as differences among the clients.  
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Ethical Issues 
Risks of the research: 
The client group to be approached are a complex and vulnerable cohort and the risks of the 
research extend to both the participant and qualitative researcher. For the interviews being 
conducted in prison, safety will be managed as per the health and safety guidance within HMP 
Chelmsford. This includes completing the visitors book upon arrival to the wing, informing staff 
where interviews will take place and with whom, checking the incident book before commencing 
interviews as well as enquiring about any known issues. The aim is for interviews to be conducted 
in a group-work room with the presence of a key-holder. The space is in full view of wing staff 
and the interviewer will be positioned nearest to the exit and alarm bell. The presence of the key-
holder means the interviewer can leave the room should anything occur. The risk of harm to the 
researcher within the community is predicted to be less, although precautions will still be taken. 
Key workers will be aware that interviews are taking place and they will occur within the offices 
of Westminster Drug Project rather than client homes.  
With regard to clients, the interview material to be explored may be of a sensitive nature. 
Should any heightened emotionality be noted during the interview and the interviewer have any 
concerns then the key worker will be informed following the interview.  
Benefits of the research: 
By understanding whether the introduction of a single service drug recovery provision has 
improved the criminological and health outcomes for this vulnerable cohort, we hope to influence 
future commissioning strategies within the sector.  We aim to add to the existing knowledge base 
surrounding the treatment of substance misusing offenders and recidivism as well as enlightening 
the discussion around the concept of recovery.  
Clients may benefit from the opportunity to give their opinion and contribute to future 
service delivery.  
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Gaining informed consent: 
At the beginning of the recovery journey (contact with “Inside Out” through arrest referral 
schemes or by way of prison referral) clients consent to having their information shared for 
generic research and monitoring purposes via the NDTMS. The quantitative researcher will be 
asking the EDAAT for permission to analyse these data.  
Specific consent will be sought for the interview process. Potential interviewees will be 
provided with an information sheet explaining the research and inviting them to engage with an 
interview. Should they be interested in participating, the nature of the research and what their role 
will consist of will be verbally explained on the day of the interview. Following both verbal and 
written information (see appendix 4) written consent will be taken by the interviewer should the 
client agree to continue with the interview (see appendix 5).  
Anonymity and confidentiality: 
All the statutory datasets and information will be held on the local authority secure servers 
in password protected folders only viewable to the DAAT information team and where necessary 
the researchers. For analytical purposes, quantitative records will be further anonymised by use of 
the so called “hash code generator”. This will facilitate off-site analyses of the data (e.g. the 
university) without compromising anonymity and confidentiality. Feedback in the form of reports 
and publications will not contain identifiable data and pseudonyms will be used for the purposes 
of qualitative reporting. 
Timetable 
Please see appendix 2. 
Dissemination 
Although this project is in fulfilment of two separate PhDs in Health Studies at the 
University of Essex, and therefore a final thesis is the end goal, interim reports will be produced to 
inform stakeholders of the progress of the project along the way. In addition, we hope to publish 
the preliminary findings in an academic journal.  A project steering group will initially meet every 
three months consisting of commissioners, researchers and their academic supervisors. On 
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completion of the project, in addition to the thesis, shorter executive summaries will be distributed 
to HMP Chelmsford (for practitioners and participants) and published on the EDAAT website. It 
is envisaged that further academic publications will follow as a result of this project. 
Budget: 
This study is funded for three years by the EDAAT. 
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APPENDIX 1 
 
Figure 1: diagrammatic representation of study design. 
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APPENDIX 3 
Reducing crime, improving health; Essex Drug and Alcohol Partnership, prison treatment outcomes and 
processes research 
         
Dear Future participant,  
We would like to invite you to take part in our research study. Before you decide we would like you to 
understand why the research is being done and what it would involve for you. Please read the information 
attached, it should take no longer than half an hour for you to read it fully. Talk to your key worker about 
the study and ask any questions you may have before making a decision.  If you think you may be 
interested please let your key worker know so we can arrange an interview. 
Many Thanks, 
 Sarah Senker. 
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APPENDIX 4 
Reducing crime, improving health; Essex Drug and Alcohol Partnership, prison treatment outcomes and 
processes research 
Information about the qualitative research 
1. What is the purpose of the study? 
There have been some changes in the way your treatment is provided. This research wants to understand 
your views and feelings about “Inside Out”, how it has impacted you, what you’d like to see made better 
and what is already quite good. We also want to understand about you and your individual journey.  
Getting such information is important so the service can continue to get better, helping you and others.  
2. Why have I been invited? 
You have been invited to take part because you have experienced “Inside Out”.  We are aiming to 
interview 15 people in HMP Chelmsford and 15 people in the community (that have also experienced 
“Inside Out”). 
3. Do I have to take part? 
It is entirely up to you whether you want to join the study or not.  Even if you agree to take part, you can 
decide to stop at any time, without giving a reason and this won’t affect the care you receive. 
4. What will happen to me if I take part? 
If you agree to be interviewed, a time and place that suits you will be arranged for this to happen. If you 
are in HMP Chelmsford, the interview will take place there and if you are in the community this will occur 
at the offices of Westminster Drug Project in Chelmsford or one of the other treatment provider offices in 
Essex depending on your location.  
You will only need to meet the researcher once. Before the interview starts you’ll be asked to sign a 
consent form, to show that you are happy to be involved.  Even if the interview begins, you can still 
decide you don’t want to take part anymore.  
The interview normally takes about an hour, sometimes a little longer. The more you talk, the longer the 
interview. There will be some questions that the interviewer particularly wants to know the answer to, 
but how you answer these and how much information you give is up to you.  The interview will be 
recorded so the interviewer can remember what you said as accurately as possible.  
5. What are the possible disadvantages and risks of taking part? 
We do not think there are any risks to taking part in the interview.  The questions asked will be about your 
recovery journey so they may be a little sensitive at times when you consider your offending and 
substance misuse. Your key worker will be aware that the interview is taking place though so you can talk 
to them if you feel upset following the interview. The researcher is entirely neutral, not there to pass 
judgement, just there to hear your story.  As mentioned before, the interview can take up to two hours so 
you should think about whether you are willing to give up some of your time. 
6. What are the possible benefits of taking part? 
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We cannot promise that this study will help you but with the information we get from this research we 
hope to improve the treatment of substance misusing offenders, not just in Essex but across England. This 
interview is a chance to give your views and opinions of “Inside Out” and tell the interviewer about your 
experiences. It is a chance to tell your story; there are no right or wrong answers. 
7. What happens when the research study stops? 
When the interviews are complete, they will be written up by the researcher and patterns will be looked 
for. Your experiences and those of others will be written into a research report, to be given to the 
researcher’s University and the Essex Drug and Alcohol Partnership. No-one will be able to match your 
name to what you said – it will be anonymous. You will be able to read a summary of the findings too on 
the Essex County Council website or your keyworker can give you a copy. 
8. What If there is a problem? 
If you feel unhappy about the way you have been dealt with during the study, you can tell your key 
worker and they will pass this information onto the researcher as soon as possible. If you wish to 
complain formally you can do this via the University of Essex Research Manager. Her details can be 
obtained from your key-worker. 
9. Will my taking part be kept confidential? 
Any information you give us will be confidential and your real name will not be used in any research 
reports. However, if you say anything to the researcher that indicates that you or somebody else is at risk 
of harm or breaches prison security then this will have to be passed on to your key worker to keep you 
safe.   The recording of the interview will only be listened to by members of the research team and it will 
not be accessible to anyone else.  The interviewer will type up the interview in written form so it is easier 
to look for patterns. Interview material will be kept securely for two years in case the interviewer wants 
to look at it again in the future.  The interviewer will also have access to your background information 
such as your age and ethnicity - this is just for the purposes of writing up the research report, so the 
researcher can report the average age of the people interviewed and will not affect how you are treated 
during the interview.  
10. What will happen if I don’t want to carry on with the study? 
If you don’t want to continue with the interview at any time you can let the researcher know. The tape 
will be stopped and it will be up to you to decide if any information already recorded can be used. If you 
decide you don’t want any information to be used, the interview so far will be deleted and destroyed. You 
may not want to answer specific questions, rather than stopping the interview altogether. This is ok too 
and the researcher can move on to a different question if you feel uncomfortable at any point.  
11. Who is organising and funding the research? 
The research is being funded by Essex Drug and Alcohol Partnership. As well as this research informing the 
running of the “Inside Out” service in the future, it is also part of the interviewer’s research degree at the 
University of Essex. 
12. Who has reviewed this study? 
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All research is looked at by an independent group of people called a Research Ethics Committee, to make 
sure you’re safe. This study has been reviewed and given favourable opinion by East of England Research 
Ethics Committee and the National Offender Management Service. 
13. What happens next? 
If, after reading this pack, you think you would like to be interviewed please let your key worker know 
within one month of receiving this (the sooner the better) so that an interview can be arranged.  You can 
always ask for more information to help you decide. The interviewer will go through this information on 
the day and explain it face to face before you agree 100% to participate. If you want to go ahead, a 
consent form will need to be signed on the day of the interview. An example of this is included in this 
pack. 
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APPENDIX 5 
Reducing crime, improving health; Essex Drug and Alcohol Partnership, prison treatment outcomes and 
processes research 
CONSENT FORM 
Please initial (not tick) all boxes you agree with. 
1. I confirm that I have read and understood the information sheet provided for the above research 
study.  
 
2. I have had the chance to think about the information, ask questions and I am happy with how these 
have been answered. 
 
 
3. I understand that taking part is my choice and I can stop at anytime without giving a reason. This 
won’t affect my treatment or care. 
 
4. If I lose the ability to take part in the study, I understand that my information up to that point will 
still be used but no further information will be requested of me. 
 
 
 
 
5. I give permission for the researcher to access information about me such as my age, ethnicity, 
offending history and substance misuse history. 
 
 
6. I understand that my key-worker knows that I am taking part in this study. 
 
 
7. I agree that the interview will be audio-recorded to help the interviewer remember what I said. 
8. I will do my best to give honest answers and information wherever possible.  I will tell the 
interviewer immediately if I feel unhappy or unwell at any point. 
 
9. I understand that all personal information about me is kept private, and in line with the Data 
Protection Act (1998). My real name will not be used in any research reports. 
 
 
10. I agree to take part in this study. 
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Name of Interviewee    Date     Signature 
 
 
Name of person taking consent   Date    Signature 
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5.0 NTA permissions 
 
 www.partsgateway.co.uk/Re… Save On Rear Lights - UKamp; Used Parts Site Genuine Parts - In Stock - 24… Sponsored 
 FW: May dashboard feedback Thursday, 17 June, 2010 15:55 
From: "Dan Hales" <Dan.Hales@essex.gov.uk>  
 To: "Donia Slyzuk" <Donia.Slyzuk@essex.gov.uk> "Ben Hughes" <Ben.Hughes@essex.gov.uk>  
"Gogarty Mike (5PW) North East Essex" <mike.gogarty@northeastessex.nhs.uk>  
 Cc: "Dominic Brown" <Dominic.Brown@essex.gov.uk> "Marc Connor EDAAT Information Consultant" <Marc.Connor@essex.gov.uk>  
 
 
From: Louise Amon [mailto:Louise.Amon@nta-nhs.org.uk]   
Sent: 17 June 2010 15:45  
To: Dan Hales; Ben Hughes  
Cc: Sherife.Hasan@dh.gsi.gov.uk; Pete Burkinshaw; Megan Jones; Rick Andrews; 
Emma Pawson Subject: May dashboard feedback 
  
Dear Dan, Ben 
  
Please find attached your May dashboard with regional feedback. 
  
Best wishes, 
  
Louise 
  
Louise Amon 
System Change Pilots Coordinator   
National Treatment Agency 
6th Floor, Skipton House 
80 London Road 
London, SE1 6LH  
T: 020 7972 1906 
F: 020 7972  
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Freedoms and Flexibilities 
F&F required How it supports the strategic vision Progress to date RAGB 
 To commission CJIS, 
combining CARAT and DIP 
Continuity of care, reduction in re-
offending   Agreed  Blue 
 Exclusion of Substance 
Misuse from Caldicott 
Strategic assessment and planning 
requirement  Agreed locally  Blue 
 Local control of DIRWeb data 
 Continuity of care, reduction in re-
offending, strategic assessment 
process 
Local access agreed, looking 
for national r/o access 
 Blue 
 Changes to Needs 
Assessment format 
Delivery of Strategic Assessment 
planning process  
Agreed regionally   Blue 
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5.1 NTA freedom and flexibilities 
Commonalities in Freedom & Flexibility Requests 
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Freedom/flexibility Partnerships Detail 
National/ 
Local 
Granted: 
yes/no ? 
Comments 
Freedom in use of DIP funding to 
support more locally relevant 
commissioning of services. 
Essex 
To commission CJIS, combining CARAT and DIP 
National Yes  
Herts 
Use of DIP funds to support offenders on  
DRRs 
National Yes  
Lambeth 
Budget: ability to transfer funds both within the 
SCP’s direct control and aligned budgets held by 
our partner commissioners. 
National Yes 
 
Leicester Sub-regional DIP MG allocation National Yes  
Flexibilities in data collection & 
reporting to streamline continuity 
of care between prison & 
community based treatment 
Bradford 
Start2Finish: brokering treatment for offenders 
leaving prison - some issues with DIP recording 
National 
Formal request not 
submitted 
 
Essex  
Local control of DIRWeb data Local Yes  
Extend use of NDTMS to HMP Chelmsford to 
support IDTS & CJIS 
Local Yes 
Agreed to use HMP 
Chelmsford as early adopter of 
planned national roll-out of 
NDTMS to prison drug 
treatment systems 
Herts Access to CARATS DIRweb National No 
DIRWeb is not a ‘case 
management tool’ and 
therefore full access to  
CARATs data not relevant. 
However, recent access to 
attributable data on clients 
referred from CARATs to CJITs 
has been helpful.   
Lambeth 
In line with the revised PMF, relaxation of HMP 
Brixton CARAT audit processes and DIP KPI-2 
targets. 
National Yes 
 
Leicester 
Local keying of Prison DIRs National Yes  
Flexibility with CARATs  process National 
Formal request being 
considered 
 
Development of overarching  Bradford Mother contract drafted  Local Yes  
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contract covering a number of  
providers, to support integrated 
treatment system Lambeth Providers invited to form a consortium  Local N/A 
Implemented without f&f 
request 
Freedom/flexibility Partnerships Detail 
National/ 
Local 
Granted: 
yes/no ? 
Comments 
Joint commissioning issues 
Bradford 
Use of Working Groups, CMB, and 
Implementation Group to identify current gaps 
in treatment system 
Local 
 Yes - though F&F not 
necessary 
 
Integrating DWP with the treatment journey 
and abstinence work.  
Local 
 
Hampshire & 
Southampton 
To develop a single set of assessment tools to 
minimise the laborious paper work for the 
client 
Local 
Often requiring negotiation 
across the two partnerships - 
but not a national F&&F Flexible housing support funding Local 
Access to funding linked to employment and 
training 
Local 
Sefton 
HSC directorate database (swift) to be changed 
to accommodate information required for the 
SPA and monitoring of the new service 
Local 
 
Community Care Grants transferred from DWP 
to HSC directorate  
Local  
HSC directorate taking ownership of the SPA 
and clients with substance misuse problems. Local 
 
Pooling of HSC training budget Local  
Wholesale use of ITEP across the system added 
to original pilot proposal 
Local  
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Downloaded from http://www.nta.nhs.uk/uploads/ffrequestscommomnalitiesmarch2012.pdf 
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6.0 InsideOut job description 
 
Inside Out Practitioner 
(Salary as advertised) 
Essex 37.5 hours Permanent 
1.  Main purpose of the role 
 To contact, assess, refer and support substance misusers in criminal justice settings (including 
courts, police stations, prisons, probation offices), treatment agencies, the community and 
other appropriate settings in order to maximise their uptake of treatment services and access 
re integration.  
 
 To work with clients using class A substances and alcohol across Inside Out settings – Essex 
community and HMP Chelmsford 
 
 To work 37.5 hours per week – flexible and to be negotiated with line manager to cover shift 
patterns. 
2.  Reporting and working relationships 
Reporting relationships: 
 Reports a Senior Practitioner 
 
 
Senior Practitioner 
Inside Out Practitioner 
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Effective working relationships: 
 The management team: County 
Manager, Senior Practitioners, 
Operations Manager 
 WDP and partnership employees 
and volunteers 
 Service users, carers and 
communities 
 Commissioners, funders, partner 
agencies. 
 
3.  Role-specific responsibilities 
3.1  To maintain a caseload of Inside Out clients. To work with clients to prepare them for 
treatment and key work clients as required. To use Other Structured Intervention 
(OSI), ITEP and Motivational Interviewing (MI) techniques when working with clients. 
To liaise with statutory and voluntary agencies on behalf of the service user. 
3.2 
 To develop and adhere to working relationships with drug treatment services, police, 
probation, prisons, courts and community services. 
3.3 
 To refer clients to the relevant professionals or treatment providers. To work with 
other professionals or treatment providers with assessing / reviewing of clients’ needs. 
To deliver satellite services as and when required across the county. 
3.4 
 Support volunteers and student placements to deliver WDP’s service objectives. 
3.5 
 To keep abreast of new developments relating to the Criminal Justice System. 
3.6 
 To attend staff meetings, training days and supervision sessions, best practice and 
organisation wide meetings as required. 
3.7 
 To attend (as and when required), and act as a WDP ambassador, at external 
meetings.  
3.8 
 To contribute towards monthly performance reports when required. 
3.9 
 To submit all required client data within specified timeframes. 
3.10 
 To support Inside Out clients to take up education, training and employment 
opportunities. 
3.11 
 To agree an initial recovery plans and conduct regular comprehensive reviews. 
3.12 
 To care co-ordinate criminal justice clients, including Drug Rehabilitation Requirement 
Inside Out 
Practitioner 
County 
Manager 
Peers 
Employees & 
Volunteers 
Service Users 
& 
Communities 
Partner 
agencies  
Line Manager 
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(DRR) and Alcohol Treatment Requirements (ATR) clients, within the Essex treatment 
system. 
3.13 
 To carry out initial screening and triage on clients as and when required. 
3.14 
 To conduct risk assessments and full comprehensive assessments on clients to 
establish their needs.  
3.15 
 To conduct carers assessments and make appropriate referrals 
3.16 
 To undertake Prolific and Priority Offenders (PPO) and DRR testing. 
3.17 
 To work in partnership with relevant criminal justice agencies to undertake assertive 
outreach. 
3.18 
 To escort clients to relevant appointments. 
3.19 
 To ensure all client interventions are well planned, monitored and evaluated. 
3.20 
 To actively re-engage clients who drop out of treatment.. 
3.21 
 To maintain up to date client records (case files and electronic data) and any other 
monitoring required by WDP. 
3.22 
 To conduct DRR and ATR assessments in the community, via video link and in prison 
establishments. 
3.23 
 To undertake OSI and other structured interventions. 
3.24 
 To provide input into pre-sentence reports and/or prepare court reports in 
consultation with probation staff.  
3.25 
 To undertake court duties as and when required. 
3.26 
 To undertake arrest referral duties. 
3.27 
 To facilitate Follow-Up Assessment (FA), Restrictions on Bail (RoB) and Conditional 
Cautioning (CC) requirements when required 
3.28 
 To develop and adhere to processes connecting Criminal Justice Intervention Service 
(CJIS) and prisons to facilitate and deliver tracking and follow up of clients at the point 
of entry and exit from the Criminal Justice System. 
3.29 
 To undertake any other duties as requested by the County Manager or Senior 
Practitioner 
4. 3
.
2
5 
WDP’s commitment to you 
WDP works within the following framework and requires all employees to do the same. 
 
 
208 
 
4.1 Equal Opportunities 
WDP is committed to promoting anti-discriminatory practices within society, its organisation 
and in the promotion of its services to the community. WDP expects all employees to 
understand, comply with and to promote its policies in their work and to challenge prejudice 
and discrimination and where necessary to undertake any appropriate training. 
4.2 Recovery 
WDP is a recovery focused organisation. Our staff and volunteers are committed to helping 
our service users improve their health and wellbeing, and to become free from dependency. 
4.3 Career Development and Progression 
At WDP we actively encourage career progression from the talent we have from within and we 
strive to provide not only promotional progression but to develop a specialist and lead 
responsibility roles with teams and other services within WDP. 
4.4 Safeguarding 
WDP is committed to ensuring the safeguarding and wellbeing of children and vulnerable 
adults, and all applicants will be required to demonstrate understanding of and commitment 
to best safeguarding practice. 
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 7.0 Agency level information sharing agreement 
 
ESSEX DRUG & ALCOHOL ACTION TEAM (EDAAT) 
Safer Essex Partnership 
Essex Drug & Alcohol Partnership (EDAP) 
Information Sharing Agreement (ISA) within Essex DAAT & between Essex DAAT & 
Partner Agencies 
 
Circulation List: 
ADAS Harlow 
CDAS Basildon 
CDAS Castle Point & Rochford 
CDAT West Essex 
Changes 
DCS Counselling Service 
Essex Drug Intervention Programme (WDP) 
Essex Young People Drug & Alcohol Service (EYPDAS) 
NEEDAS 
Open Road 
Shaw Trust 
Together Personal Development Service 
Youth Offending Team (YOT) 
 
 
Agreed:  
 
Authors:    
 
Implemented: 
 
For Review: 
 
 
Declaration: 
I agree to share client information as described in this document. 
 
Signature:    
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Printed Name: 
 
Organisation: 
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To facilitate this year’s, and future, Needs Assessments we, the Essex Drug and Alcohol Partnership 
(EDAP), are attempting to introduce a comprehensive Information Sharing Agreement (ISA) to partner 
agencies.  We think such an agreement is an essential tool for partnership working and will fundamentally 
enhance our ability to provide evidence based commissioning.  We are asking that client data be shared 
between agencies (where no agreements are currently in place) and that on a quarterly basis agencies 
transmit core client data to the DAAT for counting and quality control exercises. 
 
Historically there have been many barriers to information sharing not least the concern that the 
information might be used for nefarious purpose and so a key message we would very much like to 
reinforce is that the Partnership’s primary focus is not the individual per se, except of course in 
exceptional circumstances, and that we have little desire to monitor clients at the micro level.  Any data 
sent to EDAP will be treated within the strictest of confidentiality environments and will not be passed on 
to third parties. Also we very strongly support the notion that the sharing of information is not something 
to be afraid of and is fundamental to the success of any strategy hinged upon evidence based 
commissioning. 
 
In broad terms our objectives are to negotiate permissions that allow record level access/transfer of data 
to us and between partner agencies so that on the one hand strategic analyses can be undertaken to 
better inform our commissioning decisions and on the other that those most at risk to themselves and to 
the community are better care planned throughout the various agencies they may come into contact 
with.  A key objective for the Partnership this year is to gain a better understanding of the so called 
‘treatment naive’ population. 
 
In the first instance we are asking that client initials, date of birth, gender, ward of residence, substance of 
misuse (if available) and any relevant performance data e.g. dates, test outcomes etc. be transmitted to 
the properly designated officer (PDO) so that a matching exercise can be under taken across all the data 
sets. Any matched data will be treated as purely statistical entities and would be used solely for the 
purposes of counting.  Reports generated from the matching exercise will be produced in aggregate form 
and once ratified the data will be deleted from the council’s secure server system.  As the protocol 
becomes embedded we would very much hope and expect that partner agencies will adopt a more fluid 
approach to information sharing thereby improving the likelihood of positive outcomes for all concerned. 
 
The proposed data matching exercises will be invaluable in informing the strategic commissioning 
priorities for next year and will ensure that the partnership is more responsive to serving the needs of 
local communities in relation to substance misuse.  We very much hope that you share our vision of a 
transparent, cooperative drug treatment system and we look forward to working in partnership with you 
all. 
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Drug Treatment data flows within Essex
Essex Drug & Alcohol 
Partnership (EDAP)
‘Thin’ arrows = record level performance data reduced to initials, date of birth & gender
‘Fat’ arrows = full client details up to case management files where section 115 legislates
WDP
ADAS
Changes
CDAS
NEEDAS
Shaw
Trust
EYPDAS
DCS
Together
Open 
Roads
YOT 
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NDTMS information sharing agreement for Essex 
Purpose 
1. To facilitate the sharing of patient /client level information between drug treatment agencies and 
Essex Drug and Alcohol Action Teams (DAAT). 
 
2. To ensure that data sharing complies with legal requirements and codes of practice, particularly 
the common law duty of confidentiality, Data Protection Act, Human Rights Act, NHS Code of 
Confidentiality, Caldicott Principles. 
 
3. This agreement may be used to enter into agreements with third parties, such as academic 
researchers who may be contracted by the DAATs to undertake needs assessment research, but 
these should also be subject to local information governance protocols and appropriate 
contractual arrangements relating to data protection. 
Key principles 
Although patients are owed a duty of confidence for information collected in clinical consultations, 
the legal frameworks and codes of practice do allow health bodies to share patient information they 
hold on their users, providing they: 
 
1. Do it lawfully. Lawful sharing generally means: 
a. There is a legitimate reason to share data (justifiable purpose). 
b. The organisations have the power to do so. All NHS bodies and treatment providers have 
the statutory power to share information in the interests of their clients. 
c. Not breaching legal barriers to sharing 
 
2. Apply principles of good information management. This requires that: 
a. Clients are informed that their data is to be shared and the purposes for which it will be 
used (fair processing information). 
b. Only data necessary for the purpose is shared. 
c. Data is kept securely. 
d. Clients/ patients can refuse to have their data shared and/or can ask to see what is held 
on them. 
e. The data is accurate and kept up to date. 
f. Data is kept no longer than necessary. 
 
3. Do it securely: 
a. Ensure that data is held securely at all times 
b. Avoid the inadvertent disclosure of patient details through publication of statistics or 
inappropriate sharing 
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Parties to the agreement 
This agreement governs the sharing of NDTMS (National Drug Treatment Monitoring System) 
information between the following parties: 
1. Treatment providers commissioned to provide structured treatment for substance misuse in 
the county of Essex,  
2. Essex DAAT which is responsible for commissioning these services in the region. Since DAAT 
partnerships include a wide range of organisations, it is expected that a named individual with 
an information analysis role will be the signatory to the agreement, and will ensure that 
information is only shared with those individuals specified by job title as set out in Annex A. The 
access rights outlined in Annex A, and any subsequent changes thereto, will be agreed by all 
signatories 
It is expected that any newly commissioned treatment providers will sign up to this data sharing 
agreement before beginning to submit data to the NDTMS. Appendix B of this document lists the 
authorised signatories to this data sharing agreement.  
 
What data is to be shared and why 
The NDTMS requires the collection of a minimum dataset of information on drug clients in contact 
with treatment agencies for several reasons: 
1. to improve the commissioning of services  
2. to help plan and provide appropriate services for drug and alcohol users. 
3. to monitor the uses of national and local funding. 
4. to monitor and manage the performance of treatment services and DAAT partnerships. 
5. to understand and enhance the effectiveness of care for individuals. 
6. to improve public health for the population of problematic drug users and alcohol users. 
7. to achieve wider health improvement. 
 
 
The data is to be transferred electronically between and from agencies to the DAAT via a secure email 
system provided by CJSM.net. All files will be stored on Essex Council’s secure intranet in password 
protected folders.  The data to be shared is the NDTMS core dataset including regional fields, collected on 
a monthly basis. Latest versions of the NDTMS core dataset definition documents can be accessed at 
http://www.nta.nhs.uk/areas/ndtms/core_data_set_page.aspx. This agreement will also cover any 
amendments to the core dataset, subject to the annual review outlined in Section 6. 
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The purposes as outlined in the Data Protection Act to which the data are put are: 
1. Health administration and services 
2. Research 
3. Information and databank administration 
 
 
Some potentially patient identifiable information will be shared: 
 Patients initials, date of birth, sex and postcode, which taken together may be sufficient to 
allow the identification of an individual by a data controller (the parties to this agreement 
are all data controllers). 
 Local patient identifiers (e.g. client number). 
 
The purposes for sharing patient identifiable information are to: 
1. Remove duplicate records to ensure accurate counts of clients, episodes and modalities. 
2. Enable records to be linked to track a client’s pathway through care and provide information 
on the effectiveness of the treatment system as a whole. 
3. Undertake geographical analysis - postcodes are converted to small area geographical 
identifiers to allow improved planning of service locations, and to obtain a better 
understanding of the links between substance misuse and other social factors. 
 
Parties to this protocol agree: 
1. To share the information as set out in this protocol 
2. To transfer and store information securely  
3. To share security and confidentiality policies 
4. To allow information audit in case of breaches or potential breaches of security which could 
compromise confidentiality 
5. To inform clients/patients as to how their data is used 
6. Not to share records with other parties without explicit consent unless other statutory 
requirements apply. 
7. Not to publish disclosive or potentially disclosive statistical information (i.e. which might lead 
to inadvertent disclosure of information about an identifiable client) without prior discussion 
 
Implementation and Review This agreement is subject to endorsement by the National Treatment 
Agency and the Stakeholder Advisory Group of the Regional Drugs Health Information Unit. The 
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agreement takes effect from and will be subject to an initial review after six months, and annually 
thereafter. 
This agreement is subject to endorsement by the National Treatment Agency and the Stakeholder 
Advisory Group of the Regional Drugs Health Information Unit. The agreement takes effect from <Enter 
Date> and will be subject to an initial review after six months, and annually thereafter. 
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7.1 HMP Chelmsford information sharing agreement 
ISA Ref: EDAP/HMP Chelmsford 0001 
Purpose: To create a legislative framework for the transfer of sensitive data and 
information between Essex Drug & Alcohol Action Team and HMP Chelmsford, 
with the intention to prevent and/or reduce the amount of crime associated with 
substance misuse. 
Partners: Essex Drug & Alcohol Action Team 
HMP Chelmsford 
Date agreement comes into force: 01/03/2009 
Date agreement review: 01/08/2009 
Agreement owner: Essex Drug & Alcohol Action Team 
Location of signed agreement: Essex Drug & Alcohol Action Team County Hall 
  
 
 
218 
 
 1. Introduction 
To facilitate this year's Needs Assessment and future data requirements we, The Essex 
Drug and Alcohol Partnership (EDAP), are attempting to introduce a comprehensive Information Sharing 
Agreement (ISA) into all partner agencies. As a Partnership, we think that such an agreement is essential 
if client data is to be shared and will fundamentally enhance our ability to provide first class evidence 
based commissioning. We are asking that client data be shared between agencies (where no 
agreements are currently in place) and that on a monthly basis Essex Police transmit core client data to 
the DAAT for counting, monitoring and research purpose. 
Historically there have been many barriers to information sharing not least the concern that the 
information might be used for nefarious purpose and so a key message we would very much like to 
reinforce is that the Partnership's primary focus is not the individual per se, except of course in 
exceptional circumstances, and as such we have little desire to monitor clients at the micro level. Any 
data sent to EDAP will be treated within the strictest of confidentiality environments and will not be 
passed on to third parties unless relevant agreements are in place. Also we very strongly support the 
notion that the sharing of information is not something to be afraid of and is fundamental to the success 
of any strategy hinged upon evidence based commissioning. 
In broad terms our objectives are to negotiate permissions that allow record leve 
access/transfer of data to us and between partner agencies so that on the one hand strategic analyses 
can be undertaken to better inform our commissioning decisions and on the other that those most at 
risk to themselves and to the community are better care planned throughout the various agencies they 
may come into contact with. A key objective for the Partnership this year is to gain a better 
understanding of the so called 'treatment naive' population. 
In the first instance we are asking that client details including names, date of birth, gender, 
ward of residence, substance of misuse (if available) and any relevant performance data e.g. dates, test 
outcomes etc. be transmitted to the properly designated officer (PDO) so that a matching exercise 
linked to tier two criminal justice treatment data may be under taken. Matched data are treated as 
statistical entities and are used solely for the purposes of counting. Reports generated from the 
matching exercise will be produced in aggregate form and once ratified the data will be deleted from 
the council's secure server system. As the protocol becomes embedded we would very much hope and 
expect that partner agencies will adopt a more fluid approach to information sharing thereby improving 
the likelihood of positive outcomes for all concerned. 
The proposed data matching exercises will be invaluable in informing the strategic 
commissioning priorities for next year and will ensure that the partnership is more responsive to 
serving the needs of local communities in relation to substance misuse. We very much hope that you 
share our vision of a transparent, cooperative Drug Treatment System and we look forward to working 
in Partnership with you all. 
 2. Purpose & powers 
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2.1. To facilitate the sharing of client attributable information between HMP Chelmsford and 
Essex Drug & Alcohol Team. 
2.2. To reduce crime associated with substance misuse by improving the targeting and 
commissioning of drug treatment services 
2.3. Enable records to be linked to track a client's pathway through care and provide information 
on the effectiveness of the treatment system as a whole. 
 2.4. Undertake geographical mapping exercise with a view to identifying 'hot spots' 
2.5. To ensure that data sharing complies with legal requirements and codes of practice, 
particularly the common law duty of confidentiality, the Crime and Disorder Act 1998 
section 115, the Data Protection Act 1998 sections 29(3) & 35 (2), the Rehabilitation of 
Offenders Act 1974, the Human Rights Act (article 8), the NHS Code of Confidentiality and 
the principles underpinning the Caldecott Guardian guidelines. 
2.6. This agreement may be used to enter into agreements with third parties, such as academic 
researchers who may be contracted by the DAAT to undertake needs assessment 
research, but these should also be subject to local information governance protocols and 
appropriate contractual arrangements relating to data protection. 
3. Agreement by partners to: 
3.1. Share the information as set out in this protocol 
3.2. Transfer and store information securely I.e. via the CJSM.NET 
3.3. Share security and confidentiality policies 
  
3.4. Allow information audit in case of breaches or potential breaches of security which could 
compromise confidentiality 
3.5. Inform clients/patients as to how their data is used 
3.6. Not to share records with other parties without explicit consent unless other statutory 
requirements apply. 
3.7. Not to publish disclosive or potentially disclosive statistical information (i.e. which might 
lead to inadvertent disclosure of information about an identifiable client) without prior 
discussion 
4. Information to be shared 
 4.1. Retrospective data from April 1 st 2008 followed by monthly extracts 
 4.2. Reports drawn from the data to the police in aggregate form 
 4.3. Data to be transmitted CSV file 
4.4. The data will relate to Essex County clients only and will include drug and alcohol 
information 
 4.5. Data items to include client name, date of birth, gender, post code. 
 
5. Constraints on the use of the information 
5.1. The raw information shared by the police must not be disclosed to any party outside of 
this agreement. Any intention to do so must involve a review of this agreement 
5.2. Any police information shared is only valid at the time of provision and should only be 
used for the purposes requested  
6. Roles and responsibilities under this agreement 
6.1. Each partner must have appoint a single point of contact (SPoC), who must work together 
to ensure the processes of the agreement are fully adhered to. 
I-IMP Spoc Title: 
DAAT Spoc Title: EDAAT Information Manager 
Contact details: Tel 01245 434655 
Email Marc.Connor@essex.gov.uk 
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7. Review retention and deletion 
7.1 Partners to this agreement undertake that personal data shared will only be used for the 
specific purpose for which it was requested. The recipient of the information is 
required to keep it securely stored and will dispose of it when it is no longer required for 
the purpose for which it was requested. 
7.2 The recipient will not release the information to any party beyond the judicial system without 
first obtaining the express written authority of the partner who provided the information. 
8.0 Review of the information sharing agreement. 
8.1. This information sharing agreement will be reviewed six months after its implementation and 
annually thereafter. The nominated holder of this agreement is Essex Drug & Alcohol 
Action Team. It is based on the national template for information sharing, which forms 
part of the guidance issued on the management of police information by the Association of 
Chief Police Officers (ACPO) and the Home Office (HO), 
9.0 Indemnity 
9.1. Essex Drug & Alcohol Action Team as receivers of police information will accept total liability 
for a breach of this Information Sharing Agreement, should legal proceedings be served in 
relation to a breach. 
 
10. Signature 
10.1. By signing this agreement all signatories accept responsibility for its execution and agree to 
ensure that staff are trained so that the requests for information and the process of 
sharing itself is sufficient to meet the purposes of this agreement. 
10.2. Signatories must also ensure that they comply with all relevant legislation. 
Signed on behalf of HMP Chelmsford  
Title...  
Date.  
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7.2 InsideOut client information sharing agreement 
Client Consent Form 
 
 
 
Inside Out is a confidential service designed to help you. 
It may be helpful to share information with others to fully understand your current situation. We 
will only share information that is relevant to your health and care needs. We will respect the 
confidentiality of any information shared with agencies. The following information is designed to 
help you give us informed consent. 
  
Continuity of Care (requires informed consent) 
 
I have been asked by ______________________________________________ (Practitioner) my 
worker with Inside Out (delivered by Westminster Drug Project) whether I give my consent 
to the information I have given being used by the CJIT and CARATs as well as by those other 
agencies set out below that I have indicated so that I can get the support I need. 
 
I have ticked below the agencies that I do not agree this information being shared with and 
between.  I understand that my consent does not need to be given again in order for this 
information to be passed on and shared between these agencies.  I understand that this 
information is being shared with a view to ensuring and assisting the continuity of my care. I 
am aware that I can withdraw my consent to this information being shared with any or all of these 
agencies at any time. 
 
I have been told that where I have not agreed to my information being shared with and between 
any of the following agencies this will not prevent me getting the support that I need, but I 
understand that it may delay the process. 
 
 
The following are agencies and people who generally are able to help.   
 
Please indicate those you do not consent for us to contact: 
 
GP        Legal representatives   
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Health Services      NDTMS/NTA/Home Office*  
 
Prescribing Agencies (Tier 3)     Criminal Justice Agencies  
 
Treatment Facilities (Tier 4)     Carer/Partner    
 
Employment & Training Services    Social Services   
 
Housing Services       Probation    
 
Other – Please state ___________________________________________________   
 
Other – Please state ___________________________________________________  
 
Other – Please state ___________________________________________________  
  
 
Other – Please state ___________________________________________________  
 
Other – Please state ___________________________________________________  
 
 
* See ‘Monitoring & Research’
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Monitoring and Research 
Some information gained from your assessment interview is collected for monitoring and research 
purposes. It will enable the effectiveness of the Drug Interventions Programme (DIP) to be 
monitored and evaluated, and help to identify ways in which the programme might be improved in 
the future. The information will be sent to the Home Office which administers the scheme. 
 
The information may also be passed to other central organisations, such as the National 
Treatment Agency (NTA) or Department of Health, in order to link it with data from research and 
other criminal justice interventions.  Again, this is purely for research purposes in order to monitor 
and evaluate the effectiveness of the Programme as a whole.  
 
The NDTMS system involves collecting information about the type of treatment you receive from 
a treatment agency. Sometimes you may be seen by more than one agency. Consequently, to 
avoid duplication of reporting, NDTMS may share a minimal amount of information about you 
between the agencies from which you may have received treatment. 
 
Your full name and address are not recorded. Instead your initials, gender, and date of birth are 
collected to make sure that you are not counted twice and to match it with data from treatment 
and other criminal justice interventions. Any material that is published by the Home Office or other 
central organisations as a result of receiving this information will not identify individuals. 
 
All information, whether stored on paper or electronically, will be kept in a secure environment 
and for only as long as necessary. The Home Office will adhere strictly to all requirements of the 
Data Protection Act 1998. 
 
Personal data will not be used for purposes other than those for which it was gathered (research 
and monitoring) and all information gathered for research and monitoring will be processed 
according to the data Protection Act 1988. 
 
Confidentiality 
However, whilst you can speak to your Inside Out worker in confidence, he/she may be 
obliged to break the confidentiality of this agreement for any of the reasons stated below (and 
notify the relevant authorities accordingly). 
 
 If he/she suspects there is any neglect or mistreatment of children. 
 If he/she suspects that you would seriously harm yourself or cause serious harm to 
another. 
 If you disclose details of a serious crime committed, or that you are aware is going to be 
committed. 
 If you disclose anything that risks safety or security within these premises. 
 If there is any evidence of use or supply of illicit substances on community premises. 
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Complaints Procedure 
We endeavour to provide a good service, however we value feedback and try to learn from 
feedback we receive. If you wish to make a complaint there is a WDP complaints procedure 
which you can access if you feel the need to do so. Please ask any member of the team for a 
leaflet and further details. 
 
Client refuses to give consent to contact anyone    
Client unable to sign consent form but indicates agreement                      
 
Client Name:  Client DOB:  
 
Client Signature:  Date:  
 
Worker Signature:  Date:  
 
 
8.0 Supplementary tables 
Supplementary table 8.1:  Post hoc power calculations 
Process/Outcome 
Count of people released to the Essex County Drug Recover 
Partnership from HMP Chelmsford via the CARAT & InsideOut 
Teams between 01/04/2008 & 31/03/2012 
 n    % activity % Power 
 
CARAT  
InsideOut CARAT InsideOut 
alpha = 
0.05 
alpha = 
0.01 
Total people released 255 278 n/a n/a n/a n/a 
With continuity of care (a) 70 116 27% 42% 95.5 85.8 
Into treatment (a) 26 56 10% 20% 89.9 74.2 
Return to prison (a) 93 59 36% 21% 97.1 89.9 
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Supplementary table 8.2:  Per capita acquisitive and drug crime  
 
Area Name 
Population 
figures (mid-
2015)
3
 - rounded 
to 100 
Household 
figures  (mid-
2015)
4
- 
rounded to 
100  
Rate per 
1,000 
population7 
Theft 
offences 
Drug 
offences 
ENGLAND AND 
WALES
8
 
                       
57,885,400  
                        
24,316,900  
70.0 30.8 2.4 
ENGLAND 
                       
54,786,300  
                        
22,984,500  
69.5 30.8 2.4 
Metropolitan Police 
                         
8,665,000  
                          
3,518,400  
86.9 41.5 4.6 
West Midlands 
                         
2,833,600  
                          
1,127,100  
68.7 33.3 1.9 
Greater Manchester 
                         
2,756,200  
                          
1,167,100  
83.1 38.4 1.6 
Thames Valley 
                         
2,358,600  
                             
941,900  
56.3 28.5 2.1 
West Yorkshire 
                         
2,281,700  
                             
948,600  
96.6 43.6 2.2 
Hampshire 
                         
1,953,700  
                             
818,800  
70.7 25.4 1.9 
Kent 
                         
1,801,200  
                             
749,200  
67.8 27.4 1.6 
Essex 
                         
1,787,000  
                             
748,600  
64.6 28.5 1.6 
Devon and Cornwall 
                         
1,720,900  
                             
748,800  
46.5 16.4 2.1 
Sussex 
                         
1,665,600  
                             
728,800  
60.0 22.8 2.0 
Avon and Somerset 
                         
1,664,200  
                             
707,800  
76.1 31.8 1.9 
Lancashire 
                         
1,478,100  
                             
629,200  
69.1 30.7 1.6 
Northumbria 
                         
1,437,500  
                             
637,400  
78.6 29.9 2.2 
Merseyside 
                         
1,398,000  
                             
617,500  
74.7 31.2 4.2 
South Yorkshire
9
 
                         
1,374,700  
                             
581,200  
76.7 37.7 1.8 
South Wales 
                         
1,307,000  
                             
558,700  
72.4 28.9 2.9 
West Mercia 
                         
1,249,200  
                             
530,600  
60.6 23.9 2.0 
Surrey 
                         
1,168,800  
                             
473,000  
50.7 19.7 1.7 
Hertfordshire 
                         
1,166,300  
                             
477,500  
57.8 24.8 2.9 
Nottinghamshire 
                         
1,124,700  
                             
476,100  
63.2 29.5 2.5 
Staffordshire 
                         
1,114,200  
                             
474,600  
65.7 24.1 1.8 
Leicestershire 
                         
1,056,000  
                             
422,100  
59.4 30.8 1.1 
Cheshire 
                         
1,043,500  
                             
450,600  
54.7 21.1 2.2 
Derbyshire 
                         
1,036,600  
                             
446,900  
50.7 23.9 2.1 
Humberside 
                            
925,100  
                             
403,200  
78.2 35.8 1.5 
Norfolk
10
 
                            
885,000  
                             
385,900  
54.5 19.5 2.1 
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Cambridgeshire 
                            
841,200  
                             
342,100  
61.4 29.7 1.9 
North Yorkshire 
                            
809,100  
                             
349,700  
46.0 20.8 2.1 
Dorset 
                            
765,700  
                             
338,200  
57.1 25.4 2.2 
Suffolk
11
 
                            
741,900  
                             
320,100  
59.2 23.0 1.7 
Lincolnshire 
                            
736,700  
                             
318,300  
49.2 24.3 2.0 
Northamptonshire 
                            
723,000  
                             
301,800  
70.6 32.8 1.9 
Wiltshire
13
 
                            
703,300  
                             
295,900  
55.5 21.1 1.8 
North Wales 
                            
694,500  
                             
301,200  
57.6 20.6 1.9 
Bedfordshire 
                            
655,000  
                             
260,200  
63.6 30.8 1.8 
Durham 
                            
625,100  
                             
275,200  
66.2 25.3 1.8 
Gloucestershire 
                            
617,200  
                             
265,200  
48.5 25.6 1.4 
Gwent 
                            
581,800  
                             
247,500  
66.8 26.9 2.4 
Cleveland 
                            
562,100  
                             
241,100  
88.4 40.2 2.5 
Warwickshire 
                            
554,000  
                             
237,000  
60.3 27.4 1.8 
Dyfed-Powys 
                            
515,900  
                             
225,000  
42.5 13.0 4.2 
Cumbria 
                            
498,000  
                             
223,800  
51.2 18.3 1.9 
London, City of
12
 
                                
8,800  
                                 
4,900  
+ + + 
 
Supplementary table 8.3:  Mean waiting times to treatment 
Continuity of care Length of time to engagement with the community drug treatment system within the first twelve months 
of release from prison 
N mean min max stDev 
Yes 100 55.7 0 351 90 
No 51 119.7 1 356 113.3 
 
Supplementary table 8.4:  Mean times in treatment 
Continuity of care Length of time to engagement with the community drug treatment system within the first twelve 
months of release from prison 
N mean min max stDev 
Yes 100 192.4 0 365 126.6 
No 51 153.0 3 365 122.1 
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Supplementary table 8.5:  Mean times return to prison 
Treatment Length of time to return tp prison within the first twelve months of release from prison 
N mean min max stDev 
Yes 32 220.6 34 364 96.0 
No 147 128.0 1 347 101.8 
 
Supplementary table 8.6:  Mean waiting times InsideOut and CARAT  
Performance activity 
Organisation 
CARAT InsideOut 
Count Mean StDev Count Mean StDev 
              
Total number of people engaging with treatment 26 124.7 120.1 56 90.4 112.1 
 
 
 
 
